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LIGAND-INSTALLED POLYMERIC NANOCARRIERS FOR COMBINATION
CHEMOTHERAPY
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Supervisor: Tatiana K. Bronich, Ph.D.
Combination chemotherapy remains the mainstay of cancer treatment because such
strategy targets different cell signaling pathways to decrease the likelihood of developing
protective mechanisms by cancer cells, thereby delaying the onset of recurrence and
prolonging the survival. The co-delivery of binary drug combination via a single nanocarrier
provides benefits in reducing dose-limiting toxicities, improving the pharmacokinetic
properties of the cargo,

spatial-temporal synchronization of drug exposure, and

synergistic therapeutic effects. Rational design of such regimen is crucial for maximizing
the therapeutic effects since only certain drug ratios exposed to the target might be
synergistic while other ratios exert additive or even antagonistic effects. Cisplatin-based
chemotherapy has shown great responses in several cancer types and has been used as
the standard systemic anticancer treatment, such as triple negative breast cancer (TNBC)
and ovarian cancer. However, tumor cells are becoming less responsive to cisplatin, which
arises from altered signaling patterns of cancer cells, such as activation of pro-survival
signal transduction (e.g., epidermal growth factor receptor (EGFR), AKT, PI3-kinase) and
DNA-damage repair, etc. EGFR is a member of the HER family of oncogenic receptor
tyrosine kinases (RTK), which actively participates in sustaining the growth and the
survival of carcinoma cells as well as the pathogenesis and progression of different
carcinoma types. It is frequently overexpressed in various cancer types, such as TNBC
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and ovarian cancer, making it a major therapeutic target for the development of targeted
drug delivery. A combination of EGFR inhibitors with cisplatin have shown strong
synergistic effects in EGFR overexpressing cancers both in preclinical and clinical studies.
Moreover, the combined regimen significantly outperformed the single treatment as
reported. It has been shown preclinically that EGFR inhibitors significantly potentiate the
cytotoxic effects of cisplatin in tumors with overexpressed EGFR through blocking
oncogenic signal transduction and unfavored pro-survival signals induced by platinumbased therapy. However, inhibiting EGFR could trigger underappreciated resistance and
activate the parallel oncogenic signaling pathways through other members of HER family.
Using a pan-HER inhibitor is a common strategy to avoid this limitation. To this end,
neratinib (NRT) (an FDA-approved pan-HER inhibitor) and cisplatin (CDDP) were selected
as the combination regimen to treat EGFR+ cancers: TNBC and ovarian cancer. To
incorporate these two molecules with varied physicochemical properties in the same
carrier, we designed a biocompatible crosslinked polypeptide-based nanogel (NG) with
multifunctional compartments. Such biodegradable platform provides flexibility in adjusting
size, loading capacity, surface properties, deformability, softness, and responsive
behaviors by tuning the chemical compositions as well as crosslinking levels. For the
purpose of the current study, NGs prepared from copolymers poly (ethylene glycol)-blockpoly (L-glutamic acid) modified with phenylalanine functionalities ((PEG-P(GluGlu/Phex)150) were developed for simultaneous loading and delivery of binary CDDP and
NRT combination. Such NGs have 1) a hydrophilic PEG shell for less RES uptake and
extended circulation, 2) an anionic crosslinked core, which incorporates CDDP through
coordination with the carboxylic groups of PGlu, 3) hydrophobic regions formed by Phe
moieties, which serves as a reservoir for NRT solubilization. By tuning ratio of constituent
hydrophilic and hydrophobic moieties, NGs displayed varied dimensions, drug loading
capacities, deformability, performance in killing tumor cells, as well as penetrations in
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multicellular 3D tumor models. Consistent with properties of chemical composition, NGs
with high hydrophobic fraction displayed less swelling ability and more efficient
hydrophobic drug loading. Resulting binary drug combination-loaded NGs functionalized
with 50 units of hydrophobic Phe were able to encapsulate both CDDP and NRT at a molar
ratio of 2:1 and displayed the strongest synergistic effect towards EGFR+ TNBC cells
compared with other screened regimens. Such superior synergy was found to be selective
and only displayed in the EGFR+ TNBC cell line. Notably, NRT was found to reverse prosurvival signal transduction by CDDP mediated EGFR/Akt/Erk activation as well as
increased Cyclin D1 expression, which was believed to be the molecular basis for the
synergistic effect of the combination of CDDP and NRT. Drug-loaded carrier system
exerted the highest synergy was selected in the following studies targeting EGFR
overexpressing ovarian cancer. However, this carrier system solely depends on the EPR
effect for drug accumulation in tumor sites, which is limited by heterogeneity among tumor
masses as well as vascular density nearby influencing the permeability of nanocarriers.
Installing targeting ligands on the surface of carriers to specifically target biomarkers
overexpressed on the surface of tumor cells is a well-suited strategy to overcome
mentioned limitations and increase retention of payloads in tumors. In the next part of our
study, two targeting ligands aiming to bind with EGFR was chosen in our study: L-AE
peptide and EGFR-A protein with reported high binding specificity and affinity to EGFR
with acceptable stability. Two types of ligand-installed NGs both demonstrated success in
significantly increased cellular uptake in EGFR+ ovarian cancer cells as compared to
nontargeted NGs. Further optimization was conducted by extending the thickness of PEG
stealth layer from 114 monomer units to 228 units for sufficient protection from
opsonization. Optimized PEG-based polymeric NGs displayed more favored PK
properties, such as remarkably less spleen uptake, higher drug retention in tumor sites,
slower clearance from circulation, and more drug exposure. NGs with EGFR targeting
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ligands further improved the PK profile by directing remarkably more drugs to the target
sites. When tested in vivo, EGFR targeted peptide and protein decorated NGs carrying
CDDP and NRT drug combination significantly suppressed the growth of intraperitoneal
high-grade serous ovarian tumor xenografts outperforming their nontargeted counterparts
without extending their cytotoxicity to the normal tissues. We also confirmed the
importance of simultaneous administration of the (CDDP+NRT) via a single NG system
which provides more therapeutic benefits than a cocktail of individual drug-loaded NGs
administered at equivalent doses. Lastly, our data demonstrated the benefits of local
treatment by showing that intraperitoneal (IP) administration of targeted binary drug
combination-loaded NGs can be more effective in terms of tumor growth suppression.
These data have shown the power of our carrier system in the delivery of a drug
combination to treat EGFR overexpressing cancers.
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CHAPTER I.

INTRODUCTION

1.1 Anticancer Therapeutic approaches
Despite the availability of improved drugs, cancer is still one of the leading causes of
mortality worldwide [1]. Cancer has been defined by the national cancer institute to be a
genetic disease that arises from genome changes to cell growth and division affected by
the interactions between host and environment [2]. Cancers progress from uncontrolled
replication, evasion of apoptosis, sustained angiogenesis, and ultimately to penetration in
other tissues [3]. Complexity and heterogeneity, the hallmarks of cancer, make it
extremely difficult to have a standard therapy that can be equally effective even within the
same type of clinical tumor [4]. The generation of tumor heterogeneity owes to the genomic
instability which generally evolves to more diverse with the progression of disease,
resulting in a non-uniform distribution of distinct subpopulations across and within tumor
sites, and ultimately lead to predispose undesired clinical outcomes [5]. High mutation
potential of cancer cells increases the possibility of relapse following initial treatment
success, which creates needs for another therapeutic regimen that could be used as later
lines of therapy [1]. Altogether, it is difficult to combat cancer using a single therapeutic
regimen. Therefore, a variety of combination therapy that reduces drug resistance, while
simultaneously providing therapeutic anticancer benefits in a characteristically synergistic
or an additive manner has been developed. Traditionally, depending on the tumor location,
grade and stage, cancers are treated with a combination of surgery, radiotherapy,
chemotherapy and/or immunotherapy [6]. Briefly, 1) surgery is applied to either remove
the entire tumor or debulk a tumor to ease disease symptoms [7]. Due to the uncontrolled
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post-surgery micrometastases leading to a plateau in curability rates, the use of adjuvant
chemotherapy after surgery has been proposed to remove remaining tumor cells and
shown promising results in numerous types of tumors [8]. 2) Radiation therapy uses highenergy particles or waves to disease location to damage cancer cells or slows their growth
through making breaks in the DNA which keeps cancer cells from growing and dividing
[9]. Radiation therapy is given either before surgery to shrink the tumor or after surgery to
keep cancer from recurrence. In spite of its potential, current techniques of photon-based
radiotherapy are approaching the physical limits of delivering high doses to the target
disease volume [10]. 3) Immunotherapy use immune system components to kill tumor
cells, including using antibodies to block abnormal proteins in cancer cells, vaccines to
trigger the immune system to destroy antigens, and engineered T cells to recognize and
destroy cancer cells [11]. It shows potential in promoting long-term anticancer immune
responses, although the number of patients who benefit from this treatment is limited, and
it sometimes has severe associated side effects [12]. 4) Chemotherapy is the most widely
used form of therapy which utilizes a single drug or combination of drugs to interfere with
cancer cells’ ability to divide and reproduce. Like radiation, it can be used to shrink a tumor
before surgery or applied after surgery or remission to remove remaining cancer cells [13].
Overall, chemotherapy is an invasive treatment while it can sometimes have severe
adverse effects due to the systemic administration of drug-mediated off-target toxicities.
Apart from the mentioned conventional therapies, gene therapy and nanomedicine are the
most promising state-of-the-art therapies. 5) Gene therapy allows doctors to treat diseases
by inserting a gene into cells to either removing, inactivating a disease-causing gene or
introducing a new gene to fight diseases. Although gene therapy is a promising treatment
option for some types of cancer, this technique is risky and still under study for its safety
and efficacy [14]. 6) Nanomedicine, an emerging method for treating cancer, is defined as
the use of materials between 1 and 100 nm as anticancer medicine [15]. It improves the
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balance between the efficacy and toxicity of the active pharmaceutical ingredients carried
within nano-formulations due to favorable drug release profiles, improved biodistribution,
and accumulation at the target site [16]. In preclinical settings, nanomedicines have shown
to inhibit tumor growth and prolong survival as compared to free drugs, while in clinical
practice, patients who received nanomedicine often only benefited from the reduced side
effects. The key challenge for nanomedicine for better clinical translation is to select the
right treatment regimen and apply them in the right patient population [6]. Each type of
treatment mentioned above shows limitations either due to tumor cell heterogeneity, the
intrinsic severe side effects or acquired resistance. Overall, the anticancer therapeutic
regimen is determined based on the stage and type of cancer.
1.2 Combinatorial treatments
1.2.1 Chemotherapy
Due to the increasing knowledge of cancer biology and pharmacology, and the improved
design of clinical trials using this knowledge, chemotherapy has evolved to a part of sound
medical discipline playing an important role in the control of cancer [17].
Chemotherapeutic agents can trigger a series of cellular responses that influence the
tumor cell dividing and survival. It is now believed that the most cytotoxic action of
chemotherapeutic drugs with differing structure and specificity is through the activation,
amplification and execution of the apoptotic process, characterized by morphological and
biochemical changes mediated by a family of caspases [18]. Apoptotic cell death could be
induced through two distant pathways: intrinsic or extrinsic pathways [19]. The extrinsic
pathway could be initiated by ligation of transmembrane death receptors (such as TNF
receptor and TRAIL receptor) to activate membrane-proximal caspases (such as caspase8), which in turn cleave and activate effector caspases such as caspase-3 and -7 [20]. The
intrinsic pathway is initiated by the disruption of the mitochondrial membrane and the
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release of mitochondrial proteins, including Smac/DIABLO, HtRA2, and cytochrome c [18].
The intrinsic pathway can be activated by “intrinsic stresses”, such as oncoproteins, direct
DNA damage, and hypoxia, for which p53 is a critical initiator (Figure 1) [21]. For example,
proteins that sense DNA damage phosphorylate and stabilize p53 directly, and inhibit
MDM2-mediated ubiquitination of p53 [22]. P53 initiate apoptosis by activating 1)
proapoptotic Bcl-2 family members such as Bax and Bak [23], 2) genes that may contribute
to apoptosis, including PTEN, Apaf-1, and PERP, 3) genes that lead to increases in
reactive oxygen species (ROS), 4) both CD95 and TRAIL receptor 2 to sensitize cells to
death-receptor-mediated apoptosis [24] [25].

Figure 1. Summary of apoptotic pathways. Adapted from (Johnstone) [18].
1.2.2 Drug resistance
The development of resistance is one of the major drawbacks of monotherapy in cancer
therapy, responsible for most relapses in cancer patients following apparent remission
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after successful therapy [26]. Understanding why the cell death program fails to be
engaged in certain settings could allow us to rethink how the drug resistance may arise
and offer a novel approach to overcoming the clinical problem of drug resistance. Although
many cancers are susceptible to chemotherapy initially, they can gradually develop
resistance [27]. The causes behind the development of resistance are multi-fold and often
include different mechanisms (Figure 2), which is usually a cumulative effect of all the
targets and pathways that are affected by a particular drug treatment [26].

Figure 2. Summary of Categories of mechanisms that promote drug resistance in
human cancers. Adapted from (Meghan) [26].
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One of the most studied resistance mechanisms might be enhancing drug efflux leading
to reduced drug accumulation [27]. The key regulators enabling this efflux are the
members of the ATP-binding cassette (ABC) transporter family proteins at the plasma
membranes of healthy cells [28]. Three transporters—multidrug resistance protein 1
(MDR1), multidrug resistance-associated protein 1 (MRP1), and breast cancer resistance
protein (BCRP)—are found expressed in high level in many drug-resistant cancers
associating with poor clinical outcomes [29]. Inhibiting BCRP using the kinase inhibitor,
such as Gefitinib, was found to block the transporter function of BCRP and reverse drug
resistance [30]. Alteration of drug targets is another common drug resistance reason. As
we know that drug efficiency is affected by its molecular target and changes of this target,
including mutation or modification of expression level. Alteration of such target in cancer
ultimately leads to drug resistance. For example, resistance to camptothecin, a
topoisomerase inhibitor, can arise from altered topoisomerase I and II activity which
prevents drug-protein binding and promotes the repair of broken strand [31]. Another
frequently studied anticancer drug targets are signaling kinases, such as epidermal growth
receptor factor, which is constitutively active and/or overexpressed in certain cancers,
drives the cell cycle out of control and promotes uncontrolled cell growth. Long-term use
of kinase inhibitors targeting those kinases can result in resistances due to the mutation
of such kinases [32]. Original dose of the drug is inadequate at sites of diseases
eventually. This process might also induce the alteration in the signal transduction process
that mediates drug activation or activation in alternative signaling pathways further
contributing to the resistance [27]. Many drugs act indirectly or directly to cause DNA
damage. Cells can respond to such damage to reverse the drug-induced damage. For
example, resistance to the platinum drug, a potent DNA-crosslinking agent, arises from
increased expression of proteins responsible for DNA repair [33, 34]. The combined use
of agents for inhibiting DNA damage response with DNA damage drugs could sensitize
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tumor cells and therefor improve therapeutic efficacy [35]. Another response that tumor
cells adapt to resist anticancer drugs is the inhibition of cell death. BCL-2 family proteins,
Akt, and other antiapoptotic proteins are key regulators in the cell apoptosis, which are
found to be highly expressed and active in many types of cancer [36]. It has been shown
that the use of antiapoptotic proteins inhibitors such has histone deacetylase inhibitors
(HDACi) could sensitize breast cancer cells to cytotoxic agent TRAIL in a mouse model
[37]. Epithelial to mesenchymal transition (EMT) and metastasis are reported to be related
closely with resistance and could explain why cancer can relapse at distant sites after
apparently successful treatment and remission. During the EMT, cells reduce expression
of cell adhesion receptors while increase expression of metalloproteases on the surface
of tumor to enable moving outward of tumor cells leading to metastasis. EMT phenotype
has been demonstrated in several drug-resistant cancer cell lines, such as gemcitabine/5FU-resistant pancreatic cancer cells, oxaliplatin-resistant colorectal cancer cells, and
paclitaxel-resistant ovarian cancer cells [38] [39] [40]. Although the acquirement of EMT
is widely observed to be closely related to drug resistance, the exact mechanism of how
EMT is of how EMT regulates drug resistance still remains unanswered. Altogether,
cancer cells exposed to monotherapy can develop drug resistance through several
mechanisms.
1.2.3 Combination chemotherapy
As discussed above, cancer cells can develop multiple protective mechanisms in
response to toxic effects by mono-chemotherapy. It is therefore reasonable to propose the
use of combined drugs that work by different mechanisms, thereby decreasing the
likelihood that resistant cancer cells will develop. When drugs with different effects are
combined, each drug can be applied at its optimal dose, without intolerable side effects.
Therefore, this strategy also works for reducing systemic toxicity and increasing
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tolerability. The principles of combination chemotherapy development have remained
basically the same over the last decades. The general strategies have been to i) use drugs
with nonoverlapping toxicities so that each drug can be given at a dose close to maximal;
ii) combine agents with different effects and minimal cross-resistance in an effort to inhibit
the development of broad-spectrum drug resistance; iii) preferentially use drugs with
proven activity as individual drugs and iv) administer the combined treatment at earlystage disease and at a schedule with a minimal treatment-free duration between cycles
but enabling the recovery of sensitive healthy tissues [41]. Advantages attributed to
combination chemotherapy can be listed as follows: 1) patient compliance can be
improved due to the reduced number of administrations, 2) favorable outcomes through
various mechanisms, including synergistic effects, additive effects and potentiation effects
are achieved (Figure 3) [42], 3) multidrug resistance can be overcome or delayed and
drug dose with the consequent diminishing of toxicity to healthy tissues can be reduced.

Figure 3. Summary of the mechanisms underlying combination chemotherapy. Adapted
from (Quanyin)
One of the key contributors to drug resistance is the high expression of MDR-related
transporters, such as P-glycoprotein (P-gp), on various types of cancers, which increases
drug efflux, DNA repair capacity, dysfunctional apoptosis, or activates pro-survival
pathway leading to mitigated treatment outcome [43]. Inhibiting such transporters could
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inactivate the drug efflux pump and therefore increase the drug accumulation. Yogesh et
al. have shown that combining P-gp inhibitors, tariquidar, and cytotoxins, paclitaxel, has
shown significantly increased intracellular drug retention and enhanced cytotoxicity in
drug-resistance cell lines and mouse models comparing with monotherapy indicating that
combination treatment using P-gp modulator and the anticancer drug is a promising
strategy to overcome tumor drug resistance [44]. A similar strategy has shown improved
therapeutic outcomes in the clinic [45]. Another example is to combine molecularly
targeted agents with cytotoxins to disturb or block mutated signal pathways that are crucial
in tumorigenesis [46]. The combination of cytotoxins and epidermal growth factor receptor
(EGFR)-tyrosine kinase inhibitors (TKIs) (e.g., erlotinib and cetuximab) has shown
synergistic effects in inhibiting the proliferation of tumor cells. The mechanism of the
synergy is that TKIs may help rewire the apoptotic signal pathways, inhibiting P-gp activity
of tumor cells, thus sensitize cells to cytotoxins [47] [48]. Wang et al. have shown that
DOX uptake was enhanced in the MCF-7 cells with overexpression of drug efflux
transporters but not the cells with low-expressing drug efflux transporters when
administered DOX and lapatinib (TKI). They also showed that this combination treatment
could restore the sensitivity of breast tumors to DOX and reduce the DOX systemic toxicity
[49] [46].
1.2.3.1 Combination chemotherapy in the clinical practices
It is very difficult to determine whether a drug combination is working synergistically,
additively, or antagonistically in cancer patients [50]. The only way to judge is to see
whether a new combination achieves significantly increase in a determined endpoint such
as response rate, survival or time to progression. However, preclinical studies focusing on
biochemical and molecular mechanisms of drug interaction at the cellular level allow a
more rational design of clinical combination chemotherapy. Several factors should be
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taken into account when designing such studies, such as drug concentration & exposure,
administration schedule & sequence and analytic method [51]. Currently, the most
prevalent and widely-accepted method used for quantitative evaluation of drug
combinations is the median effect analysis proposed by Chou and Talalay [52] [53] [54].
Although valuable information about drug interaction in in vitro studies can be obtained, in
vitro synergistic activity is strongly dependent on the ratio of drugs which has profound
implications on clinical practices, since in vivo activity relies on the maintenance of those
therapeutic ratios at the tumor sites [55] [56]. Therefore, in order to achieve maximal
therapeutic efficacy in vivo, the dosing schedule is essential to expose tumor cells to
therapeutic drug concentrations [57]. Combination therapy adopted in clinics generally
includes more than one therapeutic agent co-administered simultaneously or a
combination of different therapies summarized in Figure 4, such as chemotherapy,
hormone therapy, immunotherapy and radiotherapy. Above all mentioned approaches,
the co-delivery of various chemotherapeutic agents is the most widely-used combination
therapeutic modality in clinical practice [58]. For advanced epithelial ovarian cancer
patients, a recent phase II trial using sorafenib, a multi-kinase inhibitor reducing
survival/proliferation signals by inhibiting RAS/RAF/MAPK pathway as well as the EGFR
signaling pathway, plus topotecan, a well-known chemotherapeutic genome-toxic drug, in
platinum-resistant ovarian cancer demonstrated clinically significant improvement in
progression-free survival of these patients [59]. However, single sorafenib therapy only
showed modest activity in earlier studies [60]. PARP, a validated target in cancer therapy,
is an enzyme participating in the repair of single-stranded DNA breakages. Failure to
repair single-stranded breaks eventually induce double-stranded DNA break which can be
repaired by the homologous recombination (HR) pathway [61] involving functional BRCA1
and BRCA2 [23]. Therefor factors impairing HR or BRCA1/2, such as associated
mutations, sensitize tumor cells to the genotoxic effects of PARP inhibitors. Such
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combined effect is defined as the term “synthetic lethality” [62]. In a more recent phase II
study of combining cediranib (anti-angiogenic agent) and olaparib (PARP inhibitor) versus
olaparib in relapsed platinum-sensitive ovarian cancer, Joyce et, al. has shown that a
combination of cediranib and olaparib increased progression-free survival significantly,
when compared with olaparib alone [63]. The enhanced effectiveness of combination
might arise from the fact that anti-angiogenic agents can induce the downregulation of
genes implicated in HR leading to a creation of an HR-deficient state making affected cells
more vulnerable to a PARP inhibitor [64] [65]. Similarly, a combination of PARP inhibitors
with chemotherapy has shown great potential in increasing the efficacy of PARP inhibitors
and sensitizing triple negative breast cancer patients. Jung et al. reported in a Phase I/Ib
study that the combination of olaparib and carboplatin in BRCA1 or BRCA2 mutationassociated-TNBC induced an overall response rate (ORR) as high as 88% [66]. A
combination of radiation therapy and chemotherapy has also been a very common
modality in cancer treatment especially for surgically unresectable tumors. Radiotherapy
is a major therapeutic option for non–small cell lung cancer (NSCLC) patients with
unresectable advanced lung cancer [67]. However, NSCLC cell lines are generally less
sensitive to radiation. Pretreating cancer cells with chemotherapy could sensitize cells to
radiation therapy in several preclinical studies. Zhang et al. have demonstrated that
wortmannin sensitizes NSCLC cells to radiotherapy by inhibiting PI3K/Akt survival
signaling and DNA-PKCs, a catalytic subunit required for the non-homologous end joining
(NHEJ) pathway of DNA repair [68]. Similarly, gefitinib acts as a radiosensitizer in NSCLC
cells by inhibiting ataxia telangiectasia mutated (ATM) activity which is activated by DNA
double-strand breaks and thereby inducing mitotic cell death [69]. In a randomized trial,
the delivery of cisplatin concurrently with radiotherapy to patients with Stage III inoperable
NSCLC has demonstrated improved rates of survival as compared with single
radiotherapy [70]. However, the above combination regimen demonstrated increased
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toxicity, nausea, and vomiting in this study. Altogether, the co-delivery of various
chemotherapeutic drugs has been the most practiced and well-established therapeutic
modality among different combination therapies. Therefore, the current perspective in the
treatment of cancer has progressively concentrated on developing the delivery of
chemotherapeutic drugs in a combination approach with reduced drug-associated side
effects and enhanced therapeutic anticancer effects.

Figure 4. Types of combination modalities for the treatment of cancer. Adapted from
[58].
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1.2.3.2 Combination chemotherapy in triple negative breast cancer
Breast cancer represents the second leading cause of death in women after lung cancer
and it is the most commonly occurring cancer among females globally [71]. Triple-negative
breast cancer (TNBC) accounts for 12-20% of human breast cancers, referring to the
breast cancer phenotype diagnosed pathologically by < 1% expression of Human
Epidermal Receptor 2 (HER2), estrogen (ER) and progesterone receptor (PgR) [72] [73]
[74]. TNBC is the most aggressive histologic subtype with a high potential of disease
recurrence and the possibility for distant metastases [75]. Despite optimal systemic
chemotherapy, less than 30% of women with metastatic breast cancer survive 5 years
after diagnosis, and almost all women with metastatic TNBC will eventually die of their
disease. This is due to the relative lack of recognized molecular targets for therapy, poor
prognosis and aggressive clinical behavior of the disease [76]. Due to the very limited
expression of hormonal and HER2 receptors, conventional targeted therapies (hormonal
and anti-HER2) are not effective in TNBC [77]. Currently, cytotoxic chemotherapy, such
as anthracycline, gemcitabine and carboplatin, remains the standard established systemic
treatment of TNBC showing significant benefits in the either neoadjuvant or adjuvant
setting. [76]. Although TNBC patients have a higher response to systemic chemotherapy
than those with non-TNBC, the 5-year survival rate is still less than 30% and virtually all
women with metastatic TNBC would die of this disease eventually [78]. The limited efficacy
could arise from altered signaling patterns of cancer cells leading to modulated effects of
treatment, such as activation of pro-survival signal transduction (e.g., epidermal growth
factor receptor (EGFR), AKT, PI3-kinase) and damage repair, etc [79]. Many clinical trials
have been studied to apply combination chemotherapy regimens to reduce these
undesired effects and enhance the survival of patients. Although TNBC is considered a
single clinical entity and primarily treated with chemotherapy regardless of the stage of the
disease, molecular profiling technologies has revealed that TNBC is highly heterogeneous
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[80]. It would be desirable to manage patients through taking both factors into
consideration: the current clinical practices and the molecular complexity of TNBC [76].
EGFR are transmembrane glycoproteins belonging to the HER family of receptor tyrosine
kinases (RTK), which actively participates in sustaining the growth and the survival of
carcinoma cells as well as the pathogenesis and progression of different carcinoma types
[81]. Interestingly, up to 78% of TNBC have the EGFR overexpression [82], making it a
potential therapeutic target for intervention. Besides, EGFR inhibitors might work
synergistically with standard chemotherapy by reducing the unfavored pro-survival signals
induced by the latter, which has been shown in several studies [79] [83] [84], further
increasing the sensitivity of cancer cells to the designed regimen and enhancing the
clinical benefits. FDA approved anti-EGFR agents include monoclonal antibody
Cetuximab (Erbitux™; Eli Lilly and Company) and small molecular tyrosine kinases
inhibitors (TKIs), such as Erlotinib (Tarceva; Genentech) and Gefitinib (Iressa;
AstraZeneca). A major breakthrough of targeting EGFR in TNBC was that in a phase III
study, the BALI trial demonstrated a 20% overall response rate in patients with metastatic
TNBC who received the cetuximab/cisplatin combination, compared with 10.3% response
rate in the cisplatin‒alone group [85]. The progression‒free survival duration was
increased from 1.5 to 3.7 months (HR 0.675, P = 0.032) upon the addition of cetuximab
to cisplatin. However, the response rate was considered low since it did not meet the pre‒
specified primary endpoint. The lack of benefits can arise from the fact that inhibiting
EGFR might trigger underappreciated resistance and induce activation of parallel
signaling pathways and downstream signaling pathways through other members of HER
family [86]. Besides, there is an emerging hypothesis that for TNBC patients whose HER2
expression level even is at the lowest levels, they are not going to get a great pathological
complete response rate with standard agents [87]. Given that, eliminating any trace of the
HER family of proteins could enhance the response to the standard cytotoxic treatment.
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Using pan-HER inhibitors in the treatment for TNBC has been evaluated both in preclinical
and clinical studies. I-SPY2 trial [88] has demonstrated that the preoperative inhibition of
pan-AKT with the oral agent MK-2206 or inhibition of activated EGFR, HER2 and HER4
with neratinib (NRT) can improve pathological complete response rates (pCR) of TNBC
patients achieved with cytotoxic DNA-damaging agents [87]. Furthermore, TNBC patients
treated with weekly DNA-damaging agents, with or without NRT, showed 37.5% overall
pCR in the NRT arm, but among patients demonstrating phosphorylation of HER2 or
EGFR, it rose to 63% which implies clinical benefits might be achieved when applying this
strategy to subsets with EGFR or HER2 activation since they might be especially
responsive to it. In addition, based on reverse-phase protein array data, only activation of
HER2 (p = 0.03) or EGFR ( p = 0.009 ) were found to be positive predictors of pCR [88].
To develop exceptional responsive treatment based on phenotype, several other
molecular targets are also being evaluated in clinical studies since TNBC is a highly
heterogeneous disease. Glycoprotein non-metastatic b (GPNMB) is overexpressed in 40%
to 75% of breast cancer and associated with poor prognosis. In a randomized Phase II
Study trial, triple-negative breast cancer patients with GPNMB expression were treated
with either an antibody-drug conjugate (ADC) targeting GPNMB, glembatumumab vedotin,
or selected chemotherapy. ADC showed better toxicity tolerance in heavily pretreated
patients comparing with chemotherapy arm. However, primary endpoint in all enrolled
patients with GPNMB-expressing breast cancer was not met [89]. Research is brisk for
immune checkpoint inhibitors. Although TNBC is considered a relatively immune-cold
disease, clinical trials using inhibitors of programmed cell death protein 1 (PD-1) and its
ligand (PD-L1) on TNBC patients are ongoing [90]. In a phase II study, 18.5% of heavily
pretreated patients showed response to the PD-1 inhibitor pembrolizumab (Keytruda). In
another study, 19% responded to the PD-L1 inhibitor atezolizumab, but when the agent
was combined with nab-paclitaxel (Abraxane), the response rate increased to 70% [87,
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91]. In spite of encouraging efficacy, whether there will be clinical benefits of this regimen
is unknown before more patients are recruited in future clinical trials. For the standard
chemotherapy on TNBC, people also would like to seek exceptional responders. In a 2015
Phase II Clinical Trial of platinum monotherapy on 86 patients with metastatic triplenegative breast cancer, response rates were 32.6% to single-agent cisplatin and 18.7%
to carboplatin, with highly durable responses observed in 11.7% and 5.7%, respectively.
Several cisplatin-treated long-term responders remained alive and progression-free
without any therapy after platinum treatment 3 to 6 years later. The phenotype of the
exceptional responders was BRCA wild-type diagnostic with breast, lymph node, and
parenchymal lung disease, without pleural, bone, or liver disease. Although BRCA1/2
mutation carriers exhibited a significantly higher response rate than noncarriers, there
were no differences in median progression-free survival [92].
1.2.3.3 Combination chemotherapy in ovarian cancer
Ovarian cancer (OC) is the most lethal gynecological cancers in the USA with no effective
screening strategy. It is estimated by The American Cancer Society that in 2020, there will
be about 21,750 new cases of ovarian cancer diagnosed and 13,940 women will die of
ovarian cancer in the United States [93]. Although the standard of care of OC patients
including surgical cytoreduction followed by platinum-based chemotherapy has shown
high response, mortality rates for ovarian cancer have declined only marginally in the forty
years emphasizing continued efforts toward better treatments [94]. Most patients present
with advanced-stage tumors showing metastasis outside the pelvis at the time of initial
diagnosis due to inadequate diagnostic markers and non-specific symptoms [95] [96].
Although ovarian cancer can be divided into several subtypes based on the cell of origin,
including germ, epidermoid, stromal, and border cells, epithelial ovarian cancer (EOC)
accounts for about 90% of OCs. EOC is associated with high mortality rates due to the
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intrinsic aggressive nature and limited early detection techniques. Among all the subtypes
of EOC, high-grade serous carcinoma (HGSC) is the most commonly diagnosed form with
high sensitivity to current front-line combination platinum- and taxane- based
chemotherapy [97, 98]. In spite of high response rates to the standard therapy, EOC
frequently relapses and becomes increasingly less sensitive to chemotherapy. We may
be approaching the limit of using conventional chemotherapeutics to optimize the
treatment of EOC [96]. Delaying the onset of resistance and prolonging the survival of
EOC patients will likely occur with progression in the early detection of this disease [99]
as well as through the incorporation of biologically targeted therapeutics. Aberrant EGFR
expression is reported in up to 60% of malignant ovarian tissue as demonstrated by IHC
and occurs in all histologic subtypes [100]. Due to the fact that the increased copy number
and overexpression of EGFR were found to be associated with high tumor grade and poor
patient outcomes,

EGFR expression might be used as an independent prognostic

indicator in EOC patients [101-103]. Interestingly, the increased copy number of EGFR
was reported to be associated with an increased copy number of HER2 which was also
reported to be a negative prognostic indicator in EOC in some reports [101, 104].
Therefore, inhibiting the family of HER might be a promising approach through utilizing
biological targets [105, 106]. As mentioned, EOC has been showing high sensitivity
towards platinum-based chemotherapy. Cisplatin, a widely used platinum compound, acts
by damaging DNA. Once entering the cell through either passive diffusion or active
transport, cisplatin undergoes the aquation process and becomes a potent electrophile
that reacts with a variety of nucleophiles, including nucleic acids. The formation of
cisplatin-DNA adducts disrupts the DNA structure and interferes with DNA replication &
transcription leading to either apoptotic cell death or DNA repair with cell survival. The
mechanisms of determining the fate of cells remain largely unknown [107]. The declined
sensitivity to cisplatin is believed to arise from reduced cellular uptake [108], enhanced
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intracellular detoxification, increased DNA repair, tolerance of platinum-DNA adducts and
regulation of apoptosis [109, 110]. On the other hand, NRT is an inhibitor of HER family
receptor tyrosine kinases, including EGFR, HER2 and HER4. Its mechanism of action
involves the irreversibly binding to the intracellular signaling domain of kinases to inhibit
their phosphorylation and several HER downstream signaling pathways such as ERK, PI3
kinase/AKT, JAK/STAT, etc. It has been reported that nucleotide excision repair (NER), a
primary DNA-damage repair process, may prevent cisplatin-induced apoptosis by
activating the ataxia telangiectasia mutated (ATM) pathway [107]. EGFR acts as an
upstream effector of ATM by phosphorylating ATM to mediate DNA repair. It was shown
that the treatment with EGFR inhibitor successfully blocked ATM activation and
subsequently increased tumor cell sensitivity to DNA-damaging treatments [111]. Apart
from activating the ATM pathway, EGFR was shown to epigenetically regulate DNA
damage signaling pathways by modifying chromatin at critical tyrosine residues [112] and
phosphorylating DNA-dependent protein kinase (DNA-PKcs), an enzyme required for
DNA-repair [113], to reduce the DNA damage and restored DNA repair activity. As an
inhibitor of HER family, NRT might potentiate the therapeutic efficacy of cisplatin by
reducing DNA-damage repair through interfering EGFR-mediated Histone H4/DNAPKcs/ATM pathway and pushing cells towards apoptotic death. On the other hand, EGFR
is activated in response to cisplatin in various types of cancer cells that overexpress the
receptor, including human breast cancer cells and glioma cells [114], which is believed to
be a survival-promoting or cell death-opposing response. Many studies have shown
blocking EGFR activation enhances cisplatin-induced cell death [79, 115, 116]. This
serves as another strong basis that preventing CDDP-dependent EGFR activation should
enhance drug sensitivity and improve clinical efficacy. Another minor mechanism of action
of NRT is its ability to provoke cell cycle arrest by downregulating the oncogenic Cyclin
D1 level which plays a key role in advancing the cell cycle into the late G1 and S phases
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[117]. Since tumor cells appear to be maximally sensitive to cisplatin in G1 phase and
minimally sensitive in S-phase [118], reducing Cyclin D might keep more cells blocked at
the G1 phase during cisplatin treatment and prevent DNA damage repair, which might
also explain that the increased cyclin D expression results in less tumor sensitivity to
cisplatin in several in vitro models, including fibrosarcoma [119] and pancreatic cancer
[120]. Altogether, the above mechanism of actions of both drugs then forms the rational
basis for selection of such combined therapy to achieve maximized synergistic clinical
effects for treating ovarian cancer. In spite of a strong basis for the synergy of action, this
combination was also found to have dose-limiting side effects and therefore offers the
potential for the development of nanomedicine-based approaches that can achieve
synchronized and ratiometric delivery as well as modulate toxicities associated with free
drugs.
1.3 Ligand-installed nanocarriers for combination therapy
Development of drug-delivery systems that selectively target neoplastic cells has been a
major goal of nanomedicine in cancer therapy. One major strategy for achieving this goal
is to install ligands on the surface of nanocarriers to improves targeting properties of
nanocarriers, including overcoming vascular barriers, enabling tumor extravasation,
penetrating deeper tumor region and impermeable tissues, selectively increasing retention
of payloads in tumors, activating specific molecular signaling, and promoting intracellular
delivery [121-125]. These features have allowed ligand-installed nanocarriers to improve
the efficacy of both delivered bioactive treatments and diagnosis in various preclinical
disease models, including cancer, CNS disorders, and cardiovascular diseases, with
potential to enhance the outcome of intractable diseases, such as Alzheimer's disease
and drug-resistant tumors, through the development of such novel therapeutic strategies
[126]. Such ligand-installed nanocarriers could show substantial advantages over
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conventional drugs and nanocarriers in terms of treating small metastases, as well as
circulating cancer cells [127]. An ideal strategy to design the targeted nano-drug will be to
display targeting moieties on the surface of nanoparticle formulation functioning as a
homing signal that allows unique recognition and interaction with biomarkers
overexpressed on diseased cells and/or subcellular domains for higher binding chance
and specificity, without affecting the nontargeted cells [128]. Despite of success of
nanoparticle-guided targeted therapy of cancer in reducing off-target side effects on
preclinical platforms, the bench-to-bedside translation has been far from encouraging. A
widely used strategy in clinics to develop targeted formulation is to conjugate antibodies
with potent drugs [129]. Although not easily adopted in clinics, ligand-installed
nanocarriers are able to deliver a concentrated dose of versatile drug payloads (Figure
5), which is a substantial advantage over antibody-drug conjugates (ADC). On top of that,
attachment of multiple ligands on the surface of nanocarriers enables multivalent binding
to target cells for stronger binding affinity [130], and driving cellular receptors clustering
for signaling [131].
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Figure 5. Schematic illustration of ligand-installed nanocarriers interacting with cells.
Adapted from [126].
Based on targeting ligands being employed for targeted therapy, four types of
representative targeting moieties has been categorized [126]: a) antibodies and antibody
fragments; b) aptamers; c) peptides or whole proteins; d) small molecules as receptor
ligands. Considering a scope of thesis, this dissertation is intended to focus on different
ways of delivering chemotherapeutic agents using peptide- or protein-nanoparticle
conjugates. Comparing to small molecules, peptides can be designed to fit into a shallow
and hydrophobic binding pocket with less challenge. Given that it generally consists less
than 50 residues, peptides demonstrate wide application due to the advantages in small
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size, stability, and simple synthesis and conjugation [132]. Besides, improving screening
techniques for faster ligand–substrate combinations identification has increased the use
of peptides as targeting moieties. RGD (arginine–glycine–aspartic acid) peptide family is
definitely the most prominent peptide ligand being investigated to target αvβ3 receptors
on cancer and angiogenic endothelial cells. To reduce the non-specific binding and
improve the targeting efficiency, Colombo et al. investigated that the cyclic RGD
conjugated tumor necrosis factor-alpha (TNF) showed more than 10-fold higher antitumor
efficiency than its linear counterpart. Such higher targeting efficiency for the cyclic RGD
might arise from its thermodynamically favored configuration and higher stability against
proteolysis [133]. Besides specifically targeting the biomarkers, peptides could facilitate
the penetrating of nanoparticles (NPs) across the cell membrane and into specific cell
organelles and eliciting cellular responses. These penetrating peptides usually contain a
specific C-terminal sequence, (R/K)XX(R/K) (e.g. LyP-1, iRGD, and F3 peptide) and are
capable of interacting with neurophilin-1 to facilitate the cell and tissue transportation [134136]. On top of that, peptides could stimulate the receptor as agonists or inhibit receptorinduced signaling as antagonists [137, 138], which might work synergistically in
combination with nonpeptidic cytotoxic drugs carried in the peptide-nano conjugates while
maintaining targeting effect. In spite of wide application, the limitation of peptide ligands
may include potential immune responses and influence on the pharmacokinetics [139].
Proteins or protein domains also hold great promise for the targeted delivery of NPs [140].
Due to the difficulty in engineering a full-length antibody with site-specific conjugation and
optimizing binding parameters, considerable effort has been fostered to developing
smaller binding units with antibody-like specificity and affinity. Transferrin (Tf), an 80-kDa
naturally occurring glycoprotein, is one of the most abundantly studied targeting proteins
with a high affinity to transferrin-receptor (Tf-R) [132]. NPs decorated with Tf have been
developed to target upregulated Tf-R on tumor cells and shown to substantially enhance
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the intracellular delivery and gene silencing efficacy of carried siRNA [141]. In addition,
synthetic proteins possess advantages over the naturally occurring proteins since they do
not have to compete against highly abundant, non-artificial proteins. Affibodies, a class of
polypeptide ligands, have been used to develop HER2 targeted paclitaxel-loaded
nanocarriers. Affibody-installed carriers demonstrated significantly higher uptake and
enhanced cytotoxicity over the nontargeted counterpart in HER2+ cell lines [142]. As listed
in Table 1, nanocarriers installed with ligands have been exploited to target cancer cells
in various tumors, including breast, ovarian, liver, and lung tumors.
Table 1. Ligand-installed nanocarriers in targeted tumor therapies. Adapted from [126].
Ligand
type

Proteins

Peptides

Targeting
ligands

Targets

Nanocarriers

Cargos

Tumor cells

Ref.

Transferrin

Transferrin receptor

Theranostic
nanoprobe

Indocyanin
e green

Hela cell

[143]

Transferrin

Transferrin receptor

NPs

Docetaxel

PC3-LN cell

[144]

Anti-EGFR
affibody

EGFR

Hydrogel
PRINT NPs

No drug

A431 cell

[145]

Ferritin

Transferrin receptor 1 (TfR1)

Ferritin NPs

Doxorubici
n

HT29 cell

[146]

K237 peptide

KDR receptor of tumor EC

Nanoparticle

Paclitaxel

HCT-15 cell

[147]

F3 peptide

Nucleolin protein expressed on
the surface of tumor endothelial
cells as well as on the surface
tumor cells

Hydrogel NPs

Cisplatin

A2780-GFP
cell, DsRED
HEY1 cell,
SKOV3 cell

[148]

Recombinant
murine
epidermal
growth factor

EGFR

NPs

Gemcitabin
e

MDA-MB468 cell

[149]

cRGD

αvβ3 integrin receptors

Micelles

Epirubicin

U87MG cell

[122]

Octreotide

Somatostatin receptors

Micelles

Paclitaxel

MCF-7 cell

[150]

Out of many limitations of traditional chemotherapy that can be remedied by NPs, the
most significant one remains increasing solubility and specificity of drugs with low
bioavailability. Being able to incorporate more than one type of drugs makes NPs
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prominent candidates for combination therapy. Table 2 lists some of the nanoformulation approved for use in clinics, specifically in oncology. Although liposome
remains the most popular construct in nanomedicine for clinical use, there are various
other nano-architectures being widely studied in bench-side for targeted anticancer
therapy, including metal NPs, biomimetic NPs, and polymeric NG.
Table 2. Nano-formulation for clinical application in cancer. Adapted from [151].
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1.3.1 Liposomes
Liposomes are artificially spherical vesicles consisting lipid bilayers and discrete aqueous
spaces, discovered by Alee Bangham in 1963 [152]. Owing to its special structure
properties, Liposomes are capable of incorporating hydrophilic drugs in its aqueous
spaces and hydrophobic drugs in lipid layers. However, the inefficient loading and rapid
release of amphiphilic drugs loaded via passive entrapment mitigate the therapeutic
efficacy of liposomes. To improve pharmacokinetics and stability of constructs, PEGylation
and inclusion of the highly saturated phospholipid and cholesterol is adopted for effective
drug delivery. In addition, stimuli-responsive smart liposomes (inducer: pH, temperature,
enzymes, magnetic field, ultrasound, and redox potential) could also be developed for
enhancing site-specific drug delivery. Active targeting of liposomes is achieved through
meticulous fabrication with selective ligand(s) [153]. For example, a cell-penetrating TAT
peptide moiety and cancer-specific monoclonal antibody (mAb) were installed on the
surface of liposomes to achieve targeted intracellular drug delivery. To further enhance
specificity, liposomes were shielded with a pH-detachable long PEG chain, which could
be removed at low pH (typical of solid tumors) to expose the TAT ligand for tumor cell
targeting. Such multifunctional immunoliposomal nanocarrier demonstrated enhanced
cellular association with tumor cells than normal cells as well as higher cytotoxicity when
pre-incubated at lower pH [154]. Showing tremendous potential as a carrier system for
therapeutically active agents, several targeted-liposomal formulations have been
designed and evaluated in clinical trials as listed in Table 3. EGFR-targeted Doxorubicin
liposomal formulations is an example of targeted liposomal delivery in clinical trials under
the name of C225-ILS-DOX. Phase I trial showed a good correlation between anticancer
efficacy and EGFR overexpression and the clinical Phase II trials are ongoing [155].
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1.3.2 Metallic NPs
Metallic NPs are nano-sized entities made of pure metals, including gold, platinum, silver,
and iron or their compounds (e.g., oxides, hydroxides, sulfides) [156]. Metallic NPs can be
adopted not only as carriers for therapeutic agents, but also as a diagnostic tool through
imaging. For example, iron NPs (major two types: superparamagnetic iron oxide (SPIO)
and ultra-small superparamagnetic iron oxide (USPIO)) have been used as theranostic
agents as contrasting agents for MRI and carriers for targeted drug delivery to the tumor
through magnetic guidance [157, 158]. Apart from magnetic drug delivery, SPIOs can also
be conjugated with ligands to target specific cells. Zhao et al. demonstrated that labeling
a C2 domain of synaptotagmin I (binding to the plasma membrane of apoptotic cells) with
SPIOs enabled the imaging of tumor cells which were undergoing apoptosis after
chemotherapy [159]. And when the formulation was given intravenously into mice, tumor
regions with large numbers of apoptotic cells could be observed due to the decreases in
MR image intensities. The magnetic NPs that have been approved by the FDA are listed
in Table 4. Another example of ligand-installed metallic NPs is described in a study
reported by Kirui et al that biofunctionalization of hybrid NPs (HNP) of gold and iron oxide
with tumor antigen specific antibodies resulted in a five times higher cellular uptake of
targeted HNP in antigen-expressing cells than normal cells. Besides, such multipurpose
agents also provide radiotherapy enhancement and thermal ablation [131].
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Table 3. Targeted liposomes currently in clinical trials. Adapted from [155].

Table 4. FDA-approved SPIOs [160]
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1.3.3 Biomimetic NPs
Biomimetic NPs are an emerging class of NPs that incorporate the functionality of
biological materials with the flexibility of artificial materials to mimic biofunctions and
achieve effective navigation in complex biological environment. NPs camouflaged in cell
membranes carried with imaging reporters and therapeutic cargo are the most
representative biomimetic platform. After the discovery of red blood cell (RBC) membranecoated poly (lactic-co-glycolic acid) (PLGA) NPs, such technology has significantly
expanded to the use of membranes from platelets as well as nucleated cells, such as
macrophages, neutrophils, and cancer cells. Cancer cell membrane coated NPs
(CCMCNPs) synthesized by coating NPs with a lipid bilayer of cancer cell membranes
(Figure 6) can carry tumor-specific receptors and antigens for cancer targeting. Such
targeting ability of CCMCNPs has been evaluated using PLGA NPs camouflaged with
human MDA-MB-435 cancer cell membrane, which demonstrated that CCMCNPs had a
much higher affinity with MDA-MB-435 cells compared to RBC-cloaked NPs and bare
PLGA cores [161]. The study also showed that such binding was specific to MDA-MB-435
cell indicated by the fact that MDA-MB-435 CCMCNPs exhibited only little increased
uptake compared to bare PLGA cores in the negative control cell line. Similar promiscuous
binding was observed in CCMCNPs derived from a variety of cancer cells including mouse
breast cancer 4T1 cells [162], human squamous carcinoma UM-SCC-7 cells [163], and
human breast cancer MDA-MB-231 [164]. In addition, CCMCNPs can be adopted as
effective drug delivery nanocarriers when the NP cores are loaded with chemotherapy
payloads. In a published study, NP coated with membranes of 4T1 mammary breast
cancer cells were loaded with paclitaxel (PTX). The coated NPs showed success
preservation of several membrane proteins responsible for cell adhesion and recognition.
The 4T1 CCMCNPs treated mice demonstrated selective accumulation of PTX in either
the primary tumors or the metastases in pulmonary tissues. The higher accumulation of
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drugs resulted in a remarkable antitumor and metastasis efficacy in both orthotopic and
advanced metastasis mice models [165]. However, neoantigens on tumor cell membranes
might help trigger recognition by immune cells and accelerate the clearance of NPs. A
study evaluated the pharmacokinetic profiles of CCMCNPs and uncoated NPs in
immunodeficient mice and reported that CCMCNPs were cleared from circulation much
faster than bare NPs. Authors believed that this shorter circulation time might arise from
the fact that membrane antigens presented on the CCMF-PLGA NPs may trigger tumorspecific immune responses and accelerate clearance resulting in significantly shorter
circulation time in the bloodstream [166]. Overall, such bioinspired platforms are still in
their infancy. Possible degradation of surface antigens in complex physiological
environments and potential adverse effects of immune response need to be addressed.
Besides, the mechanisms underlying the targeting and important characteristics need to
be further investigated and elucidated.

Figure 6. Schematic illustration of synthesis of CCMCNP. Adapted from [167].
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1.3.4 Nanogels
Nanogels (NGs) are nano-sized three-dimensional (3D) nonfluid hydrogel NPs made from
physically or chemically crosslinked swellable hydrophilic or amphiphilic polymer networks
with tunable size and uniformity, which can be composed of naturally occurring polymers,
synthetic polymers or a combination thereof [168, 169]. NGs are considered as soft
matters because the nanogel composition entails elastic moduli in the range of 0.1–100
kPa [170]. NGs offer a myriad of advantages for drug delivery, including: (i) their
characteristics such as size, charge, porosity, amphiphilicity, rigidity, and degradability can
be fine-tuned by adjusting the chemical composition [168, 171, 172]; (ii) they can
encapsulate a plethora of guest molecules with relatively high drug encapsulation capacity
and protect the cargo from degradation; (iii) they undergo physical or chemical changes,
including swelling, dissociation in response to stimuli (e.g. acidity, reducing agents, and
reactive oxygen species (ROS) ); (iv) they show site-specific and markedly increased drug
release at the site of action, boosting therapeutic effects of payload drugs and minimizing
off-target toxicities; (v) they are endowed with the ability to incorporate entities with very
different physical properties within the same carrier which is hard to find in other types of
nanoparticulate systems [173, 174]. Due to the great potential in chemotherapy, diagnosis,
and site-specific delivery of therapeutic active substances, NGs have emerged as an
appealing platform for targeted drug delivery in cancer therapy [175-178]. Ideal NG should
deliver payloads sufficiently to sites of action and be able to degrade without causing harm
to the healthy tissue of the body. However, no NGs are currently approved by the FDA for
in vivo use due to several constraints including the one mentioned above. There is scope
for more research in the area of development of better and translatable NG platforms.

31
1.3.4.1 Preparation and properties of polymeric NGs
Current approaches used for preparation of polymeric NGs can be categorized based on
two distinct crosslinking methods. The first crosslinking method utilizes covalent bonds to
afford robust chemical NGs. Chemical crosslinking points are formed between polymer
chains either during polymerization of low molecular weight monomers or after
polymerization illustrated in Figure 7 [179]. Developments in controlled radical
polymerization techniques have aided in the precision synthesis of robust polymeric
building blocks, such as block copolymers, to prepare NGs with diverse composition,
dimensions,

architectures,

and

functionalities

which

further

allows

multivalent

bioconjugation [180]. Other crosslinking approaches, including click reaction, thioldisulfide exchange, amide crosslinking, photo-induced crosslinking, enzyme-mediated
crosslinking etc., have been employed for the preparation of NGs from the polymer
precursors [168]. The second crosslinking method employs noncovalent interactions such
as ionic bonds, hydrogen bonds, and coordination bonds to make physical NGs which
tends to be fragile and collapses easily upon changes in the surrounding environment
[181]. One of the challenges in the formation of physical NGs lies in the control over the
particle size, which requires fine optimization of the polymer concentrations or
environmental parameters such as temperature, pH, and ionic strength [168]. Nielsen and
coworkers have reported that these challenges can be tackled by utilizing a microfluidicsbased approach [182]. Recently, NGs combined with properties of both chemical and
physical NGs have been developed with dynamic covalent bonds that can de-crosslink in
response to specific stimuli [179, 183].
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Figure 7. Two different synthetic methods toward NG. Adapted from [179].
To characterize the formed NGs, several parameters would be evaluated to confirm the
formation of objective NGs. In particular, size and polydispersity, swelling, drug loading
and release are important factors for understanding the properties of NGs. The sizes of
self-assembled NGs can be controlled by proper selection of the concentration of
polymers and external solution conditions, such as pH, electrolyte concentration, and
temperature [169]. Besides, adjusting the chemical composition such as the ratio between
hydrophilic and hydrophobic block lengths allows the control over the size as well as the
uniformity of NGs. Swelling of NGs in an aqueous environment is controlled not only by
external solution conditions, but also by nanogel structure (chemical composition,
percentage of crosslinking, charge density for polyelectrolyte gels) [177]. Bioactive agents
can be incorporated in NGs by (i) physical encapsulation, (ii) chemical conjugation, or (iii)
controlled self-assembly. Anionic polyethylene glycol-poly (methyl acrylate) (PEG-b-PMA)
NGs could encapsulate hydrophilic drug cisplatin through coordination interactions with
COOH functionalities [184]. Cisplatin-loaded NGs displayed sustained pH-sensitive
release of Pt(II) species that can be effectively modulated by changing the degree of
crosslinking of the crosslinked cores. The released platinum species preserved their
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activity and were able to trigger apoptotic cell death through forming Pt adducts with
nuclear DNA in the cancer cells. Developed NGs greatly improved drug therapeutic index
of cisplatin by improving pharmacokinetic profile, enhancing tumor delivery, boosting
antitumor efficacy, and reducing the cisplatin-mediated nephrotoxicity in a mouse model
of ovarian cancer [185]. When the same cisplatin-loaded NGs were installed with targeting
ligands (e.g., folate or LHRH peptide), tumor growth suppression was even further
enhanced [186, 187]. Polyelectrolyte NGs appears to be an appealing platform due to its
ability to incorporate small drug molecules with different physicochemical properties via
combinations of electrostatic and hydrophobic interactions as well as hydrogen bond
formation [169]. Fahmy and coworkers developed biodegradable core–shell NGs of drugcomplexed cyclodextrins and cytokine-encapsulating biodegradable polymers that can
deliver small hydrophobic molecular TGF-β inhibitor and water-soluble protein cytokine
(IL-2) in a sustained fashion to the tumor microenvironment [188]. They demonstrated that
he sustained local delivery of these agents, in combination, can induce localized
therapeutic immune responses while reducing the immune-resistant nature of the tumor
microenvironment. Simultaneous combination delivery showed synergistic therapeutic
effects due to the activation of the innate arm of the immune system which ultimately led
to delayed tumor growth and enhanced survival.
1.3.4.2 NGs as drug delivery systems
Generally, the reason for observing a relatively higher drug loading for hydrophilic NGs
than other nanocarriers such as polymeric micelles and liposomes is that there is a larger
cargo space and inner surface area for drug incorporation when NGs is swollen in aqueous
media [169]. Furthermore, the high loading in NGs can be achieved in relatively mild
conditions compared to other carriers, which is very important for the preservation of
biological activity of labile drugs and biomacromolecules, such as proteins and antibodies
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[189]. As highlighted in previous sections, what makes NGs stand out is that they are able
to immobilize desired ratios of multiple bioactive compounds differing in physical
properties within the same carrier to form stable colloidal dispersions at physiological pH
and ionic strength [190]. Such platform could tackle the challenges in dosing and
scheduling of drugs with varied pharmacokinetic and pharmacodynamic profiles. As
reported from our group, multicompartment polyelectrolyte NGs [191] prepared from
hybrid triblock copolymers poly(ethylene glycol)-block-poly(L-glutamic acid)-block-poly(Lphenylalanine) (PEG–b–PGlu–b–PPhe) have a central hydrophobic core formed by PPhe
regions, serving as a non-aqueous reservoir for solubilizing water-insoluble molecules
paclitaxel (9% wt.). Its crosslinked anionic layer of PGlu chains entraps hydrophilic
chemotherapeutic drug cisplatin with relatively high loading (15% wt.). NG with drug
combination exhibited synergistic cytotoxicity against human ovarian A2780 cancer cells
and exerted a superior antitumor activity in cancer xenograft models in vivo by comparison
to individual drug-loaded NGs or free drugs. The benefits of spatial–temporal
synchronization exposure of the platinum-taxane drug combination via a single carrier can
be further boosted by targeting NGs to the folate receptor, which are overexpressed in
most ovarian cancers [192]. In another study, our group reported an efficient coencapsulation of DOX and 17-allylaminodemethoxygeldanamycin (17-AAG) into PEG–
PGlu NGs with multiple hydrophobic regions that are located within the crosslinked anionic
PGlu core [193]. Dual drug-loaded NGs displayed selective synergistic anticancer activity
against HER2-overexpressing breast cancer cell lines. This synergistic effect was
attributed to the action of 17-AAG, HSP90 inhibitor, which induces degradation of many
of the proteins required for DNA-damage response as well as attenuation of oncogenic
signaling via degradation of HER2, thereby sensitize cancer cells to cytotoxic effects of
DOX. Consistent with the in vitro observations, combination treatment with NG exhibited
superior antitumor efficacy, both in terms of tumor inhibition and survival, in a HER2-driven
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xenograft model compared to the cocktail of free drugs at equivalent drug concentrations.
In another study, a polysaccharide-based cationic nanogel co-delivering oppositely
charged plasmid DNA along with phospholipaseA2 (PLA2) was developed [194]. As a
lipolytic enzyme, PLA2 catalyzes the hydrolysis of sn-2 ester bond into various different
phospholipids promoting membrane permeability. Upon entering the endosome after cell
uptake, PLA2 in NGs would function as an endosome escaping agent to disrupt the lipid
membrane, and subsequently trigger the release of the co-encapsulated DNA into the
cytoplasm. Transfection experiments confirmed that DNA expression level was enhanced
when complexed with PLA2. The ability of entrapping a considerable amount of payload
with different physical properties provides unprecedented opportunities for combination
therapy.
1.3.4.3 In vivo behaviors of NGs
Nanogel systems have the ability to stably encapsulate drug molecules without premature
leak and spatially localize the release of potent drugs only at target sites to ensure maximal
therapeutic efficacy with minimal side effects [175]. In order for a drug delivery device to
achieve these desired benefits it must be present in the circulation long enough to reach
or recognize its therapeutic site of action. To achieve this, NGs would have to overcome
various barriers depending on the administration routes. Generally, to prolong the
circulation time of cargo, NGs are designed to 1) avoid fast clearance especially in the
case of small molecules and 2) prevent rapid degradation or metabolism which is more
relevant for labile drugs and biomolecules [195]. However, opsonin proteins present in the
blood serum is one of the major obstacles to the realization of these goals due to the fact
that the binding between opsonin and conventional non-stealth NPs allows macrophages
of the mononuclear phagocytic system (MPS) to easily recognize and shuttle them out of
the bloodstream to liver, spleen or bone marrow within seconds of intravenous
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administration, rendering them ineffective as site-specific drug delivery devices [196, 197].
To address these challenges, several strategies have been developed to mask or
camouflage NGs from the MPS. Of these methods, the most preferred is the adsorption
or grafting of PEG to the surface of NGs [198]. The addition of PEG and PEG-containing
copolymers to the surface of NGs prolongs the blood circulation half-life of the particles
significantly. PEGylation of the nanogel surface imparts them with ‘stealth’ properties by
creating a hydrophilic protective layer on the surface, shielding a charge that the core
might carry and repelling the absorption of opsonin proteins through steric repulsion [195].
The overall shielding effect is highly dependent on the size of nanogel, its shape,
molecular weight and surface density of the PEG used [199]. Although this strategy
demonstrates success in increasing the blood circulation half-life and reducing MPS
uptake, it does not fully block the opsonization process, which eventually still occurs [200].
In addition, PEG is not completely inert, and the generation of PEG-specific IgM antibodies
after a single dose of PEGylated NPs might result in their accelerated blood clearance
and mitigate the therapeutic efficacy on subsequent dosing [201]. Apart from creating a
shielding layer, material mechanical properties should be considered in the critical design
to help NGs partially escape the splenic filtration process. Such properties are their
primary softness and deformability, which may be relevant in processes such as
phagocytosis or endocytosis [202]. For instance, erythrocytes can easily pass through the
splenic filtration bed in spite of having a size much larger than the pore size of filtration
bed, due to their flexibility and deformability [203, 204]. The biomimetic property of the
NGs shows advantageous for their in vivo application. Lyon and coworkers have recently
reported that soft spherical acrylamide-based microgel deforms and translocate through
cylindrical pores at least tenfold smaller than their hydrodynamic diameter under
hydrostatic pressure relevant to renal filtration [205]. Besides, varying Young modulus of
similar hydrogel NPs has been shown to affect the uptake rate, the mechanism of
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internalization and the concentration of internalized particles in macrophages [202].
Lowering the modulus of hydrogel particles could enable them to bypass in vivo physical
barriers that would otherwise filter particles with similar size but higher modulus [7].
Another study confirmed the advantages for in vivo application by showing that softer
PEG-based hydrogel NPs (10 kPa) offered enhanced circulation and subsequently
enhanced targeting compared to harder NPs (3000 kPa) in vivo. Furthermore, the in vitro
studies showed that softer NPs exhibit superiorly reduced cellular internalization in various
types of cells, including immune cells, endothelial cells, and cancer cells [206]. The
inclusion of electrolyte moieties into the polymer network of hydrogel particles to increase
the swelling ratio and secure cargos is another straightforward and quite efficient way to
decrease the modulus [7]. However, the distribution of charged groups on the surface of
a particle can accelerate the clearance of particles. To tackle this challenge, DeSimone
group designed an asymmetric particle containing a charged interior and a PEG-quenched
surface with near-neutral charge. The strategy was that acidic degradation of the
crosslinker allows for swelling of the particles to microgels with a desired size and
deformability while neutralized PEGylated surface could contribute to slowing the
clearance [7]. A fraction of NPs that are not cleared is then distributed into different organs
by the circulating blood. NPs are usually too big to pass through the tight junctions of the
normal endothelium but can efficiently extravasate from tumor blood vessels and
accumulate in solid tumors or site of infection/inflammation that have unique structural
features such as defective vascular architecture and meager lymphatic drainage leading
to the well-characterized enhanced permeability and retention effect (EPR) discovered by
Maeda and Matsumura [207]. However, targeting of tumor tissues solely through the EPR
effect has significant limitations for precision therapy due to its heterogeneity. For instance,
variations of EPR effects were observed between the cancer types, between patients with
the same tumors, between different tumoral lesions within the same patient, and even
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within the same tumor mass [208]. Installing ligands onto the surface of nanocarriers with
strong binding affinity to unique cellular markers on the target cell provides a strategy to
enhance targeting and internalization of nanocarriers by the target cell regardless of EPR
phenotype. As highlighted, numerous targeting ligands have been identified and employed
for targeting, including antibodies, proteins, peptides, and small molecules [126]. After
extravasation from the vasculature, NPs have to diffuse through the extracellular matrix in
the interstitial spaces, reach the targeted cells and exerts its action [209]. Increasing
evidence indicates that cellular uptake and intracellular fate of NPs are strongly influenced
by size, shape, softness, charge and surface properties, cell types and receptor being
targeted [210]. When nanoparticles reach the exterior cell membrane, they mainly enter
the cell through endocytosis which is a complex process classified into several types [211].
In general, endocytosis eventually leads to the engulfment of particles into intracellular
vesicles, from where they are transported into endosomes and ultimately lysosomes. At
each of these stages, NPs are exposed to changing pH of endosomal/lysosomal lumen,
degrading enzymes, or reducing environment, which are often utilized as stimuli for the
release of cargo carried within the NPs [9]. Nanogel carriers can also be designed to target
specific subcellular domains or escape them, depending on the type of cargo that they
carry. For example, it is essential for the NPs to facilitate endosomal/lysosomal
destabilization so that the encapsulated siRNA or oligonucleotides can be released in their
active form in the cytoplasm where they are supposed to exert their therapeutic action [11].
pH-sensitive NGs have shown significantly enhanced endosomal escape. NGs
constructed from polyelectrolytes are thought to be able to disrupt endosomes due to the
buffering-mediated sponge effect [212]. An increased effort has been devoted to
developing NGs that can release bioactive agents in response to external stimuli at the
disease site. It is also crucial to create biodegradable NPs to minimize toxicities associated
with the retention of the carrier in the body.
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1.4 Conclusions
Combination therapy shows confirmed advantages over treatment with single agents to
combat most cancers for its ability to target multiple oncogenic pathways at the same time,
delay the development of resistance, prolong the survival, and eventually enhance the
therapeutic outcome. Cisplatin (CDDP)-based chemotherapy has been the front-line
treatment for ovarian cancer since its discovery. However frequent relapse and onset of
resistance indicate that new strategic approaches are needed to enhance the outcome.
Despite high response rate to the standard therapy, frequently relapse and become
increasingly less sensitive to chemotherapy. EGFR is a viable target as aberrant
overexpression of EGFR is reported in up to 60% of malignant ovarian tissue. EGFR
actively participates in regulating several oncogenic signal transductions promoting cell
survival and proliferation. Monotherapy using EGFR inhibitors has shown limited benefits,
so it is generally given together with other chemotherapy. Combining EGFR inhibition with
cisplatin has shown strong synergistic effects in several cancers in both preclinical and
clinical studies. NRT, an FDA-approved potent irreversible pan-HER inhibitor, is proposed
here to be combined with cisplatin for treating ovarian cancer. However, the synergy of
such therapy is often sequence and dose ratio specific. Besides, administrating two
distinct drugs might require repeated dosing and prolonged duration of drug infusion in
patients. Moreover, conventional Pt-based chemotherapy generally comes with rapid
elimination and severe dose-limiting toxicities including neurotoxicity and nephrotoxicity.
Combining such drugs in one delivery carrier is therefore a desirable and convenient
strategy for controlling the pharmacokinetics and co-delivery of the desired drug ratio in
vivo, to maximize the therapeutic efficacy and minimize drug-associated toxicities.
Crosslinked polypeptide-based nanogel is an appealing platform to achieve this goal.
Such biodegradable platform provides flexibility in adjusting size, loading capacity, surface
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properties, deformability, softness, and responsive behaviors by tuning the chemical
compositions as well as crosslinking levels. Enhanced stability due to the crosslinking
adds benefits to prolonging the circulation, which in term enhances drug exposure to tumor
by EPR effect. Their mild preparation procedures allow the incorporation of labile drug
molecules and biomacromolecules. The most prominent advantage over other nano-sized
carriers is their ability to incorporate molecules with different physicochemical properties
through versatile interactions. For the purpose of the current study, NGs prepared from
copolymers

poly

(ethylene

glycol)-block-poly

(L-glutamic

acid)

modified

with

phenylalanine functionalities ((PEG-P(Glu-Glu/Phe)x)150) for simultaneous loading and
delivery of binary CDDP and NRT combination were developed. Such core-shell NGs
have 1) a hydrophilic PEG stealth shell for less RES uptake and extended circulation, 2)
an anionic core, which incorporates CDDP through coordination with the carboxylic groups
of PGlu, 3) hydrophobic regions formed by Phe moieties, which serves as a reservoir for
NRT solubilization. The crosslinks incorporated into PGlu core keep NGs stable until they
are degraded by proteases through cleaving the polypeptide chains of the block
copolymers. The developed binary drug NGs formulation showed synergy in EGFR
overexpressed cell lines from not only ovarian cancer, but also triple negative breast
cancers, while such synergy was not seen in cell lines with low EGFR overexpression.
Such drug delivery systems also showed desirable antitumor efficacy in intraperitoneal
ovarian cancer mouse model with no observable toxicities while certain toxicities were
observed in tumor bearing mice treated with free drugs at the same dose. However, this
system solely depends on EPR effect which is limited by heterogeneity among tumor mass
as well as vascular density nearby influencing the permeability of nanocarriers. Installing
targeting ligands on the surface of carriers to specifically target biomarkers overexpressed
on the surface of tumor cells is a well-suited strategy to overcome mentioned limitation
and further boosting drug performance. Two targeting ligands aiming to bind with EGFR

41
was chosen in our study: L-AE peptide and EGFR-A protein. Both ligands are relatively
new with reported high binding specificity and affinity to EGFR with acceptable stability.
Ligand installed carrier demonstrated success in increasing cellular uptake and further
boosting the therapeutic efficacy of targeted binary combination NGs in vivo. We also
confirmed the importance of simultaneous administration of the (CDDP+NRT) via a single
NGs system which provides more therapeutic benefits than a cocktail of individual drugloaded NGs administered at equivalent doses.
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CHAPTER II.

POLYMERIC NANOGELS FOR COMBINATION DRUG THERAPY
IN TRIPLE NEGATIVE BREAST CANCER

Introduction
Breast cancer represents the second leading cause of death in women after lung cancer
and it is the most commonly occurring cancer among females globally [1]. Triple-negative
breast cancer (TNBC) accounts for 12-20% of human breast cancers, referring to the
breast cancer phenotype diagnosed pathologically by < 1% expression of Human
Epidermal Receptor 2 (HER2), estrogen (ER) and progesterone receptor (PgR) [2-4].
Despite optimal systemic chemotherapy, less than 30% of women with metastatic breast
cancer survive 5 years after diagnosis, and almost all women with metastatic TNBC will
eventually die of their disease. Currently, cytotoxic chemotherapy, such as anthracycline,
gemcitabine and carboplatin, remains the standard established systemic treatment of
TNBC showing significant benefits in either neoadjuvant or adjuvant setting [5]. Although
TNBC patients have a higher response to systemic chemotherapy than those with nonTNBC, 5-year survival rate is still less than 30% and virtually all women with metastatic
TNBC would die of this disease eventually [6].The limited efficacy could arise from altered
signaling patterns in cancer cells leading to modulated effects of treatment, such as
activation of pro-survival signal transduction (e.g., epidermal growth factor receptor
(EGFR), AKT, PI3-kinase) and damage repair, etc. Many clinical trials have been studied
to apply combination chemotherapy regimens to reduce these undesired effects and
enhance the survival of patients. It would be desirable to manage patients through taking
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both factors into consideration: the current clinical practices and the molecular complexity
of TNBC [5]. EGFR are transmembrane glycoproteins belonging to the HER family of
receptor tyrosine kinases (RTK), which actively participates in sustaining the growth and
the survival of carcinoma cells as well as the pathogenesis and progression of different
carcinoma types [7]. Up to 78% of TNBC have the EGFR overexpression [8] making it a
potential therapeutic target for intervention. EGFR inhibitors work synergistically with
standard chemotherapy by blocking oncogenic signal transduction and reducing the
unfavored pro-survival signals induced by those chemotherapies which has been shown
in several studies [9-11], further increasing the sensitivity of cancer cells to the designed
regimen and enhancing the clinical benefits. A major breakthrough of targeting EGFR in
TNBC was that in a phase III study, the BALI trial demonstrated 20% overall response rate
in patients with metastatic TNBC who received the cetuximab (anti-EGFR monoclonal
antibody) / cisplatin combination, compared with 10.3% response rate in the cisplatin‒
alone group [12]. However, the response rate for this combination treatment was
considered low which can arise from the fact that inhibiting EGFR might trigger
underappreciated resistance and induce activation of parallel signaling pathways and
downstream signaling pathways through other members of HER family [13]. In another
clinical study, TNBC patients treated with weekly DNA-damaging agents, with or without
neratinib (a pan-HER inhibitor), showed 37.5% overall pCR in the neratinib arm, but
among patients demonstrating phosphorylation of HER2 or EGFR, it rose to 63% which
implies clinical benefits might be achieved when applying this strategy to subsets with
EGFR or HER2 activation [14]. Altogether, it is rational to propose here that combining
neratinib, a pan-HER inhibitor, and cisplatin, a potent DNA-damaging chemotherapeutic
drug, to combat EGFR-overexpressing triple negative breast cancer could enhance the
therapeutic response to the standard cytotoxic treatment by targeting multiple cell-survival
pathways.

59
However, the synergy of such therapy is often sequence and dose ratio specific. Besides,
administrating two distinct drugs might require repeated dosing and prolonged duration of
drug infusion in patients. Moreover, conventional Pt-based chemotherapy generally
comes with rapid elimination and severe dose-limiting toxicities including neurotoxicity and
nephrotoxicity. Combining such drugs in one delivery carrier is therefore a desirable and
convenient strategy for controlling the pharmacokinetics and co-delivery of the desired
drug ratio in vivo, to maximize the therapeutic efficacy and minimize drug-associated
toxicities. Crosslinked polypeptide-based nanogel is an appealing platform to achieve this
goal. The most prominent advantage over other nano-sized carriers is their ability to
incorporate molecules with different physicochemical properties through versatile
interactions. For the purpose of the current study, nanogels (NGs) prepared from
crosslinked poly (ethylene glycol)-block-poly (L-glutamic acid) modified with phenylalanine
functionalities (PEG-P(Glu-Glu/Phe)) were developed for simultaneous loading and
delivery of binary CDDP and NRT combination. Such NGs have 1) a hydrophilic PEG shell
for less RES uptake and extended circulation, 2) an anionic crosslinked core, which
incorporates CDDP through coordination with the carboxylic groups of PGlu, 3)
hydrophobic regions formed by Phe moieties, which serves as a reservoir for NRT
solubilization. To maximize the synergistic therapeutic effects, the cargo ratio was tuned
by adjusting the ratio of constituent hydrophilic PGlu units and hydrophobic Phe moieties
in copolymer chains. The developed binary drug NGs formulation showed synergy in
EGFR overexpressed TNBC cell lines, while such synergy was not seen in cell lines with
low EGFR overexpression. Such NGs also demonstrated preferable retention in tumor
cells while less was seen in the fibroblasts in a multicellular tumor spheroids model
containing both cell types.
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Materials and methods
2.2.1 Materials
Poly (ethylene glycol)-b-poly (L-glutamic acid) (PEG-b-PGlu) diblock copolymer
(Mw/Mn=1.01, MW 28,000 g mol-1) was purchased from Alamanda Polymers, Inc. (Madison,
AL, USA). The block lengths were 114 and 150 repeating units for PEG and PGlu,
respectively.

L-phenylalanine

methyl

ester

hydrochloride

(Phe),

1-(3-

dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC), ethylenediamine and
other chemicals were obtained from Sigma-Aldrich (St Louis, MO) and were used without
further purification. Fetal bovine serum (FBS) was purchased from Invitrogen Inc.
(Carlsbad, CA). HyClone™ Minimum Essential Medium with alpha modification, EGF
Recombinant Human Protein, Pierce™ BCA protein assay kit, CellBrite™ Blue and
CellBrite™ Green for cell membrane staining was purchased from Thermo Fisher
Scientific (Waltham, MA). CellTiter-Blue® reagent was purchased from Promega
(Madison, WI). MammoCult™ human medium kit was purchased from STEMCELL
Technologies (Cambridge, MA). Cyanine 5 (Cy5) amine was obtained from Lumiprobe
(Hallandale Beach, FL). Cell lysis buffer and protease inhibitor cocktail were purchased
from Cell Signaling Technology (Danvers, MA). The following primary antibodies were
used in this study: Rabbit anti-EGFR (ab52894) mAb, rabbit anti-phospho-EGFR
(phospho Y1068) (ab40815) mAb, rat anti-HSC70 (ab19136) mAb, mouse anti-beta actin
(ab8226) mAb used for Western blotting studies, were purchased from Abcam™
(Cambridge, MA); the rabbit anti-Phospho-Akt (D9E) mAb, rabbit anti-phospho-p44/42
MAPK (Erk1/2) (4370T) mAb, rabbit anti-Cyclin D1 (92G2) mAb was kindly provided by
Dr. Surinder K. Batra (University of Nebraska Medical Center, Omaha, NE).
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2.2.2 Synthesis of NGs
NGs were prepared using a diblock copolymer, PEG-PGlu150, in which part of the Glu units
were modified with hydrophobic Phe functionalities via polymer-analogous modification of
the PGlu segment with the Phe methyl ester using carbodiimide-chemistry in aqueous
media. The targeted degree of modification was set at 25, 50, and 75 Phe units per chain,
respectively. The obtained products were characterized by proton nuclear magnetic
resonance (1H NMR). Micellar precursors based on PEG-P(Glu-Glu/Phex)150 copolymers
were prepared by dialysis method using water/organic solvent mixtures followed by direct
crosslinking of COOH groups of Glu units with 1,2-ethylenediamine (ED) in the presence
of EDC at r.t.. The crosslinking reactions were performed at a molar ratio of
[COOH]/[EDC]/[ED]=10/2/1 to obtain a targeted 20% crosslinking degree. The prepared
nanogel was abbreviated as NGs (further denotes as rNGx/150). To prepare Cy5 labeled
NGs for evaluating penetration in multicellular tumor spheroids, Cy5 amine (0.5 w/w%)
was conjugated to cores of NGs using EDC chemistry.
2.2.3 Drug loading
NGs based on PEG-P(Glu-Glu/Phex)150 copolymers were used to prepare neratinib (NRT)
and cisplatin (CDDP) drug formulations. The primary procedure for loading of NRT in NGs
involved the addition of NRT dissolved in ethanol to the aqueous dispersion of NGs upon
stirring followed by evaporation of organic solvent and removal of unbound NRT. Then
CDDP was loaded through incubation with aqueous dispersions of NRT-loaded NGs for
48h at pH 9 followed by centrifugation to remove unbound CDDP. The amount of CDDP
incorporated into NGs was assayed by inductively coupled plasma mass spectrometry
(ICP-MS, NexION 300Q, PerkinElmer, Waltham, MA). NRT content was assayed by
HPLC under isocratic conditions using an Agilent 1200 HPLC system with a diode array
detector set at 266nm. As the stationary phase a Nucleosil C18 column was used (250
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mm × 4mm), and a mobile phase of acetonitrile+0.1%TEA/water +0.1%TEA mixture
(80/20,v/v) was applied at a flow rate of 1ml/min with a column temperature of 40°C. NGs
can entrap considerable amounts of CDDP and NRT, respectively.
2.2.4 Physicochemical characterization of the NGs
The 1H NMR spectra for the copolymers were acquired in TFA-d1 at 25 °C using a Bruker
500 MHz spectrometer. Effective hydrodynamic diameters (Deff) and ζ-potential of NGs
were determined by dynamic light scattering (DLS) using a Zetasizer Nano ZS (Malvern
Instruments Ltd., Malvern, UK). All measurements were performed in automatic mode at
25°C. Software provided by the manufacturer was used to calculate the size,
polydispersity indices (PDI), and ζ-potential of NGs. All measurements were performed at
least in triplicate to calculate mean values ± SD. Swelling behavior of NGs in aqueous
dispersion was evaluated through recording the Deff and ζ-potential upon pH variation
between pH 6-9 using a Zetasizer Nano ZS.
2.2.5 Drug release
Drug release from the NGs was examined in PBS (pH 7.4), and acetate buffered saline
(ABS, pH 5.5, 0.14 M NaCl) at 37°C by dialysis method using a membrane with 3,500 Da
cutoff. Both media contained 10% FBS. The concentrations of NRT and Pt(II) released
were determined by HPLC and inductively coupled plasma mass spectrometry (ICP-MS),
respectively, and expressed as a percentage of the total NRT or Pt(II) available vs. time.
2.2.6 Cell culture and cytotoxicity studies
MDA-MB-468 human TNBC cells were provided by Dr. Hamid Band (University of
Nebraska Medical Center, NE). Cells were maintained in alpha-MEM medium
supplemented with 10% (v/v) FBS in the presence of penicillin and streptomycin (100 U/ml
and 0.1 mg/ml, respectively) at 37°C in a humidified atmosphere containing 5% CO2. Cells
were harvested with trypsin-EDTA (0.25%) (Life Technologies) after 80% confluence.
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Cells seeded in 96-well plates (3,000 cells/well) 24 h prior the experiment were exposed
to various doses (0-10 μg/mL on CDDP or NRT basis) of CDDP alone, free binary drugs,
CDDP/NG, NRT/NG, a cocktail of individual-drug-loaded NGs and (CDDP+NRT)NGs for
72 h at 37°C. Cytotoxicity of either free drugs or drug-loaded NGs was assessed by a
standard CellTiter-Blue® cell viability assay [15] with untreated cells served as 100% cell
viability. The IC50 values were calculated using GraphPad Prism software. The
combination index (CI) analysis based on Chou and Talalay method [16] was performed
using CompuSyn software for CDDP and NRT combinations, determining synergistic,
additive, or antagonistic cytotoxic effects against MDA-MB-468 TNBC cells. Values of CI
< 1 demonstrate synergism while CI = 1 and CI > 1 values represent additive and
antagonistic effects of the drug combination, respectively. Cytotoxicity against TNBC cells
with low EGFR expression was conducted on MDA-MB-453 and MDA-MB-231 following
the similar protocol mentioned above.
2.2.7 Western blot analysis
Cells were treated with either EGF, EGF + CDDP, EGF + NRT, or EGF + CDDP + NRT
for 2h at a concentration of 100 ng/mL EGF, 10 µM/mL CDDP, and 5 µM/mL NRT. Cells
were then lysed with cell lysis buffer supplemented with protease inhibitor cocktail.
Supernatants were collected after removing cell debris by centrifugation (14,000 g for 20
min), and the protein amount was determined by BCA assay. 5–10 μg of proteins were
separated by 8% sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDSPAGE), transferred to polyvinylidene difluoride (PVDF) membranes (Millipore,
Massachusetts). Non-specific protein binding was blocked in Tris-buffered saline Tween20 (TBS-T) (50 mM Tris–HCl, 150 mM NaCl, 0.1% Tween 20, pH 7.6) containing 5% dry
milk for 30 mins at 37oC. Proteins of interest were immunoblotted with the appropriate
monoclonal antibodies used at 1:1000 to 1:10000 dilutions at 4°C overnight followed by
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the secondary horseradish peroxide-conjugated antibodies used at 1:1000 dilutions at r.t.
for 1 hour. Antibody interactions were visualized with enhanced chemiluminescence (ECL)
horseradish peroxidase (HRP) substrate (Thermo fisher scientific, Massachusetts) using
iBright Western Blot Imaging Systems (Invitrogen). HSC70 and β-actin has been used as
a loading control. Band intensities were analyzed by ImageJ software.
2.2.8 Penetration in tumor spheroids
A suitable 3D composite spheroid model was created using a mixture of the mouse
embryonic NIH 3T3 fibroblasts and MDA-MB-468 TNBC cells. Multicellular spheroids were
generated using the forced-floating method: 500 cells (MDA-MB-468: 3T3=1:1) were
seeded in ultra-low attachment 96-well plates in the presence of MammoCult® medium
and incubated at 37°C for 6 days. On day 6, the spheroid morphology was recorded by
an inverted microscope. MDA-MB-468/NIH 3T3 spheroids were further used for
assessment of penetration of rNGx/150 NGs. Cy-5-labeled rNGx/150 (0.5 mg/mL) were
incubated with 6-day old MDA-MB-468/NIH 3T3 spheroids for various periods of time (2,
4, and 8 h). After the treatment, spheroids were washed with PBS ( 3 gentle washes)
followed with fixing by 4% formaldehyde solution in PBS for 20 mins at r.t. . Then the
spheroids were transferred to the Lab-Tek® chambered coverglass (NUNC, NY), and
stained by 4’,6-diamidino-2-phenylindole (DAPI, Thermo Fisher Scientific, MA) overnight.
Overall distribution and penetration of NGs within spheroids were analyzed by confocal
microscopy using Z-stack imaging with 10 µm intervals and presented as maximum pixel
intensity Z-projections. To further get insight into the cellular composition of co-culture
MDA-MB-468/NIH 3T3 spheroids, MDA-MB-468 cells were transfected with F-Luc-GFP
Lentivirus (Capital Biosciences, Rockville, MD) which is a lentivirus engineered to
constitutively express the green fluorescent protein. Spheroid formation was continuously
monitored using Nikon Eclipse E400 microscope. On day 1,3 and 6, spheroids were
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dissociated using Accutase (STEMCELL Technologies, MA) and cell composition was
quantified by flow cytometry analysis. The % of gated cells were analyzed using BD
Biosciences LSR II flow cytometer and FACSDiva software (BD Biosciences, San Jose,
CA). At least 10,000 events were acquired in linear mode, gated to exclude debris and
dead cells, and visualized in logarithmic mode. The cellular uptake of rNG50/150 in co-culture
MDA-MB-468(GFP+)/NIH 3T3 spheroids was further evaluated. On day 6, 48 MDA-MB468(GFP+)/NIH 3T3 spheroids were incubated with Cy5-labeled rNG50/150 (0.5mg/mL) for
4 hours followed by flow cytometry analysis.
2.2.9 Statistical analysis
Each sample was analyzed based on results that were repeated at least three times.
Statistical comparisons were carried out using GraphPad Prism 5 software (GraphPad
Software, Inc.). In all cases, differences at P < 0.05 were regarded as statistically
significant; ones at P < 0.01 or P < 0.001 were considered higher statistical significances.
Results and discussion
2.3.1 Synthesis of polymer PEG-P(Glu-Glu/Phex)150
To drive the self-assembly of hydrophilic copolymer PEG-PGlu, hydrophobically modified
PEG-b-PGlu derivatives were synthesized via EDC amidation mediated modification of
PGlu backbone with L-phenylalanine methyl ester (Phe) moieties. The synthesis of the
amphiphilic hybrid polypeptide-based polymer PEG-P(Glu-Glu/Phex)150 is illustrated in
Scheme 8.
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Figure 8. Scheme for the synthesis of PEG-P(Glu-Glu/Phex)150 polymer via
carbodiimide-chemistry.
PEG-b-PGlu diblock copolymer (PEG Mw = 5,000 g mol-1), in which different percentages
of Glu units were modified with hydrophobic phenylalanine moieties, were utilized for the
synthesis of biodegradable NGs. The Phe grafting degree was varied by adjusting the
feed molar ratio of the reaction components, PEG-PGlu:Phe (1:27.5, 1:55, 1:82.5).
Followed by the purification of polymers via dialysis against the water using a membrane
with 3,500 Da cutoff for 48 hrs, the chemical composition of three resulting PEG-P(GluGlu/Phex)150 copolymers was determined by 1H NMR analysis (Figure 9) using the peak
intensity ratios of the methylene protons of PEG and the methyl protons of the ester of Lphenylalanine (500 MHz in TFA-d1: δ =3.86 (s, 4H, -OCH2CH2-), 3.8 (s, 3H, -CH3)). These
copolymers had a constant PEG block (114 repeating units), identical anionic PGlu block
(about 150 repeating units), and they were differed in the amount of Phe hydrophobic
moieties (26, 51, and 75 units) functionalized to the backbone. They are further denoted
as rNG25/150, rNG50/150, and rNG75/150, respectively. The characteristics of synthesized PEGP(Glu-Glu/Phex)150 copolymers are summarized in Table 5.
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Figure 9. 1H NMR spectrum for PEG-P(Glu-Glu/Phex)150 (TFA-d1, 298K).
Notes: peak assignments are as follows: PEG-P(Glu-Glu/Phex)150 1H NMR (TFA-d1): δ
ppm= 2.07 (2H, m, -CH2-), 2.55 (2H, s, -CH2-), 3.06 (2H, m, -CH2-), 3.80 (3H, s, -CH3),
3.85 (2H, s, -CH2-), 4.55 (1H, s, -CH-), 4.77 (1H, m, -CH-), 4.94 (1H, m, -CH-); 7.20 (5H,
m, C6H5)
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Table 5. Characteristics of the PEG-P(Glu-Glu/Phex)150 copolymers.
Polymer

Feed molar ratio (mmol)

Repeating Units Ratio*

Mn* (g/mol)

PEG-b-PGlu150

Phe

PEG

PGlu

Phe

PEG-P(Glu-Glu/Phe25)150

1

27.5

114

150

26

32191

PEG-P(Glu-Glu/Phe50)150

1

55

114

150

51

36221

PEG-P(Glu-Glu/Phe75)150

1

82.5

114

150

75

40093

*Calculated from 1H NMR spectrum.

2.3.2

Synthesis of NGs

The amphiphilic nature of resulting copolymers was anticipated to drive the formation of
micellar particles in aqueous medium due to the incorporation of hydrophobic Phe
moieties. After the polymer synthesis, polymeric micelles were then prepared by mixing
the solution of the copolymer in dimethylformamide with water (1: 1 v/v) following the
dialysis against water for 48 h. Indeed, the formation of small particles with relatively
narrow particle size distribution (PDI < 0.2) and the net negative charge was detected in
aqueous solutions for all three types of copolymers (Table 6). However, the formed
micellar structures were not stable against pH change. When pH was increased to
physiological pH, these micelles could not maintain structural integrity indicated by sharply
increased particle size distributions. To solve this issue, PEG-P(Glu-Glu/Phex)150 were
further crosslinked to form NGs. The crosslinking of the PEG-P(Glu-Glu/Phex)150 was
achieved via condensation reactions between the carboxylic groups of PGlu segments
and the amine groups of ethylenediamine in the presence of a water-soluble carbodiimide,
EDC. The targeted extent of crosslinking (20%) was controlled by the molar ratio of
crosslinker to carboxylic acid groups of the glutamic acid residues. The size of the nanogel
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dispersion was similar to that of the precursor micelles at the same pH, confirming that the
micelles retained their integrity and that no observable intermicellar fusion can be
detected. After exhaustive dialysis against water, NGs were characterized at pH 7 (Table
7). The resulting NGs are uniform and possess a net negative charge. Furthermore, the
prepared NGs retained the structural integrity and relatively small particle size distribution
(PDI <0.2) when pH increased up to 9.
Table 6. Physicochemical characteristics of micelles based on PEG-P(Glu-Glu/Phex)150
copolymers at pH 5.5
Polymers

Deff (nm)

PDI

PEG-P(Glu-Glu/Phe25)150

84 ± 3

0.12

PEG-P(Glu-Glu/Phe50)150

64 ± 2

0.12

PEG-P(Glu-Glu/Phe75)150

52 ± 3

0.17

Effective hydrodynamic diameters (Deff) and polydispersity index (PDI) were determined
by DLS (water, pH 5.5, 25oC). Data are presented as average ± SD from three
experiments.

Table 7. Physicochemical characteristics of NGs based on PEG-P(Glu-Glu/Phex)150
copolymers at pH 7
Deff (nm)

PDI

ζ-potential, mV

rNG25/150

119 ± 1

0.11

-29.3 ± 2.1

rNG50/150

83 ± 1

0.10

-21.2 ± 1.0

rNG75/150

63 ± 2

0.14

-15.0 ± 1.4

Effective hydrodynamic diameters (Deff), polydispersity index (PDI), and ζ-potential were
determined by DLS (water, pH 7, 25oC). Data are presented as average ± SD from three
experiments.
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The NGs investigated here are composed of poly(L-glutamic acid), a weak polyelectrolyte
(pKa 4.4). Since ionization degree of PGlu increased at higher pH, dissociation of the
glutamic acid carboxylic groups within the NGs induced intramolecular electrostatic
repulsions and, thus, caused the overall swelling of the nanogel particles. Furthermore,
PGlu chains was reported to undergo a coil-to-helix transition at pH around the pK(a) [17]
and these conformational changes can also influence the swelling behavior of NGs
containing PGlu block. The pH-induced dimensional changes of the prepared three types
of NGs were studied by DLS and electrophoretic mobility measurements, and the results
are presented in Figure 10. A decrease of hydrodynamic diameter with a concomitant
increase in negative ζ-potential was observed upon the decrease of pH for all three types
of NGs. Reduced electrostatic repulsions and transition to an ordered conformation upon
protonation of carboxylic acid of the crosslinked PGlu chains led to the collapse of the
PGlu network resulting in the shrink of constructs and increase in ζ-potential. However, a
sharper change in terms of size and ζ-potential was observed for NGs with less fraction
of Phe units in the cores. NGs with higher number of Phe moieties would be anticipated
to demonstrate less polyelectrolyte behavior leading to less swelling ability. The observed
changes were reversible and the particle size distribution of NGs remained relatively
narrow (PDI <0.2).
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Figure 10. Swelling behavior of rNG25/150, rNG50/150, and rNG75/150 represented by the
change of the effective diameter, Deff (left) and ζ-potential (right) of NGs upon pH change.
Data are presented as average ± SD from three experiments

2.3.3 Drug loading and release profile of loaded drugs
PEG-P(Glu-Glu/Phex)150 NGs have a well-defined structure with a swollen crosslinked
polyelectrolyte network functionalized with hydrophobic Phe moieties and external PEG
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shell surrounding the network. Each of these three nanoregions contributes to the function
of NGs as drug nanocarriers. Phe regions function as a reservoir to encapsulate waterinsoluble molecules. PGlu ionic network can incorporate hydrophilic drug molecules
through electrostatic interaction or covalent bonding while PEG shell stabilizing NGs in
dispersion also minimize the recognition and uptake of the NGs by RES system.
Therefore, such NGs have the potential to simultaneously incorporate and deliver multiple
chemotherapeutic drugs with very different physical properties and mechanisms of actions
via single nanocarrier in an effort to achieve a synergistic effect and improve the treatment
outcome. In the present study NGs with a binary drug combination of hydrophilic CDDP
and hydrophobic NRT were prepared. At first, NRT was solubilized into the Phe regions
using an extraction method. According to this method, NRT-loaded NGs were prepared
by adding ethanol solution of NRT (2 mg/mL) dropwise into the aqueous dispersion of
NGs (1 mg/mL) upon agitation and the mixture was then stirred at r.t. overnight in an openair system to allow slow evaporation of ethanol. The residual ethanol was then removed
at reduced pressure. Unincorporated NRT was removed by ﬁltration using 0.8 μm syringe
ﬁlters (Thermo Scientiﬁc). Under these conditions NRT loading capacity (the net amount
of drug loaded into a carrier) varied from 5 to 12 w/w% weight as was quantified by HPLC.
The resulting nanoparticles (NPs) had an average hydrodynamic diameter from 76 to 135
nm and were characterized by narrow particle size distributions as determined by DLS.
The size of the NRT-loaded NGs was slightly increased compared to those of empty NGs,
while ζ-potential remained comparable indicating that the NRT incorporation into Phe
regions did not induce substantial structural rearrangement and significantly affected the
macroscopic characteristics of the pre-formed NGs. As the next step, CDDP was loaded
into NGs via coordination binding of CDDP with COOH groups of the PGlu units. To this
end, the aqueous dispersions of NRT-loaded NGs were incubated with CDDP for 48 h at
pH 9.0 at a 1 : 4 molar ratio of CDDP to carboxylate groups of NG [18]. Such conditions
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were chosen to maximize the swelling of the polyelectrolyte network, completely ionize
carboxylic groups of the NGs and endow higher accessibility of the carboxylate groups to
CDDP. Unbound CDDP was then removed by ultrafiltration using Amicon® Ultra-15
centrifugal filter units (MWCO 3,000 Da, Millipore). As expected, the net negative charge
and particle size of NGs decreased upon CDDP loading consistent with neutralization of
PGlu segments by CDDP and collapse of PGlu network (Table 8).

Table 8. Physicochemical characteristics of NGs before and after drug loading.
Samples

pH 7

LC*, w/w%

Deff, nm

PDI

ζ-potential, mV

CDDP

rNG25/150

119 ± 1

0.11

-29.3 ± 2.1

NRT/rNG25/150

135 ± 3

0.20

-24.9 ± 1.9

CDDP/rNG25/150

110 ± 1

0.19

-3.6 ± 1.3

14 ± 2

(CDDP+NRT)/rNG25/150

129 ± 4

0.18

-4.5 ±1.5

15 ± 2

rNG50/150

81 ± 3

0.10

-21.2 ± 1.0

NRT/rNG50/150

89 ± 2

0.16

-17.5 ± 0.5

CDDP/rNG50/150

66 ± 2

0.15

-2.3 ± 1.8

9±2

(CDDP+NRT)/rNG50/150

83 ± 3

0.19

-5.7 ± 0.9

10 ± 2

rNG75/150

63 ± 2

0.14

-15.0 ± 1.4

NRT/rNG75/150

76 ± 2

0.18

-13.5 ± 0.7

CDDP/rNG75/150

59 ± 2

0.16

-6.2 ± 2.2

5±1

(CDDP+NRT)/rNG75/150

72 ± 5

0.17

-5.2 ± 1.5

5±2

NRT

Molar Ratio
CDDP:NRT

4±1

4±1

7:1

9±1

9±2

2:1

12 ± 2

11 ± 2

1:1

Pt and NRT content were determined by ICP-MS and HPLC, respectively. *: Loading
capacity (LC) is expressed as the mass of incorporated drug per mass of drug-loaded
NGs (w/w). Effective hydrodynamic diameters (Deff), polydispersity index (PDI) and ζpotential were determined in water (pH 7). Data are expressed as mean ± SD (n = 3).
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As expected, NGs with higher numbers of Phe moieties modified on the PGlu chains
demonstrated the highest NRT loading capacity (11 w/w%), while NGs with the lowest
number of Phe functionalities were able to encapsulate not more than 5 wt. % of NRT.
The loading of hydrophilic molecules of CDDP appears to show a completely opposite
trend compared with that of NRT, which is consistent with the number of available Glu
units available for binding of CDDP. This study indicates that we could use PEG-P(GluGlu/Phex)150as a template to prepare NGs with the ability to vary the ratio of hydrophobic
and hydrophilic drugs that they can carry. Determining a suitable drug-loading ratio is
necessary because one drug can affect the release kinetics of the other, thus altering the
activity [19]. Besides, varied ratios of drugs results in different modes of interaction, which
can either be synergy, antagonism, or additivity [20]. NGs developed in this study were
granted with the ability to further boost therapeutic efficacy of carrier drugs through
screening the drug ratio. Notably, drug-loaded NGs were stable in aqueous dispersions,
exhibiting no aggregation or precipitation for a prolonged period of time (weeks).
The release of the drugs from NGs was studied by equilibrium dialysis at 37°C at either
pH 7.4 (PBS) or pH 5.5 (ABS) in the presence of 10% (v/v) fetal bovine serum (FBS),
which mimics conditions encountered in plasma and in intracellular compartments
(lysosomes), respectively. rNG25/150 was chosen as a model construct for evaluating the
release

kinetic

of

both

drugs.

The

kinetic

profiles

of

drug

release

from

(CDDP+NRT)/rNG25/150 are presented in Figure 11. As seen from these data sustained
but temporally distinct releases of Pt (II) species and NRT was observed. Notably, NRT
release was much faster than that of Pt (II) in both conditions, which is expected since
NRT is physically entrapped into the Phe regions through hydrophobic interactions. In
contrast, CDDP binds with PGlu chains through electrostatic and coordination interactions
and its release usually proceeds via ligand exchange reactions with surrounding
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biologically abundant anions, thus delaying its liberation from the NGs. Pt (II) is released
from the NGs in a pH-dependent behavior. Specifically, Pt (II) species were liberated from
the NGs faster at pH 5.5 than at pH 7.4 (Figure 11B). The protonation of carboxylic groups
of PGlu and subsequent weakened electrostatic coupling of CDDP and PGlu might
account for this speeded release as was discussed previously [21]. For example, during
24 hrs (CDDP+NRT)/NGs released 27.01 ± 2.0% of loaded Pt (II) at pH 5.5 and only 17.7
± 1.3% at pH 7.4, respectively. Besides, the release of Pt from NGs in a pure buffer system
without FBS was also studied and presented in Figure 11B. Pt (II) liberation from
(CDDP+NRT)/NG was further accelerated in the presence of FBS in the media probably
due to the consumption of released Pt (II) molecules by protein binding. Notably, pH
changes practically did not affect the release of NRT.
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Figure 11. In vitro release profiles for NRT (A) and CDDP (B) from NGs: (CDDP + NRT)
/ rNG25/150) in different buffer systems at 37°C (PBS, pH 7.4; ABS, pH 5.5; PBS + 10%
FBS; or ABS + 10% FBS). Data are expressed as mean ± SD (n=3).
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2.3.4 Penetration of NGs in tumor spheroids
It is critical to accurately predicting the responsiveness to therapeutic agents through
screening pipelines. Among these screening models, multicellular tumor spheroids
(MCTS), a three-dimensional multicellular culture system of human cells, is a more
physiologically relevant platform providing a high-throughput means to test the efficacy
and/or toxicity of new compounds [22]. They have a 3D spatial arrangement with
enhanced cell to cell contact and the ability to maintain the specificity and homeostasis of
a specific tissue with proliferative gradients, hypoxia, and necrosis [23] as summarized in
Figure 12. For example, it was reported that cells from the outer region of the spheroid
proliferate and behave healthily while cells in the inner region were apoptotic or injured
with chromatin compaction and segregation mimicking the distribution of cells in tumor
tissue in vivo [24]. Such platform allows us to study the penetration, distribution, and
uptake of NPs due to their potential to form penetration barriers and mimic the
heterogenous tumor microenvironment [25-27]. Since stromal fibroblasts have been
shown to play an important role in determining tumor cell behavior, as well as conditioning
the tumor microenvironment, we created a suitable 3D composite spheroid model
containing a mixture of the mouse embryonic NIH 3T3 fibroblasts and MDA-MB-468 TNBC
cells. Multicellular spheroids were generated using the forced-floating method: 500 cells
(MDA-MB-468: 3T3=1:1) were seeded in ultra-low attachment 96-well plates in the
presence of MammoCult® medium and incubated at 37°C for 6 days. On day 6, the
spheroid morphology was recorded by an inverted microscope as shown in Figure 13.
Spheroids were formed tightly packed in spherical dimension. Within the spheroid,
connections between the cells were very close and compact, which is similar to in vivo
tumor tissue, but different from 2D monolayer cells. The average diameter of formed
spheroids was around 500µm. The forced-floating method enabled us to modulate the
spheroid dimension by varying the number of cells in the starting suspension. In particular,
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for a mixture of MDA-MB-468 and NIH 3T3 cells at 1:1 ratio, we obtained compact cellular
aggregates with a diameter of 700–800 μm starting from a cellular suspension of 1500
cells. However, spheroids prepared from 1500 cells showed high shape variability. To
design experiments with more reliability and repeatability, 500 cells was chosen as the
starting number of cells.

Figure 12. Comprehensive demonstration of the cells and microenvironment inside a
MCTS. Adapted from [22]
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Figure 13. Representative phase-contrast image of MDA-MB-468/NIH 3T3 co-culture
spheroid (Day 6).

We further used MDA-MB-468/NIH 3T3 spheroids for the assessment of penetration of
rNGx/150 NGs. Cy5 amine (0.5 w/w%) was conjugated to cores of NGs using EDC
chemistry. The particle size of Cy-5-labeled rNGx/150 remained practically the same as
those of the unlabeled NGs (Table 9). Cy-5-labeled rNGx/150 (0.5 mg/mL) were incubated
with 6-day old MDA-MB-468/NIH 3T3 spheroids for various periods of time (2, 4, and 8 h).
Overall distribution and penetration of NGs within spheroids were analyzed by confocal
microscopy using Z-stack imaging with 10 µm intervals and presented as maximum pixel
intensity Z-projections (Figure 14). A comparative analysis of the fluorescence intensity
data obtained from the spheroid images depicts the different pattern of interaction
occurring with rNGx/150

having varied content of hydrophobic Phe units: an average

fluorescence in the spheroid was increased as fraction of Phe units in the cores of NGs
increased and appeared to coincide with the decrease of the size of rNGx/150 (Figure 1516). This demonstrates the improved efficiency of the rNGx/150 with a higher content of
hydrophobic Phe units in terms of penetrating the 3D tumor model and delivering the drug
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when compared with rNGx/150 with less Phe units, which helps for a further selection of the
appropriate carrier candidate to maximize therapeutic efficacy of the cargo.
Table 9. Physicochemical characteristics of Cy5-labeled NGs
NGs

Deff (nm)

PDI

ζ-potential, mV

rNG25/150

143 ± 8

0.15

-27.7 ± 2.5

rNG50/150

75 ± 7

0.10

-16.2 ± 1.5

rNG75/150

61 ± 5

0.14

-12.0 ± 4.4

Effective hydrodynamic diameters (Deff), polydispersity index (PDI), and ζ-potential were
determined by DLS (water, pH 7, 25oC). Data are presented as average ± SD from three
experiments.

81

A

B

C

2h

4h

8h

Figure 14. Time-dependent penetration of Cy5-labeled rNGs throughout MDA-MB468/NIH 3T3 spheroids (Day 6): (A) rNG25/150, (B) rNG50/150, (C) rNG75/150.
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Figure 15: 3D surface plot analysis using maximum intensity projection of treated
spheroids a: rNG25/150, b: rNG50/150, c: rNG75/150
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Figure 16. Qualitative evaluation of the distribution of NGs in MDA-MB-468/NIH 3T3
spheroids. (A) Corrected Cy5 fluorescence intensity vs distance from the periphery
quantitates the NG association in spheroids. (B) Fluorescence intensity profile of Cy5NGs showed the different distributions/penetrations of NGs in spheroids at 50 µm depth.
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To further get insight into the cellular composition of co-culture MDA-MB-468/NIH 3T3
spheroids, MDA-MB-468 cells were transfected with a lentivirus engineered to
constitutively express the Green Fluorescent Protein. Spheroid formation was
continuously monitored using Nikon Eclipse E400 microscope (Figure 17). On days 1, 3
and 6, spheroids were dissociated using Accutase and cell composition was quantified by
flow cytometry analysis (Figure 18). As it seen in Figure 17, MDA-MB-468/GFP+ cells
were clustering on the edges of the growing spheroids and their number was decreased
over the time as evident by the decrease in fluorescent signal (Figure 17), which was
further confirmed by cell sorting analysis (Figure 18).
We further studied cellular uptake of rNG50/150 in co-culture MDA-MB-468/NIH 3T3
spheroids. On day 6, 48 MDA-MB-468(GFP+)/NIH 3T3 spheroids were incubated with
Cy5-labeled rNG50/150 (0.5 mg/mL) for 4 hours followed by flow cytometry analysis (Figure
19). While all gated cells were associated with Cy5 fluorescent signal, only small cell
population (ca. 2%) was GFP/Cy5 positive. Interestingly, median Cy5 fluorescence
intensity measured in MDA-MB-468/GFP+ cells (MFI: 259797) was 10-fold higher than in
fibroblasts (MFI: 29606.5) suggesting relatively higher accumulation of rNGs in cancer
cells. Although we don’t know the exact mechanism behind this finding, there was a study
demonstrating a strong cell line dependence of the NPs uptake and excretion dynamics
[28]. It was particularly reported that retention of gold NPs coated with dithiolated
diethylenetriaminepentaacetic acid was found to be higher in cancer cells than in
fibroblasts in a 2D monolayer culture format. The exact mechanism of our observations
will be further investigated.
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Day 1

Day 3

Day 6

Figure 17. Formation and growth of heterotypic MDA-MB-468/NIH 3T3 spheroids from
TNBC MDA-MB-468/GFP+ (green) and murine fibroblasts (3T3). Fluorescence (top) and
phase contrast (bottom) images of MDA-MB-468/NIH 3T3 spheroids (top) on days 1, 3
and 6.
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Figure 18. Left: Percentage of MDA-MB-468 (GFP+, red) and 3T3 (GFP-, blue) cells in
MDA-MB-468/NIH 3T3 spheroids as a function of time. Spheroids (96) were dissociated
on days 1,3 and 6 (n = 2). Right: Flow cytometry data representing cellular compositions
of tumor spheroids on D1 (up) and D6 (down).
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Figure 19. Cellular uptake of Cy5-labeled rNG50/150 in MDA-MB-468-GFP+/NIH 3T3
spheroids after incubation for 4h was detected by flow cytometric analysis. GFP+ cells
represent MDA-MB-468 which was transfected to express GFP. GFP- cells represent NIH
3T3 cells.
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2.3.5 In vitro cytotoxicity of the drug-loaded NGs
CDDP is a well-known DNA-damaging agent. Its mechanism of action involves the
formation of cisplatin-DNA adducts to disrupt DNA structure and interfere with DNA
replication & transcription and ultimately induce apoptotic cell death. Herein we studied
the synergy of CDDP and NRT, which is an irreversible inhibitor towards EGFR, HER2
and HER4. NRT might potentiate the therapeutic efficacy of cisplatin by reducing DNAdamage repair through interfering EGFR-mediated Histone H4/DNA-PKcs/ATM pathway
and pushing cells towards apoptotic death. Besides, NRT could further sensitize cells to
CDDP by downregulating oncogenic Cyclin D1 to keep cells blocked at G1 phase during
cisplatin treatment since tumor cells appear to be maximally sensitive to cisplatin in G1
phase and minimally sensitive in S-phase [29]. In vitro cytotoxicity of either free drugs or
single drug-loaded and drug combination in a panel of nanogel formulations were
evaluated in human TNBC cell line MDA-MB-468 with high EGFR expression. After 72hour treatment, the surviving cell population was assessed by a CellTiter Blue assay
(CTB), which measures the metabolic activity of viable cells. The half-maximal inhibitory
concentrations (IC50) of free drugs, single and combination-drug-loaded NGs are
compared in Table 10. Indeed, the combination of CDDP and NRT was significantly more
efficient in killing EGFR overexpressing cell line MBA-MD-468 than just CDDP treatment
indicated by a significant drop in the IC50 value of CDDP when administered in combination
with NRT in a single carrier for 72 hours. Combination index analysis at IC50 using the
Chou and Talalay method [30] showed that the strongest synergy between the two drugs
was observed at the CDDP:NRT ratio of 2:1 compared with ratio of 7:1 and 1:1, both in
the form of free drugs (CI=0.40 ± 0.03) and combination in rNG50/150 (CI = 0.40 ± 0.06).
When both drugs were administered in the form of a cocktail of single drug-loaded NGs at
equivalent doses, the synergy of action was still retained with less prominent effect
compared with that seen in case of a combination of dual drug-loaded NGs at the CDDP:
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NRT ratio of 7:1 and 2:1. In case of drug ratio at 1:1, the combination of two separate NG
formulations (CDDP/rNG75/150 + NRT/rNG75/150) even displayed antagonistic CI value of
1.22 at IC50. These data suggest that synchronized delivery of this drug combination in the
same nanogel formulation may play an essential role in the cytotoxic activity.

Table 10. Comparison of IC50 values for various drug-loaded NGs, free NRT and CDDP
against EGFR+ MDA-MB-468 as determined by CellTiter-Blue® assay.
IC50, µM (MDA-MB-468 cells)
CDDP/NGs

NRT/NGs

Dual-drug/
NGs*

Single drug NGs
cocktail*

Free drug
cocktail*

rNG25/150

4.45 ± 1.21

0.52 ±
0.04

0.91 ± 0.36

1.11 ± 0.37

0.59 ± 0.19

rNG50/150

4.05 ± 0.51

0.52 ±
0.05

0.36 ± 0.12

0.57 ± 0.30

0.34 ± 0.04

rNG75/150

1.98 ± 0.10

0.40 ±
0.10

0.29 ± 0.04

0.37 ± 0.06

0.25 ± 0.05

Empty
CDDP

3.17 ±
0.27

NRT

0.62 ±
0.04

CI** at IC50
CDDP:NRT (Molar Ratio)

Dual-drug/NGs

Single drug NGs
cocktail

Free drug
cocktail

rNG25/150

7:1

0.66 ± 0.09

0.74 ± 0.12

0.78 ± 0.32

rNG50/150

2:1

0.40 ± 0.06

0.63 ± 0.02

0.40± 0.03

rNG75/150

1:1

0.85 ± 0.05

1.22 ± 0.14

0.45 ± 0.10

*calculated with respect to CDDP.
**: Combination index was calculated with respect to CDDP
Data presented as mean ± SD. N=3
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Since binary drug combination carried in rNG50/150 displayed the highest synergy among
three types of nanogel formulations, rNG50/150 was selected for the best-suited carrier
system in further in vitro and in vivo studies. Cytotoxicity of the single drug-loaded and
combination rNG50/150 was further evaluated in a panel of human TNBC cell lines with
differential EGFR expression: MDA-MB-468 (EGFR high), MDA-MB-453 (EGFR low), as
well as MDA-MB-231 (EGFR low). As described, after 72-hour treatment, the surviving
cell population was assessed by CTB assay. The half-maximal inhibitory concentrations
(IC50) of free drugs, single and combination drug-loaded NGs are compared in Table 11.
We found that (CDDP + NRT)/NGs were significantly more effective in killing EGFRpositive MDA-MB-468 compare to corresponding TNBC cells with low EGFR expression.
The combination index (CI) values for drug combination at IC50 were less than 1 indicating
synergistic cytotoxicity against MDA-MB-468 TNBC cells and thus confirming the benefit
of selecting this combination of drugs. The lowest CI value for (CDDP+NRT)/rNGs (CI:
0.4) suggests that this drug combination displays clear synergistic activity at loading
CDDP/NRT molar ratio of ca. 2:1. When the same formulations were applied to EGFR low
MDA-MB-453 and MDA-MB-231 cells, the drug actions showed a mere additive effect
because the CI values were close to 1. Importantly, rNG50/150 alone were not toxic at
concentrations used for the treatment by CDDP/rNG50/150 formulations. CDDP/rNG50/150
displayed lower cytotoxic activities than free CDDP which probably arises from the
sustained release of CDDP from NGs. These data indicate that the binary drug
combination loaded NGs exerted selective synergistic effects in EGFR+ TNBC cells while
such synergy was not observed in EGFR- TNBC cells.
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Table 11. Comparison of IC50 values for various drug-loaded NGs and free drugs
against panel of TNBC cell lines as determined by CTB assay.
IC50, µM
MDA-MB-468

MDA-MB-453

MDA-MB-231

CDDP

3.17 ± 0.27

4.11 ± 0.16

4.67 ± 1.06

NRT

0.62 ± 0.04

0.87 ± 0.30

1.46 ± 0.26

CDDP/rNG50/150

4.05 ± 0.51

7.07 ± 4.89

7.13 ± 0.70

NRT/rNG50/150

0.52 ± 0.05

0.71 ± 0.06

1.68 ± 0.39

0.36 ± 0.12

1.01 ± 0.47

2.05 ± 0.13

(0.40 ± 0.06)

(1.17 ±0.36)

(1.01 ± 0.26)

0.57 ± 0.30

0.92 ± 0.48

3.31 ± 0.47

(0.63 ± 0.02)

(0.74 ± 0.22)

(1.30 ± 0.50)

0.34 ± 0.04

0.78 ± 0.22

2.80 ± 0.37

(0.40 ± 0.03)

(1.44 ± 0.56)

(1.04 ± 0.11)

(CDDP + NRT)/rNG50/150

CDDP/rNG50/150 + NRT/rNG50/150

Free CDDP + NRT

IC50 values and combination index (CI, labeled red) for drug combination loaded NGs

#

were calculated with respect to CDDP. Data presented as mean ± SD. N=3
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2.3.6 Mechanism of synergy
To investigate the molecular basis for the synergistic effect of combination of CDDP and
NRT at molar ratio of ca. 2:1 observed in the previous cell viability studies, we used
western blot analysis to first determine the level of EGFR activation using expression of
phosphor-EGFR as the indicator in EGFR+ MDA-MB-468 cell lines under various
treatments (Figure 20). Cells were treated with either single CDDP (10µM), NRT (5µM)
or the binary drug combination at the same dose for 2h. Then cells were treated with or
without EGF for 5mins to stimulate EGFR phosphorylation at a concentration of 100ng/ml.
Notably, higher phosphor-EGFR was found in cells treated with CDDP or EGF, a ligand
for activation and phosphorylation of EGFR, indicating that CDDP treatment triggered the
activation of EGFR which is considered as a pro-survival signal leading to mitigated
therapeutic efficacy. No obvious change in terms of the level of phosphor-EGFR was
found in cells treated with NRT in the presence of EGF, indicating that NRT successfully
suppressed the EGF-mediated activation and phosphorylation of EGFR. Similarly, no
observable change in phosphor-EGFR was found in cells treated with combination of
CDDP, NRT and EGF, further indicating that NRT was able to suppress EGFR activation
induced by CDDP and EGF, suggesting that the CDDP-mediated pro-survival signal could
be reversed by NRT, enhancing the cell response to CDDP.
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Figure 20. Effect of NRT and CDDP on total EGFR and phosphorylation of EGFR in MDAMB-468 cells. Cells were incubated in medium containing the indicated concentrations of
treatments for 2 hours. At the end of the 2-hour incubation, 100 ng/mL EGF was added
for 5 minutes. Total proteins (10 µg) were prepared and separated by 8% SDS-PAGE.
After transferring to a PVDF membrane, blots were probed with anti-phospho-EGFR, antiEGFR, anti-β-actin, respectively. The values underneath the blots represent relative
changes of p-EGFR levels present in the treated cells compared to the basal level of those
in control cells after normalization to β-actin, quantified by densitometric analysis using
software ImageJ. Blots are representative of 3 independent experiments.
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HER1/EGFR activates several cytoplasmic signal-transduction pathways such as
mitogen-activated protein kinase (MAPK), PI3 kinase/Akt, JAK/STAT [31]. Among them,
MAPK and Akt are the major two downstream effectors of EGFR investigated in many
studies due to their crucial roles in transporting signals for promoting cell division and
survival. We investigated whether NRT would inhibit the activity of these two downstream
effectors: MAPK (ERK) and Akt which may correlate with the strong synergy between
CDDP and NRT in EGFR+ MDA-MB-468. Similarly, a panel of treatments were given to
MDA-MB-468 cells at various concentrations with or without the receptor stimulator EGF
(100 ng/mL). As seen in Figure 21, NRT at 5 µM markedly inhibited ERK1/2 (MAPK) as
well as Akt activity in EGF-stimulated MDA-MB-468, suggested by more than 2 folds
reduction in the level of kinase phosphorylation. Notably, NRT almost completely blocked
ERK1/2 activity in MDA-MB-468 cells. Most importantly, CDDP was able to induce almost
the same level of Akt/MAPK activation as the stimulator EGF, which was completely
reversed by the addition of NRT, further suggests that the reverse of CDDP-induced prosurvival signal by NRT might be the molecular mechanism for strong synergistic effect of
the combination in the EGFR+ MDA-MB-468 cell line.
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Figure 21. Effect of NRT and CDDP on phosphorylation of MAPK (ERK1/2) and Akt in
MDA-MB-468 cells. Cells were incubated in medium containing the indicated
concentrations of listed treatments for 2 hours. At the end of the 2-hour incubation, 100
ng/mL EGF was added for 5 minutes. Total proteins (10 µg) were prepared and separated
by 8% SDS-PAGE. After transferring to a nitrocellulose membrane, blots were probed with
anti-phospho-ERK1/2,

anti-phospho-Akt,

anti-β-actin,

respectively.

The

values

underneath the blots represent the relative changes of p-ERK1/2 and p-Akt levels present
in the treated cells compared to the basal level of those in control cells after normalization
to β-actin, quantified by densitometric analysis using software ImageJ. Blots are
representative of 3 independent experiments.
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Cyclin D1 displays proto-oncogenic function due to its contribution in promoting cell cycle
progression. Cyclin D1 promotes the cell cycle to transit from G1 to S phase through
binding to cyclin-dependent kinase subsequently triggering the transcription of genes
required for this progression [32, 33]. Since cells remains most sensitive to CDDP if they
are in G1 phase, least sensitive in S phase [29], higher expression of Cyclin D1 would
mitigate the therapeutic efficacy of CDDP. Here we further evaluated the changes in the
expression level of Cyclin D1 of treated cells. As demonstrated in Figure 22, CDDP
treatment or addition of EGF increased the expression of Cyclin D1 up to 2 folds
comparing to the basal level which might result in the attenuation of CDDP-induced cell
death. Cyclin D1 overexpression was thought to be at least partly dependent on the
mitogenic effects of EGF signaling through the EGFR, which is consistent with what was
observed in our study [34]. However, the addition of NRT reduced the Cyclin D1
expression back to the the basal level. Thus, we believed that the NRT-directed
suppression of cyclin D1 expression might help to maintain tumor cells in G1 phase for
enhanced susceptibility to CDDP-mediated apoptosis.
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Figure 22. Effect of NRT and CDDP on Cyclin D1 expression level in MDA-MB-468 cells.
Cells were incubated in medium containing the indicated concentrations of listed
treatments for 2 hours. At the end of the 2-hour incubation, 100 ng/mL EGF was added
for 5 minutes. Total proteins (10 µg) were prepared and separated by 8% SDS-PAGE.
After transferring to a nitrocellulose membrane, blots were probed with anti-Cyclin D1,
anti-β-actin, respectively. The values underneath the blots represent the relative changes
of Cyclin D1 levels present in the treated cells compared to the basal level of those in
control cells after normalization to β-actin, quantified by densitometric analysis using
software ImageJ. Blots are representative of 3 independent experiments.
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Conclusion
In the present study, a series of NGs based on amphiphilic PEG5K-P(Glu-Glu/Phex)150
copolymers were evaluated as potential vehicles for co-delivery of chemotherapeutic
drugs with distinct physicochemical properties and mechanisms of action. These
nanostructures were designed to have multifunctional compartments for drug loading and
were crosslinked within a polyelectrolyte core of the polymeric NGs to ensure their
enhanced stability upon systemic administration. These NGs simultaneously bared a
sufficient load of hydrophilic CDDP and hydrophobic NRT, exhibited differential release
profiles and synergistic cytotoxic effect against EGFR+ MDA-MB-468 triple negative breast
cancer cells. By tuning hydrophilic and hydrophobic fraction ratio, NGs displayed varied
dimensions, drug loading capacities, deformability, performance in killing tumor cells, as
well as penetrations in multicellular 3D tumor models. Consistent with properties of
chemical composition, NG with a high fraction of hydrophobic moieties displayed less
swelling ability and more efficient hydrophobic drug loading. Resulting binary-drug-loaded
NGs with 50 units of hydrophobic Phe functionalities were able to encapsulate both CDDP
and NRT in a molar ratio of 2:1 and displayed the strongest synergistic effect towards
MDA-MB-468 cells compared with other screened regimens. Such superior synergy was
found to be selective and only displayed in EGFR+ cell line. rNG50/150 also displayed
preferential uptake by tumor cells in the tumor spheroids model consisting of tumor cells
as well as fibroblasts. NRT was found to reverse pro-survival signal transduction by CDDP
mediated EGFR/Akt/Erk activation as well as increased Cyclin D1 expression, which was
believed to be the molecular basis for the synergistic effect of the combination of CDDP
and NRT. Altogether, this study demonstrated a fundamental possibility for the
simultaneous delivery of chemotherapeutics via single well-defined and structurally
tunable polymeric nanocarrier. Besides, such carriers grant us with flexibility in adjusting
cargo ratio as well as dimensions for enhanced therapeutic outcomes of carrier drugs.
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CHAPTER III.

LIGAND-INSTALLED NANOGELS FOR COMBINATION DRUG
THERAPY IN OVARIAN CANCER

3.1 Introduction
Ovarian cancer (OC) is the most lethal gynecological cancers in the USA with no effective
screening strategy. It is estimated by The American Cancer Society that in 2020, there will
be about 21,750 new cases of ovarian cancer diagnosed and 13,940 women will die of
ovarian cancer in the United States [1]. Although the standard of care of OC patients
including surgical cytoreduction followed by platinum-based chemotherapy has shown
high response, mortality rates for ovarian cancer have declined only marginally in the forty
years emphasizing continued efforts toward better treatments [2]. Most patients present
with advanced-stage tumors showing metastasis outside the pelvis at the time of initial
diagnosis due to inadequate diagnostic markers and non-specific symptoms [3, 4].
Although ovarian cancer can be divided into several subtypes based on the cell of origin,
including the germ, epidermoid, stromal, and border cells, epithelial ovarian cancer (EOC)
accounts for about 90% of OCs. EOC is associated with a high mortality rate due to the
intrinsic aggressive nature and limited early detection techniques. Among all the subtypes
of EOC, high-grade serous carcinoma (HGSC) is the most commonly diagnosed form with
high sensitivity to current front-line combination platinum-

and taxane-based

chemotherapy. In spite of high response rate to the standard therapy, EOC frequently
relapse and become increasingly less sensitive to chemotherapy. We may be approaching
the limit of using conventional chemotherapeutics to optimize treatment of EOC [4].
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Delaying the onset of resistance and prolonging the survival of EOC patients will likely
occur with progression in the early detection of this disease [5] as well as through the
incorporation of biologically targeted therapeutics. Aberrant EGFR expression is reported
in up to 60% of malignant ovarian tissue as demonstrated by IHC and occurs in all
histologic subtypes [6]. Since the increased copy number and overexpression of EGFR
were found to be associated with high tumor grade and poor patient outcomes, EGFR
expression might be used as an independent prognostic indicator in EOC patients [7-9].
Interestingly, the increased copy number of EGFR was reported to be associated with the
increased copy number of HER2 which was also reported to be a negative prognostic
indicator in EOC in some reports [7, 10]. Therefore, inhibiting the family of HER might be
a promising approach through utilizing biological targets [11, 12]. As mentioned, EOC has
been showing high sensitivity towards platinum-based chemotherapy. Cisplatin (CDDP),
a widely used platinum compound, acts by damaging DNA. Once entering the cell through
either passive diffusion or active transport, cisplatin undergoes the aquation process and
becomes a potent electrophile that reacts with a variety of nucleophiles, including nucleic
acids. The formation of CDDP-DNA adducts disrupts the DNA structure and interferes with
DNA replication & transcription leading to either apoptotic cell death or DNA repair with
cell survival. The mechanisms of determining the fate of cells remain largely unknown [13].
The declined sensitivity to cisplatin is believed to arise from reduced cellular uptake [14],
enhanced intracellular detoxification, increased DNA repair, tolerance of platinum-DNA
adducts and regulation of apoptosis [15, 16]. On the other hand, NRT is an inhibitor of
HER family receptor tyrosine kinases, including EGFR, HER2 and HER4. Its mechanism
of action involves the irreversibly binding to the intercellular signaling domain of kinases
to inhibit their phosphorylation and several HER downstream signaling pathways such as
ERK, PI3 kinase/AKT, JAK/STAT, etc. It has been reported that nucleotide excision repair
(NER), a primary DNA-damage repair process, may prevent cisplatin-induced apoptosis
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by activating the ataxia telangiectasia mutated (ATM) pathway [13]. EGFR acts as an
upstream effector of ATM by phosphorylating ATM to mediate DNA repair. Treatment with
EGFR inhibitor successfully blocked ATM activation and subsequently increased tumor
cell sensitivity to DNA-damaging treatments [17]. Apart from activating the ATM pathway,
EGFR was shown to epigenetically regulate DNA damage signaling pathways by
modifying chromatin at critical tyrosine residues [18] and phosphorylating DNA-PKcs, an
enzyme required for DNA-repair [19], to reduce the DNA damage and restore DNA repair
activity. As an inhibitor of HER family, NRT might potentiate the therapeutic efficacy of
CDDP by reducing DNA-damage repair through interfering EGFR-mediated Histone
H4/DNA-PKcs/ATM pathway and pushing cells towards apoptotic death. On the other
hand, EGFR is activated in response to CDDP in various types of cancer cells that
overexpress the receptor including human breast cancer cells and glioma cells [20], which
is believed to be a survival-promoting or cell death-opposing response. Many studies have
shown blocking EGFR activation enhances CDDP-induced cell death [21-23]. This serves
as a strong basis that preventing CDDP-dependent EGFR activation should enhance drug
sensitivity and improve clinical efficacy. Another minor mechanism of action of NRT is its
ability to downregulate the oncogenic Cyclin D1 level which plays a key role in advancing
the cell cycle into the late G1 and S phases [24]. Since tumor cells appear to be maximally
sensitive to cisplatin in G1 phase and minimally sensitive in S-phase [25], reducing Cyclin
D might keep more cells blocked at the G1 phase during cisplatin treatment and maximize
cisplatin efficacy, which might also explain that the increased cyclin D expression results
in less tumor sensitivity to cisplatin in several in vitro models, including fibrosarcoma [26]
and pancreatic cancer [27]. Altogether, the above mechanism of actions of both drugs
then forms the rational basis for the selection of such combined therapy to achieve
maximized synergistic clinical effects for treating ovarian cancer. However, the synergy
of such therapy is often sequence and dose ratio specific. Besides, administrating two
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distinct drugs might require repeated dosing and prolonged duration of drug infusion in
patients. Moreover, conventional Pt-based chemotherapy generally comes with rapid
elimination and severe dose-limiting toxicities including neurotoxicity and nephrotoxicity
[28]. Combining such drugs in one delivery carrier is therefore a desirable and convenient
strategy for controlling the pharmacokinetics [29, 30] and co-delivery of the desired drug
ratio in vivo, to maximize the therapeutic efficacy and minimize drug-associated toxicities.
Crosslinked polypeptide-based nanogel (NG) is an appealing platform to achieve this goal.
Such a biodegradable platform provides flexibility in adjusting the size, loading capacity,
surface properties, deformability, softness, and responsive behaviors by tuning the
chemical compositions as well as crosslinking levels. Enhanced stability due to the
crosslinking adds benefits to prolonging the circulation, which in term enhances drug
exposure to tumors by EPR effect. Their mild preparation procedures allow the
incorporation of labile drug molecules and biomacromolecules. The most prominent
advantage over other nano-sized carriers is their ability to incorporate molecules with
different physicochemical properties through versatile interactions. For the purpose of the
current study, poly (ethylene glycol)-block-poly (L-glutamic acid) modified with
phenylalanine functionalities (PEG-P(Glu-Glu/Phe)) for simultaneous loading and delivery
of binary CDDP and NRT combination. Such NGs have 1) a hydrophilic PEG shell which
imparts a stealth character against the immune system and extends the systemic
circulation, 2) an anionic core, which incorporates CDDP through coordination with the
carboxylic groups of PGlu, 3) hydrophobic regions formed by Phe moieties, which serves
as a reservoir for NRT solubilization. The crosslinks incorporated into PGlu block layer
keep NG stable until they are degraded by proteases through cleaving the polypeptide
chains of the block copolymers. The developed binary drug NG formulation showed
synergy in several EGFR overexpressed ovarian cancer cell lines, while such synergy was
not seen in cell lines with low EGFR overexpression. Such drug delivery systems also
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showed desirable antitumor efficacy in an intraperitoneal ovarian cancer mouse model
with no observable toxicities while certain toxicities were observed in tumor-bearing mice
treated with free drugs at the same dose. However, this system solely depends on the
EPR effect which is limited by heterogeneity among tumor mass as well as vascular
density nearby influencing the permeability of nanocarriers. Installing targeting ligands on
the surface of carriers to specifically target biomarkers overexpressed on the surface of
tumor cells is a well-suited strategy to overcome the mentioned limitation and further
boosting drug performance. Two targeting ligands aiming to bind with EGFR was chosen
in our study: L-AE peptide [31] and EGFR-A protein [32]. Both ligands are relatively new
with reported high binding specificity and affinity to EGFR with acceptable stability. Ligand
installed carrier demonstrated success in increasing cellular uptake and further boosting
the therapeutic efficacy of targeted binary combination NGs in vivo. We also confirmed
the importance of simultaneous administration of the (CDDP+NRT) via a single NG system
which provides more therapeutic benefits than a cocktail of individual drug-loaded NGs
administered at equivalent doses.
3.2 Materials and methods
3.2.1 Materials
Poly (ethylene glycol)-b-poly (L-glutamic acid) (PEG-b-PGlu) diblock copolymer
(Mw/Mn=1.01, Mw 28,000 g mol-1) was purchased from Alamanda Polymers, Inc.
(Madison, AL, USA). The block lengths were 114 and 150 repeating units for PEG and
PGlu, respectively. Methoxypolyethylene glycol amine (mPEG-NH2) polymer (Mw/Mn=1.04,
Mw 10,000 g mol-1, 228 repeating units), maleimide-PEG-Amine (Mal-PEG-NH2) polymers
with different molecular weights , Mw 7,500 g mol-1 (ĐM = Mw/Mn = 1.02) and Mw 15,000 g
mol-1 (ĐM = 1.04) were purchased from JenKem Technology (TX, USA). L-glutamic acid
γ-benzyl ester (BGlu), L-phenylalanine methyl ester hydrochloride (Phe), 1-(3-
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dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC), tris (2-carboxyethyl)
phosphine (TCEP), ethylenediamine (ED) and other chemicals were obtained from SigmaAldrich (St Louis, MO) and were used without further purification. Fetal bovine serum (FBS)
was purchased from Invitrogen Inc. (Carlsbad, CA). RPMI 1640 medium, EGF
Recombinant Human Protein, Pierce™ BCA protein assay kit, CA125 Human ELISA kit
was purchased from Thermo Fisher Scientific (Waltham, MA). CellTiter-Blue® reagent
was purchased from Promega (Madison, WI). Cyanine 5 (Cy5) amine was obtained from
Lumiprobe (Hallandale Beach, FL). Cell lysis buffer and protease inhibitor cocktail were
purchased from Cell Signaling Technology (Danvers, MA). The following primary
antibodies were used in this study: Rabbit anti-EGFR (ab52894) mAb, rabbit antiphospho-EGFR (phospho Y1068) (ab40815) mAb, rat anti-HSC70 (ab19136) mAb,
mouse anti-beta actin (ab8226) mAb used for Western blotting studies, were purchased
from Abcam™ (Cambridge, MA); the rabbit anti-Phospho-Akt (D9E) mAb, rabbit antiphospho-p44/42 MAPK (Erk1/2) (4370T) mAb was kindly provided by Dr. Surinder K.
Batra (University of Nebraska Medical Center, Omaha, NE).
3.2.2 Synthesis of NGs
NGs were prepared using a diblock copolymer, PEG-PGlu150, in which part of the Glu units
was modified with hydrophobic Phe functionalities via polymer-analogous modification of
the PGlu segment with the Phe methyl ester using carbodiimide-chemistry in aqueous
media. The targeted degree of modification was set at 50 Phe units per chain since binarydrug-loaded NGs prepared from such polymers showed the highest synergy in the EGFR+
TNBC cell line as we observed in the previous chapter. The obtained products were
characterized by proton nuclear magnetic resonance (1H NMR). Micellar precursors based
on PEG-P(Glu-Glu/Phe50)150 copolymers were prepared by a dialysis method using
water/organic solvent mixtures followed by direct crosslinking of COOH groups of glutamic
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acid units with 1,2-ethylenediamine (ED) in the presence of EDC at r.t.. The crosslinking
reactions were performed at a molar ratio of [COOH]/[EDC]/[ED]=10/2/1 to obtain a
targeted 20% crosslinking degree. The prepared nanogel was abbreviated as NG (further
denotes as rNG5k). To prepare Cy5 labeled NGs for evaluating cellular uptake, Cy5 amine
(0.5 w/w%) was conjugated to cores of NGs using EDC chemistry.
3.2.3 Synthesis of ligand-installed NGs and drug loading
NGs were functionalized with EGFR-A protein ligands (Mw 13,400 Da, provided by Dr. Liu,
University of North Carolina at Chapel Hill, NC) that specifically and tightly bind to the
extracellular domain of EGFR (further denoted as EGFR-A-NGs). To prepare the protein
ligand EGFR-A, a codon-optimized DNA sequence encoding an FN3 domain-based
targeting ligand that specifically binds to the extracellular domain of human EGFR
(denoted as EGFR-A) was synthesized (by Genscript) and cloned into the pET28b vector
according to the previously published procedures (Cite PMID: 30842091). To facilitate
affinity purification and site-specific conjugation with NGs, a His×6 tag and the only
cysteine residue were genetically engineered at the C-terminus that is far away from the
target-binding regions. Once the purified recombinant protein EGFR-A (~13.4 kDa) was
obtained and measured by SDS-PAGE, it was conjugated to drug-loaded NGs via PEG
spacer having a maleimide group (Mal-PEG7.5k-NH2). Firstly, Mal-PEG-NH2 (0.013 mmol,
0.0007 eq with respect to the number of carboxylate groups and 1.5 eq with respect to
required EGFR-A) was conjugated to the free carboxyl groups (18.57 mmol) of NGs via
EDC (0.13 mmol) chemistry. The reaction was allowed to proceed for 4 h followed by
ultrafiltration (MWCO 30,000 Da) to remove the byproducts and unreacted PEG linkers.
PEG-NGs were then loaded with CDDP through mixing with an aqueous solution of CDDP
(1mg/mL) at pH 9.0 at a 0.25 molar ratio of CDDP (0.06mmol) to carboxylate groups
(0.24mmol) of the NGs followed by incubation at 37°C for 24h. Unbound CDDP was
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removed by Ultracon filter units (MWCO 10,000 Da, Millipore) at 1690 g for 15 min.
Activated EGFR-A was further conjugated to maleimide terminus of the PEG linker via
thiol groups (PBS, pH 7.4, 2 h). EGFR-A-NGs were purified from unconjugated protein
using ultrafiltration (MWCO 100k Da). The amount of conjugated ligand was determined
by micro-BCA assay using non-modified PEG-conjugated NGs as a reference. Finally,
NRT was encapsulated into the hydrophobic domain of NGs through an extraction method.
Briefly, NRT dissolved in ethanol was added dropwise to the aqueous dispersion of NGs
upon stirring followed by evaporation of organic solvent [33]. Unbound NRT was removed
by filtration with 0.8 μm syringe filters (Thermo Scientific). Single drug-loaded NGs were
prepared though the similar procedure. Pt content in NGs (194Pt/195Pt) was assayed by
inductively coupled plasma mass spectrometry (ICP-MS, NexION 300Q, PerkinElmer,
Waltham, MA) calibrated with Pt (0.8 to 500 ng/mL). NRT content was assayed by HPLC
under isocratic conditions using an Agilent 1200 HPLC system with a diode array detector
set at 266nm. As the stationary phase a Nucleosil C18 column was used (250 mm × 4mm),
and a mobile phase of (acetonitrile+0.1%TEA)/(water+0.1%TEA mixture) (80/20,v/v) was
applied at a flow rate of 1ml/min with a column temperature of 40°C. NGs can entrap
considerable amounts of CDDP and NRT, respectively. L-AE (FALGEA), a novel
hexapeptide ligand identified through a mixture-based synthetic combinatorial library, has
demonstrated selective binding affinity to EGFR and EGFRvIII as reported [31, 34]. L-AE
is another EGFR targeting ligand evaluated in our study as well. We designed cysteine
terminated L-AE (sequence: CGGGGFALGEA) to allow site-specific conjugation to NGs.
A spacer (GGGG) was added between the cysteine and the peptide to avoid hinderance
for more efficient ligand-receptor interaction. The peptide (synthesized by Genscript) was
conjugated to NGs through the similar procedure mentioned above (further denoted as
LAE-NGs).
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3.2.4 Physicochemical characterization of the NGs
The 1H NMR spectra for the monomers and copolymers were acquired in CDCl3 or TFAd1 at 25 °C using a Bruker 500 MHz spectrometer, respectively. Effective hydrodynamic
diameters (Deff) and ζ-potential of NG were determined by dynamic light scattering (DLS)
using a Zetasizer Nano ZS (Malvern Instruments Ltd., Malvern, UK). All measurements
were performed in automatic mode at 25°C. Software provided by the manufacturer was
used to calculate the diameters, polydispersity index (PDI), and ζ-potential of NGs. All
measurements were performed at least in triplicate to calculate mean values ± SD.
3.2.5 Cellular uptake of NGs
Cellular uptake of NGs was assessed using flow cytometry. Cells ( EGFR+: SKOV-3 &
OVCAR-5, EGFR-: NIH 3T3 ) were seeded in 6-well plates at a density of 1 × 105 cells per
well, and cultured at 37°C in 5% CO2 for 24 h. Cells grown in RPMI media then were
exposed to Cy5-labeled bare NGs or EGFR-A-NGs or LAE-NGs at 4 °C. Following
incubation for 1 h, cells were washed three times with PBS, further incubated with fresh
medium for 30 mins at 37°C, trypsinized, centrifuged (423 g, 5 min) and resuspended in
PBS (pH 7.4). Cells were stored in darkness at 4°C before measurements. The % of gated
cells were analyzed using BD Biosciences LSR II flow cytometer and FACSDiva software
(BD Biosciences, San Jose, CA). At least 10,000 events were acquired in linear mode,
gated to only include non-aggregated live cells, and visualized in logarithmic mode. The
results are reported as the percentage of cells associated with fluorescence versus the
number of gated cells.
3.2.6 Cell culture and cytotoxicity studies
Cytotoxicity studies were conducted on three human ovarian cancer cell lines: SKOV-3,
OVCAR-5 and A2780 (provided by Dr. P.Rogers, Institute of Cancer Research, University
of Bristol, UK). First two cell lines overexpressed EGFR while the third one was found to
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have negligible expression. Cells were maintained in RPMI medium supplemented with
10% (v/v) FBS in the presence of penicillin and streptomycin (100 U/mL and 0.1 mg/mL,
respectively) at 37°C in a humidified atmosphere containing 5% CO2. Cells were harvested
with trypsin-EDTA (Life Technologies) after 80% confluence. Cells seeded in 96-well
plates (3,000 cells/well) 24 h prior the experiment were exposed to various doses (0-10
μg/mL on CDDP or NRT basis) of CDDP alone, free binary drugs, CDDP-loaded NGs,
NRT-loaded NGs, a cocktail of single drug-loaded NGs, (CDDP+NRT)-loaded NGs and
targeted-(CDDP+NRT)-loaded NGs for 48 h at 37°C. Cytotoxicity of either free drugs or
drug-loaded NGs was assessed by a standard CellTiter-Blue® cell viability assay [35] with
untreated cells served as 100% cell viability. The IC50 values were calculated using
GraphPad Prism software. Combination index (CI) analysis based on Chou and Talalay
method [36] was performed using CompuSyn software for CDDP and NRT combinations,
determining synergistic, additive, or antagonistic cytotoxic effects against ovarian cancer
cells. Values of CI < 1 demonstrate synergism while CI = 1 and CI > 1 values represent
additive and antagonistic effects of drug combination, respectively.
3.2.7 Western blot analysis
Cells were treated with either EGF, EGF + CDDP, EGF + NRT, or EGF + CDDP + NRT
for 2h at a concentration of 100 ng/mL EGF, 10 µM/mL CDDP, and 5 µM/mL NRT. Cells
were then lysed with cell lysis buffer supplemented with protease inhibitor cocktail.
Supernatants were collected after removing cell debris by centrifugation (14,000 g for 20
min), and the protein amount was determined by BCA assay. 5–10 μg of proteins were
separated by 8% SDS-PAGE, transferred to polyvinylidene difluoride (PVDF) membranes
(Millipore, Massachusetts). Non-specific protein binding was blocked in Tris-buffered
saline Tween-20 (TBS-T) (50mM Tris–HCl, 150mM NaCl, 0.1% Tween 20, pH 7.6)
containing 5% dry milk for 30mins at 37°C. Proteins of interest were immunoblotted with
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the appropriate monoclonal antibodies used at 1:1000 to 1:10000 dilutions at 4°C
overnight followed by the secondary horseradish peroxide-conjugated antibodies used at
1:1000 dilutions at RT for 1 hour. Antibody interactions were visualized with enhanced
chemiluminescence (ECL) horseradish peroxidase (HRP) substrate (Thermo fisher
scientific, Massachusetts) using iBright Western Blot Imaging Systems (Invitrogen, kindly
provided by Dr. Ram Mahato, University of Nebraska Medical Center, Omaha, NE).
HSC70 and β-actin have been used as a loading control. Band intensities were analyzed
by ImageJ software.
3.2.8 Optimization of NG by extending the PEG block
A preliminary study of biodistribution of cisplatin loaded into rNG5k after intravenous
administration was conducted in Dr. Kabanov’s lab at the University of North Carolina
using a TNBC mouse model. Their data suggested that CDDP/ rNG5k mainly accumulated
in liver and spleen with very little amount going to the tumor tissue. To better optimize the
pharmacokinetic properties of the carrier system and reduce the clearance by the
mononuclear phagocyte system (MPS), we developed NGs with a doubled length of PEG
block using the same templating method. Instead of 114 of EG repeating units, the new
NGs have 228 repeating units with similar numbers of Glu units and Phe moieties.
3.2.8.1 Synthesis of N-carboxyanhydrides (NCA) of BGlu
As described before [37], BGlu (0.020 mole) and anhydrous tetrahydrofuran (THF) were
added into a dried glass reactor to form a suspension under inert (nitrogen) atmosphere.
Triphosgen (0.023 mole) was then dissolved in fresh anhydrous THF and injected drop
wise into the reaction mixture. The reaction was conducted under inert atmosphere with
nitrogen bubbled through the mixture. The mixture was heated at about 55°C with constant
stirring till the mixture became transparent. The solution was precipitated in n-hexane and
then stored at -20°C overnight in order to allow complete precipitation of γ-benzyl L-
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glutamate-N-carboxyanhydride (BGlu-NCA). The white solids obtained were collected and
purified further by repeated precipitation with n-hexane. The resulting NCA monomers
were dried under vacuum for 24 h and characterized by the proton nuclear magnetic
resonance (1H NMR).
3.2.8.1 Synthesis of PEG-b-PGlu150 diblock copolymer
mPEG10k-NH2 (0.02 mmol) was dissolved under stirring in 10 mL of anhydrous
dimethylformamide (DMF) under nitrogen atmosphere at 40°C. BGlu-NCA (5 mmol, the
feed molar ratio of mPEG-NH2 to BGlu-NCA was 1:250) dissolved in 5 mL of anhydrous
DMF was added dropwise and the solution was stirred for 10 days under a nitrogen
atmosphere on a Schlenk line. To monitor the reaction, the aliquot of the reaction mixture
was precipitated using excess of diethyl ether and dried in a vacuum. The composition of
PEG-PBGlu diblock copolymer was determined by 1H NMR from the peak intensity ratios
of the methylene protons of PEG and the phenyl protons of the γ-benzyl groups (500 MHz
in TFA-d1: δ =3.5 (s, 4H, -OCH2CH2-), 4.8 (m, 2H, benzyl), 7.3 (m, 5H, aryl)). Once the
target polymerization degree of PGlu block (150 units) was achieved, the reaction mixture
was precipitated using excess of diethyl ether, purified by repeated precipitation in diethyl
ether, and dried under vacuum. The benzyl groups of PEG-b-PBGlu were removed in the
presence of mixture of trifluoroacetic acid (TFA) and hydrogen bromide (HBr) at a ratio of
3:1 (v/v) to obtain PEG-b-PGlu. Polymer sample was dissolved in 9 mL of trifluoroacetic
acid followed by dropwise addition of 3 mL of hydrogen bromide solution (33 wt. % in
acetic acid). After stirring overnight at 25°C, mixture was precipitated in excess of diethyl
ether and purified by repeated precipitation in diethyl ether. Crude product was dissolved
in water, neutralized by 1M HCl, and dialyzed using a dialysis membrane (MWCO 3,500
Da) against distilled water for 48 hrs. After dialysis, the produce was lyophilized to obtain
the purified product PEG10k-b-PGlu150.
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3.2.8.1 Preparation

of

EGFR-targeted

drug-loaded

NGs

from

PEG10k-P(Glu-

Glu/Phe50)150
Phe functionalities were introduced in PEG10k-b-PGlu150 copolymer by polymer-analogous
modification of the PGlu segment with the Phe methyl ester using carbodiimide-chemistry
as described above. The targeted degree of modification was set at 50 Phe units per
chain. The obtained products were characterized by proton nuclear magnetic resonance
(1H NMR). Micellar precursors based on PEG-P(Glu-Glu/Phe50)150 copolymers were
prepared by the dialysis method using water/organic solvent mixtures followed by direct
crosslinking the COOH groups of glutamic acid units with 1,2-ethylenediamine (ED) in the
presence of EDC at RT. The crosslinking reactions were performed at a molar ratio of
[COOH]/[EDC]/[ED]=10/2/1 to obtain a targeted 20% crosslinking degree. The prepared
nanogel was abbreviated as NG (further denotes as rNG10k). Non-decorated rNG10k and
EGFR-targeted drug-loaded rNG10k was prepared through the same process as described
for preparing the panel of rNG5k. Only the linker between the NG and the ligand was
replaced by maleimide-PEG-amine with longer chain length (Mw 15,000 g mol-1) to expose
the ligand for sufficient interaction with the targeted receptor.
3.2.9 Pharmacokinetic studies
Upon arrival, animals were placed in a facility accredited by the Association for
Assessment and Accreditation of Laboratory Animal Care. Food and reverse osmosis
water were available ad libitum throughout the study. All animal studies were performed
based on the protocols approved by the University of Nebraska Medical Center
Institutional Animal Care and Use Committee. Pharmacokinetics of CDDP and CDDPloaded NGs was conducted on six-week-old female athymic (Ncr-nu/nu) mice purchased
from the Charles River Laboratories (Boston, MA). Before the tumor inoculation, mice
were quarantined for 7 days to minimize the risk of infection. Mice were xenografted with
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human EOC OVCAR-5 cells (2 × 106 cells/mice) administered intraperitoneally (i.p.) in
sterile PBS. On day 20, 30 animals were randomized into 5 treatment groups and given
either free CDDP or CDDP/rNG10k or CDDP/rNG5k or CDDP/PEG-rNG10k or CDDP/LAErNG10k by tail vein injection at an equivalent dose of 5 mg CDDP/kg of body weight. About
25 µl of blood of animals in groups of six (n = 6) were collected at each time point (0, 5,
15 and 30 minutes and 1, 1.5, 2, 4, 6, 8, 12, 24, and 48 hours) in heparinized vials through
the tail vein. After the final time point, animals were sacrificed and then perfused with
about 30 mL saline. Heart, liver, spleen, lungs, kidney and tumors were excised, washed
with saline and frozen over dry ice before storage at -80°C. Blood was immediately
centrifuged at 2,000 g for 5 minutes to obtain plasma, and frozen at -80°C prior to further
analysis. The results were expressed in ng of CDDP accumulated in mg of each organ or
mL of plasma. Pharmacokinetic parameters were estimated using non-compartmental
analysis in Phoenix WinNonlin software (Certara, Princeton, NJ).
3.2.10 Sample preparation and drug content measurements in tissue samples
Known weights of thawed tissue (about 30 mg) from sacrificed mice were decomposed by
wet-ashing in 5 mL Eppendorf tubes with 1.5 mL of mixture of concentrated nitric acid and
30% hydrogen peroxide at ratio of 3:1 (v/v). The mixture was kept at r.t. overnight. An
iridium internal standard was added prior to digestion. Platinum concentrations were
measured on ICP-MS (NexION 300Q, PerkinElmer, Waltham, MA) using iridium correction.
The calibration range for the assay was platinum 0.8–500 ng/mL with extrapolation to
platinum 1000 ng/mL. Necessary dilutions were made if the platinum concentration
exceeded the calibration range. Assay sensitivity was 0.8 ng Pt/mL, with inter- and
intraday assay variability not exceeding 5%. However, this assay did not differentiate
between platinum carried in NGs and released from NGs or between free and proteinbound platinum.
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3.2.11 Animals bioluminescence imaging procedure
Mice carrying tumors with genetic modifications to express firefly luciferase gene can be
injected with luciferin to emit visual bioluminescence (BLI) signals for non-invasive
longitudinal monitoring of disease progression. It provides quantitation since the photon
flux from the tumor is proportional to the number of light-emitting cells [38]. In this study,
bioluminescence imaging was conducted with the IVIS® Spectrum in vivo imaging system
(PerkinElmer, Waltham, MA). Before in vivo imaging, animals were anesthetized with
isoflurane (Henry Schein, Dublin, OH) and injected IP with D-luciferin (PerkinElmer,
Waltham, MA) at the dose of 150 mg/kg (reconstituted in sterile DPBS). Whole-body
Imaging was performed 5 min after injection. Total bioluminescence signal in the regions
of interest (ROIs) drawn around the whole abdomen region was quantified using Living
Image® software (version 4.5; PerkinElmer) and expressed as photons/s/cm2/sr (average
radiance).
3.2.12 Evaluation of therapeutic efficacy
Peritoneal high-grade serous ovarian carcinoma was generated by intraperitoneal
injection of 2×106 OVCAR-5/Luc cells (kindly provided by Dr. Adam Karpf, University of
Nebraska Medical Center, NE) into six-week-old female athymic nude mice. After the
development of tumors (10 days after injection) animals were randomized into 10
treatment groups with 13 mice per group. NRT was given as the water-soluble form:
neratinib maleate. All treatments were supplemented with dextrose at 5% final
concentration and were administered via the tail vein at 4-day intervals. We used one
additional group which received IP injection of LAE-(CDDP+NRT)/NG. The treatment
groups and the doses of each drug are presented in Table 12. Drug amount was
calculated based on the average animal body weight. Animal body weight and tumor
progression, as assessed by BLI, were monitored every fourth day. All images were
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acquired using identical BLI system settings. Tumors were allowed to grow until ascites
developed or animal exhibited body weight loss of 20% or low body condition scoring, then
the mice were euthanized via CO2 asphyxiation. At necropsy, tissues (heart, liver, spleen,
lung, kidney, tumor) were collected followed with either fixing in 10% buffered formalin or
storing at -80 °C for further analysis. The abdominal cavity was carefully checked, and the
spread of the tumor was determined. For evaluating the therapeutic effects on delaying
the cancer-induced muscle wasting [39], gastrocnemius and soleus muscles of mice were
isolated, weighed for comparison, and stored at -80 °C.

Table 12. Treatment groups and dose of drugs used in antitumor efficacy in vivo studies
Treatment groups

Routes of administration

CDDP (mg/kg)

NRT (mg/kg)

4

5% dextrose

IV

EGFR-A-NG

IV

LAE-NG

IV

Free CDDP + NRT

IV

4

CDDP/LAE-NG

IV

4

CDDP/NG + NRT/NG

IV

4

4

(CDDP+NRT)/NG

IV

4

4

CDDP/LAE-NG + NRT/LAE-NG

IV

4

4

(CDDP+NRT)/LAE-NG

IV

4

4

(CDDP+NRT)/EGFR-A-NG

IV

4

4

(CDDP+NRT)/LAE-NG

IP

4

4

3.2.13 Immunohistochemical evaluation of cell proliferation and apoptosis markers
Tumors from mice that received different treatments were excised at day 14 (2-3 mice per
group). The tumors were dissected and fixed in 10% neutral buffered formalin. Then, the
tissues were processed routinely into paraffin, sectioned at a thickness of 5μm.
Proliferating and apoptotic cells were detected using an antibody against Ki-67 and
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caspase-3, respectively. Ki-67 and caspase-3 expression was quantified and evaluated
by Definiens Tissue Studio 64 with corresponding modules (Definiens, Inc., Cambridge,
MA).
3.2.14 Blood chemistry, Cancer antigen (CA)-125 assay and histopathology
Mice (2-3) from each treatment group were sacrificed at 24 hrs after the final dosing.
Serum from the blood of sacrificed animals was collected and analyzed for CA-125 levels
using the CA-125 ELISA kit (Abcam, MA) according to the manufacturer's instructions.
Blood from the sacrificed animals was collected in heparinized tubes and analyzed for
blood cell count and liver enzymes using Hematology Analyzer and Vetscan VS2 (Abaxis,
CA), respectively. Collected tissues were processed, sectioned, inserted into tissue
cassettes, fixed in 10% formalin (Azer scientific, Morgantown, PA) for 48h, dehydrated in
70% ethanol overnight, and paraffin embedded (UNMC Tissue Sciences facility, Omaha,
NE). Sectioned tissues (5 μm) were stained with either hematoxylin and eosin (H&E) or
by immunohistochemistry (IHC). For histopathological diagnosis, H&E-stained slides were
examined by light microscopy and photomicrographs were taken using a Nikon camera
mounted on a Nikon Eclipse 600 microscope (both Nikon Instruments, Melville, NY) with
Adobe Elements 3.0 software (Adobe Systems, San Jose, CA).
3.2.15

Statistical analysis

Statistical comparisons for in vitro studies were carried out using the Students t-test. Each
sample was analyzed based on results that were repeated at least three times. In animal
studies, group means bioluminescence signal intensity, body weights and associated data
generated in animal studies were analyzed using a one-way analysis of variance [40].
Survival was estimated using Kaplan–Meier analysis and compared using the log-rank
test. Analysis of variance and Kaplan–Meier analysis tests were carried out using
GraphPad Prism 5 software (GraphPad Software, Inc.). In all cases, differences at P <
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0.05 were regarded as statistically significant; ones at P < 0.01 or P < 0.001 were
considered higher statistical significances.

3.3 Results and discussion
3.3.1. Synthesis of PEG-P(Glu-Glu/Phe50)150
The primary objective of this study was to develop a carrier system for the co-delivery of
active molecules with varied physicochemical properties and to use it in cancer therapy.
To this end, amphiphilic copolymer PEG-P(Glu-Glu/Phe50)150 was utilized for the synthesis
of such multi-compartment carrier systems. As reported by our group, the introduction of
aromatic Phe moieties into hydrophilic PEG-PGlu block copolymers facilitated selfassembly of copolymers in aqueous solution, allowing the carrier systems to solubilize
hydrophobic molecules [33, 37]. Besides, carrier systems with incorporated aromatic
unites were reported to show improved stability, drug retention in carriers and loading
capacity, which might be attributed to hydrophobic and π–π stacking interactions of the
aromatic units and the cargos [41, 42]. Therefore, the incorporation of Phe moieties in our
carrier system may provide a suitable environment for solubilization of NRT. To drive the
self-assembly of hydrophilic copolymer, PEG-PGlu (Mw/Mn=1.01, Mw 28,000 g mol-1),
hydrophobically modified PEG-b-PGlu derivatives were synthesized via EDC amidation
mediated grafting of PGlu backbone with L-phenylalanine methyl ester (Phe) moieties.
PEG-b-PGlu diblock copolymer (PEG Mw= 5,000 g mol-1), in which 30% of Glu units were
modified with hydrophobic phenylalanine moieties, were utilized for the synthesis of NGs.
The synthesis of the amphiphilic hybrid polypeptide-based copolymer PEG-P(GluGlu/Phe50)150 is illustrated in Figure 23.
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Figure 23. Scheme for the synthesis of PEG-P(Glu-Glu/Phe50)150 polymer via
carbodiimide-chemistry.
The chemical composition of PEG-P(Glu-Glu/Phe50)150 copolymers was determined by 1H
NMR analysis (Figure 24) from the peak intensity ratios of the methylene protons besides
carboxylic acid of PGlu and the phenyl protons of the benzyl groups from Phe. The
characteristics of the PEG-P(Glu-Glu/Phe50)150 copolymer are summarized in Table 13.
These copolymers had a PEG block (114 repeating units) and anionic PGlu block (about
150 repeating units), in which about 30% of Glu units were modified with hydrophobic Phe
moieties.
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Figure 24. 1H NMR spectrum for PEG-P(Glu-Glu/Phe50)150 (TFA-d1, 298K).
Notes: peak assignments are as follows: PEG-P(Glu-Glu/Phe50)150 1H NMR (TFA-d1): δ
ppm= 2.23 (2H, m, -CH2-), 2.62 (2H, broad s, -CH2-), 3.21 (2H, m, -CH2-), 3.86 (3H, m, CH3), 3.91 (2H, s, -CH2-), 4.59 (1H, broad s, -CH-), 4.82 (1H, broad s, -CH-), 5.00 (1H,
broad s, -CH-); 7.11 (5H, m, C6H5)
Table 13. Characteristics of the PEG-P(Glu-Glu/Phe50)150 copolymer.
Polymer

PEG-P(Glu-Glu/Phe50)150

Feed molar ratio (mmol) Repeating Units Ratio* Mn*(g/mol)
PEG-b-PGlu150

Phe

PEG

PGlu

Phe

1

55

114

150

51

*Calculated from 1H NMR spectrum.

36221
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3.3.2. Synthesis and characterization of ligand-installed NGs
The resulting amphiphilic copolymers were anticipated to self-assemble into micellar
particles in aqueous medium due to the incorporation of hydrophobic Phe moieties. After
the polymer synthesis, polymeric micelles were then prepared by mixing the solution of
polymer precursor in dimethylformamide with water (1: 1 v/v) following the dialysis against
water for 48 h. The formation of small particles with relatively narrow particle size
distribution (PDI < 0.2) and net negative charge (~-16 mV) was detected in aqueous
dispersions. Micelles prepared from PEG-P(Glu-Glu/Phe50)150 were further crosslinked to
form NGs. The crosslinking of the PEG-P(Glu-Glu/Phe50)150 was achieved via
condensation reactions between the carboxylic groups of PGlu segments and the amine
groups of ethylenediamine in the presence of a water-soluble carbodiimide, EDC. The
targeted extent of crosslinking (20%) was controlled by the molar ratio of crosslinker to
carboxylic acid groups of the glutamic acid residues. After exhaustive dialysis against
water, NGs were characterized at pH 7 (Table 15). Detected by dynamic light scattering
(DLS) using a Zetasizer Nano ZS (Malvern Instruments Ltd., Malvern, UK), the resulting
NGs displayed an average diameter of about 75 nm and were uniform (monomodal,
narrow size distribution) with net negative charge (ζ-potential = −16.2 mV) which can be
explain by the presence and ionization of polyelectrolyte network formed by PGlu chains.
NGs were further modified by EGFR targeting ligands via a PEG linker for delivering a
drug combination to EGFR-overexpressing ovarian tumors. Briefly, EDC-activated NGs
were first reacted with Maleimide-PEG7.5k-NH2 which was chosen to be longer than the
PEG stealth layer on NGs to avoid steric interference with receptor binding and display
sufficient targeting moieties on the surface for receptor recognition. The hydrodynamic
diameter of PEGylated NGs was 80 ± 2 nm, which is marginally larger than that of
precursor NGs (75 ± 7 nm). However, the ζ-potential of the PEG-modified NGs significantly
increased to -10.6 ± 0.3 mV compared to -16.2 ± 1.3 mV for the unmodified NGs (Table
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15), which might be attributed to the consumption of the PGlu carboxylate groups that
reacted with the amine-terminated PEG linkers as well as additional shielding of surface
charge by tethered PEG chains. Finally, sulfhydryl groups of TCEP (thiol reduction
reagent) activated targeting ligands (EGFR-A or L-AE) were reacted to maleimide terminal
groups on NG-attached PEG linkers. Such selective and efficient cysteine conjugation
using maleimide–thiol reactions is widely used to produce site-specific protein–polymer
conjugates [43]. After the conjugation, the particle size and ζ-potential of ligand-installed
NGs remained practically the same as those of the PEGylated NGs (Table 14).
3.3.3. Preparation and characterization of drug-loaded polymeric NGs
As mentioned, the carriers are developed to co-deliver two potent anticancer drugs: CDDP
and NRT to achieve boosted synergistic therapeutic effects to combat EGFR
overexpressing ovarian cancers. To prepare the binary drug combination-loaded NGs, two
steps were conducted to achieve the goal. We have previously shown that the attachment
of the targeting groups should be carried out after NGs loading with CDDP to avoid
inactivation of protein through CDDP binding with its reactive functional groups, such as
carboxylic groups [44]. Therefore, in this study to prepare targeted NGs with binary drug
combination (further abbreviated as EGFR-A-(CDDP + NRT)/NGs and LAE-(CDDP +
NRT)/NGs), CDDP was first loaded into PEGylated NGs through incubation with PEGNGs aqueous dispersion for 24h at pH 9 followed by conjugation of EGFR targeting
ligands to PEG linkers. At the next step, NRT was solubilized into the hydrophobic domain
of targeted CDDP/ NGs through an extraction method. Scheme for the preparation of
EGFR-targeted NGs is presented in Figure 25. Targeted (CDDP+NRT)/NG were small
particles (hydrodynamic diameter of approximately 80 nm) with unimodal particle size
distribution (PDI < 0.2) as determined by DLS and contained 0.003 μmol EGFR-A or 0.031
μmol L-AE per mg of polymer. As expected, the net negative charge and particle size of
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NGs decreased upon CDDP loading consistent with neutralization of PGlu segments by
CDDP and collapse of PGlu network (Table 15). The loading capacities for CDDP and
NRT, alone or in combination, remained relatively the same as for bare NGs (Table 14).
The average molar ratio of the CDDP and NRT incorporated into NGs was close to 2:1,
which has been previously shown to provide strong synergistic cytotoxic effects in TNBC
cells with high EGFR expression. A similar procedure was used to prepare nontargeted
(CDDP + NRT)/NGs from unmodified NG precursors.

Figure 25. Scheme for the preparation of EGFR-targeted NGs
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Table 14. Physicochemical characteristics of EGFR-targeted NGs

Samples

ζ-potential, mv µg of protein or
peptide /mg of
polymer

Deff (nm) PDI

µmol of protein
/mg of polymer

rNG5k

75 ± 7

0.16

-16.2 ± 1.3

PEG-rNG5k

80 ± 2

0.17

-10.6 ± 0.3

LAE-rNG5k

81 ± 2

0.18

-11.0 ± 2.1

29 ± 4

0.031

EGFR-A- rNG5k

83 ± 5

0.17

-13.7 ± 0.5

75 ± 10

0.003

Effective hydrodynamic diameter (Deff), polydispersity index (PDI), and ζ-potential were
determined by DLS (PBS, pH 7, 25oC). Amount of conjugated protein or peptide was
determined by BCA assay. Data are presented as average ± SD from three experiments.

Table 15. Physicochemical characteristics of drug-loaded EGFR-targeted rNG5k
LC, w/w%

Samples

Deff (nm)

PDI

ζ-potential, mV

NRT/rNG5k

85 ± 2

0.16

-17.5 ± 0.5

CDDP/rNG5k

66 ± 2

0.15

-2.3 ± 1.8

9±2

(CDDP+NRT)/rNG5k

83 ± 3

0.19

-5.7 ± 0.9

10 ± 2

NRT/EGFR-A-rNG5k

88 ± 4

0.18

-12.4 ± 1.8

CDDP/EGFR-A-rNG5k

78 ± 3

0.17

-9.5 ± 1.9

8±1

(CDDP+NRT)/EGFR-A-rNG5k

86 ± 3

0.19

-5.4 ± 1.2

7±1

NRT/LAE-rNG5k

87 ± 5

0.19

-13.3 ± 1.1

CDDP/LAE-rNG5k

74 ± 4

0.16

-7.4 ± 1.6

10 ± 1

(CDDP+NRT)/LAE-rNG5k

82 ± 6

0.18

-9.0 ± 2.4

9±1

CDDP

NRT
9±1

9±2
9±1

7±1
10 ± 1

9±1

Effective hydrodynamic diameters (Deff), polydispersity index (PDI), and ζ-potential were
determined by DLS (PBS, pH 7, 25oC). Data are presented as average ± SD from three
experiments.

127

3.3.4. Cellular association
EGFR, a transmembrane receptor promoting cell proliferation and survival, is the receptor
of interests being targeted in our studies. To demonstrate the effect of attachment of
targeting ligand on cellular association of NGs, we used EGFR+ human ovarian carcinoma
OVCAR-5 and SKOV-3 cells, MDA-MB-468 TNBC cells as well as a non-EGFRpresenting NIH 3T3 cells. Cultured cells were exposed to fluorescent Cy5-labeled EGFRA-rNG5k (0.3 mg/mL) for 2h at 4oC followed by thorough washing with cold PBS to ensure
particle removal from the medium. The cells were further incubated with fresh media for
an additional 1 h at 37°C. 4oC was chosen as the temperature for exposing cell to NGs to
exclude the cellular uptake by energy-dependent vesicular transport since the
participating proteins and enzymes are sensitive to temperature. However, the ligandreceptor binding is not inhibited at 4oC, thus the observed cellular association with NGs
will be mainly mediated by the interaction between ligand and the corresponding receptor.
As shown in Figure 26, the EGFR-A-rNG5k were effectively associated with EGFR positive
MDA-MB-468 cells as compared to NIH 3T3 cells demonstrated by up to 4 folds difference
in the percentage of cells associated with EGFR-A-rNG5k. In contrast, the interaction of
non-decorated NGs with both cell types was practically negligible. This selective targeting
could be attributed to the complementary binding to the EGFR by the EGFR-A ligands on
the surface of NGs. Notably, such enhanced cellular association was also observed in
another two EGFR positive cell lines: OVCAR-5 and SKOV3. This further demonstrates
that this selective targeting is not cell specific, but more related to the amplified expression
of EGFR on the cell surface. We also compared the cell uptake of NGs when they are
applied at different concentrations. As shown in Figure 27, when EGFR-A- rNG5k
concentration was below 0.15 mg/mL, the percentage of cells associated with NGs was
almost equal for both EGFR+ cells and EGFR- cells. However, when concentration
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increased to 0.3 mg/mL, significantly higher cell association with NG was observed in
OVCAR-5/ EGFR+ compared with 3T3/EGFR-. As we know that lowering the culture
temperature will affect the diffusion of the NGs, reduced diffusion would result in the
hampered NGs uptake in cells [45]. Low temperature hampered the diffusion of NGs which
might explain the significantly reduced uptake of EGFR-A-rNG5k in EGFR+ cells. For the
peptide ligand L-AE, we performed the similar experiment using LAE-rNG5k and also
observed that LAE-rNG5k association with EGFR positive OVCAR-5 cells significantly
exceeded that of NIH 3T3 cells as shown in Figure 28 (p < 0.01).
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Figure 26. Cellular association of Cy-5-labeled EGFR-A-rNG5k (T) and nondecorated rNG5k (NT) in MDA-MB-468/EGFR+, OVCAR-5/EGFR+, SKOV-3/EGFR+
and NIH 3T3/EGFR- cells as analyzed by flow cytometry. [NGs] = 0.3 mg/mL and 75
μg protein per mg of polymer.
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Figure 27. Cellular association of Cy-5-labeled EGFR-A-rNG5k (T) and non-decorated
rNG5k (NT) in MDA-MB-468/EGFR+ and NIH 3T3/EGFR- cells as analyzed by flow
cytometry. [NGs] = 0.3 mg/mL, 0.15 mg/mL and 0.075 mg/mL with 75 μg protein per mg
of polymer.
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Figure 28. Cellular association of Cy-5-labeled LAE-rNG5k (T) and non-decorated rNG5k
(NT) in OVCAR-5/ EGFR+ and NIH 3T3/EGFR- cells as analyzed by flow cytometry. [NGs]
= 0.3 mg/mL and 29 μg peptide per mg of polymer.

3.3.5. In vitro cytotoxicity studies
CDDP is a well-known DNA-damaging agent. Its mechanism of action involves formation
of cisplatin-DNA adducts to disrupt DNA structure and interfere with DNA replication and
transcription and ultimately induce apoptotic cell death. Herein we studied the synergy of
CDDP and NRT, which is an irreversible inhibitor towards EGFR, HER2 and HER4. As an
inhibitor of HER family, NRT might potentiate therapeutic efficacy of CDDP by reducing
DNA-damage repair through interfering with EGFR-mediated Histone H4/DNA-PKcs/ATM
pathway and pushing cells towards apoptotic death. Besides, NRT further sensitizes cells
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to CDDP by downregulating oncogenic Cyclin D1 to keep cells blocked at G1 phase during
cisplatin treatment since tumor cells appear to be maximally sensitive to cisplatin in G1
phase and minimally sensitive in S-phase [25]. Cytotoxicity of either free drugs or single
drug-loaded and combination nanogel formulations were evaluated in human ovarian
cancer cell lines SKOV-3 and OVCAR-5 with high EGFR expression as well as in A2780
cells with negligible EGFR expression. After 48-hour treatment, the surviving cell
population was assessed by a CellTiter Blue assay (CTB), which measures the metabolic
activity of viable cells. The half-maximal inhibitory concentrations (IC50) of free drugs,
single and combination-drug-loaded NGs are compared in Table 16. Indeed, the
combination of CDDP and NRT was significantly more efficient in killing EGFR
overexpressing cell lines than just CDDP treatment indicated by a significant drop in the
IC50 value of CDDP when administered in combination with NRT in a single carrier for 48
hours. When the treatment was given to EGFR+ SKOV-3, combination index analysis at
IC50 using the Chou and Talalay method [36] showed that the synergistic cytotoxicity
(CI<1) between the two drugs was observed both in the form of free drugs (CI=0.43 ±
0.03) and combination in rNG5k (CI = 0.29 ± 0.02). When both drugs were administered in
the form of a cocktail of single drug-loaded NGs at equivalent doses, the synergy of action
was still retained with less prominent effect compared with that seen in the case of
combination of dual-drug-loaded NGs. These data suggest that synchronized delivery of
this drug combination in the same nanogel formulation may play an essential role in the
cytotoxic activity. We also observed a similar trend in another EGFR overexpressing cell
line OVCAR-5, which is a high-grade serous ovarian cancer (HGSOC) cell line, the most
commonly diagnosed form of EOC with advanced stage at onset of diagnosis and high
mortality rate. However, such strong synergy was not displayed in A2780 with negligible
EGFR expression indicated by a CI value close to 1 when cells were given the combination
treatments. Importantly, rNG5k alone was not toxic at the range of concentrations used for
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the treatment with CDDP/rNG5k formulations (Figure 29). CDDP/rNG5k displayed lower
cytotoxic activities than free CDDP which probably arises from the relatively slow release
of CDDP from NGs. The functionalization of EGFR-A or L-AE to the NGs didn’t remarkably
enhance the cytotoxicity of binary-drug-loaded NGs probably attributed to the fact that the
long-term static incubation could enhance non-specific uptake of NGs.
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Figure 29. In vitro toxicity of empty rNG5k in both SKOV-3 and OVCAR-5 cancer cells as
determined by CTB assay. Cells (4000cells/well) were treated with empty NGs at various
concentrations for 48 h at 37°C.
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Table 16. Comparison of IC50 values for various drug-loaded NGs, free NRT and CDDP
against EGFR+ SKOV-3 and OVCAR-5 cells and EGFR- A2780 cells as determined by
CellTiter-Blue® assay.
IC50, µM
SKOV-3

OVCAR-5

A2780

CDDP

3.4 ± 0.8

2.9 ± 0.7

1.3 ± 0.2

NRT

1.6 ± 0.3

2.5 ± 0.4

0.50 ± 0.19

CDDP/rNG5k

12 ± 2.3

29.7 ± 3.7

6.2 ± 2.4

NRT/rNG5k

1.5 ± 0.3

2.9 ± 0.3

0.75 ± 0.14

1.1 ± 0.1

2.8 ± 0.5

1.3 ± 0.1

CI**= 0.29 ± 0.02

CI= 0.41 ± 0.04

CI= 0.82 ± 0.05

1.9 ± 0.7

3.4 ± 0.4

1.4 ± 0.2

CI= 0.50 ± 0.17

CI= 0.52 ± 0.19

CI= 0.98 ± 0.13

1.2 ± 0.5

1.7 ± 0.2

0.50 ± 0.24

CI= 0.43 ± 0.03

CI= 0.61 ± 0.05

CI= 1.20 ± 0.36

0.87 ± 0.1

2.4 ± 0.2

1.0 ± 0.2

2.7 ± 0.3

*(CDDP+NRT)/rNG5k
*CDDP/rNG50/150 +
NRT/rNG5k
*Free CDDP+NRT
*(CDDP+NRT)/EGFR-ArNG5k
*(CDDP+NRT)/LAErNG5k

*calculated with respect to CDDP. **: Combination index was calculated with respect to
CDDP. Data presented as mean ± SD. N=3
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3.3.6. Insights in molecular mechanisms of synergistic drug interaction at the cellular
level
To investigate the molecular basis for the synergistic effect of combination of CDDP and
NRT at a molar ratio of ca. 2:1 observed in the previous cell viability studies, we used
western blot analysis to first determine the level of HER1/EGFR expression and phosphorEGFR level in EGFR+ SKOV-3 and OVCAR-5 cell lines after various treatments (Figure
30 & 31). Cells were treated with either single CDDP (10 µM), NRT (5 µM) or the binary
drug combination at the same dose for 2h. Then cells were treated with EGF (100 ng/mL)
for 5 mins to stimulate EGFR phosphorylation. Cells without EGF treatment were used as
a control. Notably, EGFR expression was relatively the same among a panel of all treated
cells, indicating that the treatment with EGF, CDDP or NRT does not change the cell
expression level of EGFR. However, higher phosphor-EGFR was found in cells treated
with CDDP or EGF, a ligand for activation and phosphorylation of EGFR, indicating that
CDDP treatment triggered the activation of EGFR, which is considered as a pro-survival
signal leading to mitigated therapeutic efficacy. Such trend was more obvious in SKOV-3
cell line compared to OVCAR-5 cell line. No obvious change in terms of the level of
phosphor-EGFR was found in cells treated with NRT in the presence of EGF, indicating
that NRT successfully suppressed the EGF-mediated activation and phosphorylation of
EGFR. Similarly, no observable change in phosphor-EGFR was found in both cells treated
with a combination of CDDP, NRT and EGF, further indicating that NRT was able to
suppress EGFR activation induced by CDDP and EGF, suggesting that the CDDPmediated pro-survival signal could be reversed by NRT, rendering cancer cells more
vulnerable to the cytotoxic effects of CDDP when such combination was given to EGFR+
cell lines.
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HER1/EGFR activates several cytoplasmic signal-transduction pathways such as
mitogen-activated protein kinase (MAPK), PI3 kinase/Akt, JAK/STAT [46]. Among them,
MAPK and Akt are the major two downstream effectors of EGFR investigated in many
studies due to their crucial roles in transporting signals for promoting cell division and
survival. We investigated whether NRT would inhibit the activity of these two downstream
effectors, MAPK (ERK) and Akt, which may correlate with the synergistic toxicity between
CDDP and NRT in EGFR+ SKOV-3 and OVCAR-5 ovarian cancer cells. Similarly, a panel
of treatments was given to both cell lines at various concentrations with or without the
receptor stimulator EGF (100 ng/mL). As seen in Figure 32, NRT at 5 µM markedly
inhibited ERK1/2 (MAPK) as well as Akt activity in EGF-stimulated OVCAR-5 as evident
by more than 7 folds reduction in the level of ERK1/2 kinase phosphorylation and 2 folds
reduction in the level of Akt activation. Notably, NRT almost completely blocked ERK1/2
activity in OVCAR-5 cells. Most importantly, CDDP was able to induce almost the same
level of Akt/ERK1/2 activation as the stimulator EGF, which was completely reversed by
the addition of NRT, further suggesting that the reverse of CDDP-induced pro-survival
signal by NRT might be the molecular mechanism for the strong synergistic effect of the
drug combination in the EGFR+ OVCAR-5 cell line. Similarly, CDDP induced an increase
in the activation of Akt and ERK1/2 in SKOV-3 cells but not so dramatic as OVCAR-5
(Figure 33). Besides, NRT was able to completely reverse the activation of the prosurvival signal induced by CDDP. When the combination treatment was given to SKOV3, the p-ERK1/2 level was suppressed even below the the basal level. The appearance of
the cleaved-PARP band indicates that CDDP treatment successfully triggered the cell
apoptosis (Figure 32). Evaluation of the effects of treatment by CDDP and NRT on EGFR
signaling in EGFR- cells was conducted on A2780 cells, a widely investigated ovarian
cancer cell line for establishing ovarian cancer xenograft tumor model. As shown in Figure
34, the level of activated EGFR after the treatment with EGF was quite low compared to
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EGFR+ SKOV-3 or OVCAR-5 cells. The treatment with CDDP didn’t induce the increase
in the activation of EGFR, Akt and ERK1/2. Activation level of kinases in cells was almost
the same when given with single drug or binary drug treatments, which might explain the
low synergy between CDDP and NRT in A2780 cells.
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Figure 30. Effect of NRT and CDDP on total EGFR and phosphorylation of EGFR in
OVCAR-5 cells. Cells were incubated in medium containing the indicated concentrations
of treatments for 2 hours. At the end of the 2-hour incubation, 100 ng/mL EGF was added
for 5 minutes. Total proteins (10 μg aliquot) were prepared and separated by 8% SDSPAGE. After transferring to a PVDF membrane, blots were probed with anti-phosphoEGFR, anti-EGFR, anti-HSC70, respectively. The values underneath the blots represent
relative changes of p-EGFR levels present in the treated cells compared to the basal level
of those in control cells after normalization to HSC70, quantified by densitometric analysis
using software ImageJ. Blots are representative of 3 independent experiments.
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Figure 31. Effect of NRT and CDDP on total EGFR and phosphorylation of EGFR in
SKOV-3 cells. Cells were incubated in medium containing the indicated concentrations of
treatments for 2 hours. At the end of the 2-hour incubation, 100 ng/mL EGF was added
for 5 minutes. Total proteins (10 µg) were prepared and separated by 8% SDS-PAGE.
After transferring to a PVDF membrane, blots were probed with anti-phospho-EGFR, antiEGFR, anti-HSC70, respectively. The values underneath the blots represent relative
changes of p-EGFR levels present in the treated cells compared to the basal level of those
in control cells after normalization to HSC70, quantified by densitometric analysis using
software ImageJ. Blots are representative of 3 independent experiments.
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Figure 32. Effect of NRT and CDDP on phosphorylation of MAPK (ERK1/2) and Akt in
OVCAR-5 cells. Cells were incubated in medium containing the indicated concentrations
of listed treatments for 2 hours. At the end of the 2-hour incubation, 100 ng/mL EGF was
added for 5 minutes. Total proteins (10 µg) were prepared and separated by 8% SDSPAGE. After transferring to a nitrocellulose membrane, blots were probed with antiphospho-ERK1/2, anti-phospho-Akt, anti-HSC70, respectively. The values underneath the
blots represent the relative changes of p-ERK1/2 and p-Akt levels present in the treated
cells compared to the basal level of those in control cells after normalization to HSC70,
quantified by densitometric analysis using software ImageJ. Blots are representative of 3
independent experiments.
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Figure 33. Effect of NRT and CDDP on phosphorylation of MAPK (ERK1/2) and Akt in
SKOV-3 cells. Cells were incubated in medium containing the indicated concentrations of
listed treatments for 2 hours. At the end of the 2-hour incubation, 100 ng/mL EGF was
added for 5 minutes. Total proteins (10 µg) were prepared were prepared and separated
by 8% SDS-PAGE. After transferring to a nitrocellulose membrane, blots were probed with
anti-phospho-ERK1/2,

anti-phospho-Akt,

anti-HSC70,

respectively.

The

values

underneath the blots represent the relative changes of p-ERK1/2 and p-Akt levels present
in the treated cells compared to the basal level of those in control cells after normalization
to HSC70, quantified by densitometric analysis using software ImageJ. Blots are
representative of 3 independent experiments.
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Figure 34. Effect of NRT and CDDP on phosphorylation of EGFR, MAPK (ERK1/2) and
Akt in A2780 cells. Cells were incubated in medium containing the indicated
concentrations of listed treatments for 2 hours. At the end of the 2-hour incubation, 100
ng/mL EGF was added for 5 minutes. Total proteins (10 µg) were prepared and separated
by 8% SDS-PAGE. After transferring to a nitrocellulose membrane, blots were probed with
anti-phospho-EGFR, anti-phospho-ERK1/2, anti-phospho-Akt, anti-HSC70, respectively.
The values underneath the blots represent the relative changes of p-EGFR, p-ERK1/2 and
p-Akt levels present in the treated cells compared to the basal level of those in control
cells after normalization to HSC70, quantified by densitometric analysis using software
ImageJ. Blots are representative of 3 independent experiments.
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3.3.7. Optimization of NGs by extending the length of PEG block
PEG10k-P(Glu-Glu/Phe50)150 copolymer was synthesized as illustrated in Figure 35. BGluNCA was synthesized first as a monomer. The diblock copolymers PEG-b-PBGlu were
then synthesized via ring-opening polymerization of BGlu-NCA monomers using aminoterminated PEG (Mw = 10,000 g mol-1) as macroinitiator. The length of PBGlu block was
set constant by using feed molar ratio of mPEG-NH2 to BGlu-NCA at 1 : 250 to obtain
target product: PEG-b-PBGlu150. To remove the protective benzyl groups from PBGlu
block, the deprotection of the glutamate residues was carried out by acidic hydrolysis to
obtain PEG-b-PGlu. The chemical composition of BGlu-NCA, diblock copolymers before
and after deprotection were determined by 1H NMR analysis (Figure 36-38). The success
in complete deprotection was indicated by the disappearance of benzyl methylene proton
signals at δ ppm=5.08 as shown in 1H NMR (Figure 38). The polymer precursors PEGP(Glu-Glu/Phe50)150 were then synthesized as described previously via polymer-analogous
modification of the 30% Glu units with the Phe methyl ester using carbodiimide-chemistry
in aqueous media. The resulting copolymer had a PEG block (228 repeating units), anionic
PGlu block (150 repeating units), in which about 30% of Glu units were modified with
hydrophobic phenylalanine moieties as determined by
polymerization

degree of the resulting polymers

summarized in Table 17.

H NMR (Figure 38). The

1

PEG10k-P(Glu-Glu/Phe50)150 is
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Figure 35. Scheme for the synthesis of PEG10k-P(Glu-Glu/Phe50)150
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Figure 36. BGlu-NCA. 1H NMR (CDCl3): δ ppm= 2.14 (2H, m, -CH2-), 2.60 (2H, m, -CH2), 4.37 (1H, m, -CH-), 5.14 (2H, s, -CH2-), 7.35 (5H, m, C6H5)
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Figure 37. PEG-b-PBGlu 1H NMR (TFA-d1): δ ppm= 1.95 (2H, m, -CH2-), 2.17 (2H, m, CH2-), 3.88 (4H, s, -CH2CH2-), 4.67 ( 1H, m, -CH-), 5.08 (2H, m, -CH2-); 7.23 (5H, m,
C6H5).

147

Figure 38. PEG-PGlu 1H NMR (TFA-d1): δ ppm= 2.14 (2H, m, -CH2-), 2.31 (2H, m, -CH2), 3.88 (4H, s, -CH2CH2-), 4.81 ( 1H, m, -CH-).
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Figure 39. PEG10k-P(Glu-Glu/Phe50)150 1H NMR (TFA-d1): δ ppm = 2.24 (2H, m, -CH2-)
2.69 (2H, m, -CH2-), 3.93 (3H, broad s, -CH3), 3.97 (4H, s, -CH2CH2-), 7.18 (5H, m, C6H5)
Table 17. Characteristics of the PEG-P(Glu-Glu/Phe50)150 copolymer.
Polymer

Feed molar ratio (mmol) Repeating Units Ratio* Mn*(g/mol)
PEG-b-PGlu150

Phe

PEG

PGlu

Phe

1

55

228

150

51

PEG-P(Glu-Glu/Phe50)150

41221

*Calculated from 1H NMR spectrum.
The polymer precursors PEG-P(Glu-Glu/Phe50)150 were used to prepare NGs through the
same procedure as described. The optimized NGs were further denoted as rNG10k. The
EGFR-targeted and drug-loaded rNG10k were prepared using the same procedures
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described above and their physicochemical characteristics are presented in Table 18.
Notably, dimensions as well as ζ-potentials of rNG10k were comparable with those of rNG5k
indicating that the elongation of PEG block didn’t significantly change the microscopic
characteristics of NGs. The loading capacities for NRT and CDDP, alone or in
combination, remained relatively the same as for rNG5k.
Table 18. Physicochemical characteristics of EGFR-targeted rNG10k
µg of Protein
/mg of polymer

µmol of Protein
/mg of polymer

-16.0 ± 2.1

26 ± 3

0.027 ± 0.0032

-18.7 ± 0.5

70 ± 7

0.0028 ± 0.00027

ζ-potential, mv

Samples

Deff
(nm)

PDI

rNG10k

61 ± 4

0.16

-23.1 ± 2.4

PEG-rNG10k

68 ± 3

0.17

-16.6 ± 1.3

LAE-rNG10k

69 ± 4

0.18

EGFR-A-rNG10k

72 ± 5

0.17

Effective hydrodynamic diameters (Deff), polydispersity index (PDI), and ζ-potential were
determined by DLS (PBS, pH 7, 25oC). Data are presented as average ± SD from three
experiments.
Table 19. Physicochemical characteristics of drug-loaded rNG10k
LC, w/w%

Samples

Deff (nm)

PDI

ζ-potential, mV

NRT/rNG10k

71 ± 3

0.18

-24.5 ± 1.5

CDDP/rNG10k

54 ± 3

0.17

-9.2 ± 2.1

9±1

(CDDP+NRT)/rNG10k

73 ± 5

0.16

-10.7 ± 1.2

9±1

NRT/EGFR-A-rNG10k

80 ± 4

0.19

-17.3 ± 0.7

CDDP/EGFR-A-rNG10k

68 ± 4

0.15

-7.3 ± 0.8

10 ± 1

(CDDP+NRT)/EGFR-A-rNG10k

79 ± 3

0.17

-6.9 ± 2.1

10 ± 1

NRT/LAE-rNG10k

77 ± 6

0.19

-15.8 ± 0.9

CDDP/LAE-rNG10k

61 ± 3

0.15

-5.6 ± 2.8

10 ± 1

(CDDP + NRT)/LAE-rNG10k

78 ± 4

0.16

-8.5 ± 1.5

9±2

CDDP

NRT
9±1
9±2
9±1
9±1
9±1
9±1
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Effective hydrodynamic diameters (Deff), polydispersity index (PDI), and ζ-potential were
determined by DLS (PBS, pH 7, 25oC). Data are presented as average ± SD from three
experiments.
3.3.8. Pharmacokinetic properties of NGs
Pharmacokinetics (PK) of CDDP and CDDP-loaded NGs after single intravenous
administration was determined by measuring platinum concentrations in plasma at
different time points over 48 hours and peripheral tissues at the end of study by ICP-MS
(Figure 40-41). As frequently observed [47, 48], free CDDP was quickly eliminated from
the blood by renal filtration into the urine, with only about 15% of the injected dose
detectable in plasma 5 minutes after injection. In contrast to the fast clearance of free
CDDP from systemic circulation, up to 80% of the injected CDDP/NGs retained 5 minutes
after dosing. Mice treated with CDDP/NGs had a more than the four-fold higher maximum
observed platinum concentration (C0) and up to 13-fold higher plasma area-under-thecurve (AUC) compared with that of free CDDP. Both observed volume of distribution
(Vz_obs) and observed total body clearance (Cl_obs) were decreased by up to 50-fold
and 8-fold, respectively. Importantly, we observed that the plasma Pt concentration in mice
treated with CDDP/rNG5k was decreasing faster than that of CDDP/rNG10k especially in
the first 6 hrs. The PK profile in the plasma was fitted using a non-compartment model to
obtain key PK parameters that quantitatively describe how the mice body handles the drug
or NGs (Table 20). Consistent with what was observed in the concentration-time profile of
plasma Pt (Figure 40A), Pt plasma exposure of CDDP/rNG10k determined by AUC was
1.5 folds higher than CDDP/rNG5k. Both Cl_obs and Vz_obs were decreased by 1.5-fold
and 4.4-fold, respectively. Further functionalization by PEG and the targeting ligand L-AE
did not significantly affect the key PK parameters of CDDP/rNG10k. At 48 hours, the last
point of evaluation, tumor platinum levels after CDDP/rNG10k treatment remained threefold higher (p < 0.01) compared with free CDDP treatment, and about 1.9-fold higher (p <
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0.05) compared with CDDP/rNG5k treatment. Notably, CDDP/LAE-rNG10k exhibited a 1.7fold increase in tumor uptake compared with CDDP/rNG10k treatment indicating that the
EGFR targeting ligand successfully enhanced the tumor retention of the decorated carriers
due to the EGFR-specific interaction of ligand-installed NGs with cancer cells, which was
also consistent with the higher specific cellular uptake observed in in vitro studies. Indeed,
the liver and spleen, which are organs responsible for removing opsonized foreign
particles through phagocytosis in the liver and splenic filtration, showed a strong
accumulation of CDDP/NGs (Figure 41). However, liver and spleen platinum contents
were reduced significantly with CDDP/rNG10k treatment compared to CDDP/rNG5k
treatment (p < 0.001). The functionalization of CDDP/rNG10k with additional PEG chains
further reduced the spleen uptake by 1.9 folds. Since kidney is the major excretory organ
for free CDDP, mice treated with free CDDP showed a greater Pt level in kidney compared
with all other organs tested which is consistent with previously reported studies [48].
CDDP loaded in NGs displayed comparable renal platinum accumulation as the free
CDDP, probably due to the macromolecular nature of NGs which exceeded the glomerular
filtration threshold. Overall, these preliminary data suggest that rNG10k showed more
favored pharmacokinetic properties than rNG5k by prolonging circulation time of CDDP,
slowing its elimination, and distributing more CDDP into tumor tissue. The ligand L-AE
further boosted the specific tumor tissue drug accumulation through EGFR-mediated
receptor interaction.
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Figure 40. Concentration–time profile of platinum in OVCAR-5 intraperitoneal tumorsbearing female nude mice in 48h (A) and first 6h (B). Notes: Platinum levels were
measured following a single intravenous dose of 5 mg/kg of cisplatin/NGs or cisplatin.
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Table 20. Pharmacokinetic parameter estimates of platinum in plasma for CDDP or
CDDP/NGs-treated OVCAR-5 human ovarian cancer peritoneal xenograft-bearing female
nude mice
Free
CDDP

CDDP/rNG5k CDDP/rNG10k

CDDP/PEGrNG10k

CDDP/LAErNG10k

C0, ug/mL

24.72

105.03

98.20

127.59

101.50

AUCall,
h*ug/mL

28.6 ± 2.8

209.8 ± 8.2

319.6 ± 22.6

382.4 ± 10.3

366.4 ± 13.9

Vz_obs, L/kg

6.60

0.58

0.13

0.13

0.13

Cl_obs, L/h/kg

0.11

0.022

0.015

0.013

0.015

MRTlast, h

14.51

6.30

4.94

6.08

6.16

Notes: The pharmacokinetic parameters were calculated according to noncompartmental
analysis (Phoenix WinNonlin). C0 represents the maximum observed concentration at the
earliest evaluated time point of 5 min post-injection.
Abbreviations: C0, maximum platinum concentration at the earliest evaluated time point;
AUCall, area under the curve using all the given points including trailing zero
concentrations; Cl_obs, observed total body clearance rate; Vz_obs, observed volume of
distribution; MRTlast, mean residence time from the time of dosing to the time of last
measurable concentration.
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Figure 41. Tissue distribution of platinum in different carriers as determined by ICP-MS.
Mice were sacrificed at 48h post-injection with free CDDP or CDDP/rNG10k or CDDP/rNG5k
or CDDP/PEG-rNG10k or CDDP/LAE-rNG10k. Data are presented as mean ± SD (n= 4). *
p <0.05. *** p < 0.001.
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3.3.1. Evaluation of therapeutic efficacy in vivo
Motivated by the enhanced tumor uptake by targeted formulation in PK studies, we
evaluated its antitumor efficacy in a OVCAR-5 HGSOC intraperitoneal xenograft mice
model which mimics the most common and deadly form of the ovarian cancer [49]. Tumor
model was established by injecting 2 million OVCAR-5/luc cells into the peritoneum of
female nude mice to trigger formation of tumor nodules throughout the abdominal
peritoneum. Almost 100% tumor take rate was seen following i.p. injection of 2 million
OVCAR-5/luc cells. Tumor burden was detectable by BLI as early as 3 days post
inoculation. This disease is associated with marked weight loss and often results in
mortality within 3-4 weeks. If the mice were left untreated, disseminated tumor nodules
would appear on peritoneal surfaces, liver, reproductive tissues, the gastrointestinal tract,
particularly the small intestine, which are all typical sites of metastasis clinically observed
with advanced stage HGSOC [49]. Although not common, gross metastases to the
diaphragm and pancreas were observed. Rare cases of formed ascites fluid in 3-4 weeks
were also observed. Treatments were initiated 10 days post OVCAR-5/luc inoculation. IV
administrations of each formulation were given 4 times at 4-day intervals at 4 mg/kg CDDP
and 4mg/kg NRT equivalents per dose. In this aggressive model, we observed that all
treatments were effective in delaying tumor progression in comparison with control group
(5% dextrose) as shown in Figure 42 and 43. Of note, the mice in the control group found
to be dead even before they reached the euthanization point (Figure 44). In contrast,
formulation treated mice were found to survive much longer and remained alive until the
euthanization threshold indicating the benefits in extending survival. Importantly, therapy
with targeted binary drug combination-loaded NGs, (CDDP+NRT)/LAE-NG, was more
effective in inhibiting tumor growth as compared to nontargeted (CDDP+NRT)/NG (p <
0.05) (Figure 42A and B) with significantly longer median survival (50.5 days vs 42 days,
p < 0.05) (Table 21). The strong synergy of the binary drug regimen seen in vitro was also
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observed in in vivo, and targeted binary combination (CDDP+NRT)/LAE-NG showed
significant inhibition of tumor growth compared to the targeted single CDDP/LAE-NG (p <
0.05) (Figure 42A) with markedly extended median survival (50.5 days vs 38.5 days, p <
0.05) (Table 21). To compare the ability of the carriers to deliver a cytotoxic payload to
the tumor sites as well as whether delivered drugs caused any toxicities in normal tissues,
we sacrificed 3 mice per group at 24 hrs after the final dosing. Consistent with what we
observed in PK studies, targeted formulations, either targeted single drug NG or binarydrug NG, were able to induce a significantly higher Pt accumulation in the target site
compared to nontargeted (CDDP + NRT)/NG (p < 0.05).

This observation further

reinforced our hypothesis that installation of the EGFR targeting ligand L-AE to the delivery
vehicle could enhance drug retention in the target site thereby further boost the cytotoxic
activity of (CDDP + NRT) combination chemotherapy in EGFR+ ovarian cancer.
Table 21. Median survival and p-values of different treatment regimens with respect to
control group (5% dextrose).

Treatment group

Median
Survival (days)

p-values (vs. 5%
dextrose control)

% survival at
censoring date
(80 days)

5% Dextrose

31

-

0

CDDP/LAE-rNG10k

38.5

0.0046

0

(CDDP+NRT)/rNG10k

42

0.0009

0

(CDDP+NRT)/LAE-rNG10k

50.5

<0.0001

37.5%
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Figure 42. In vivo antitumor efficacy of (CDDP + NRT)/LAE-rNG10k in OVCAR-5/Luc
human ovarian cancer intraperitoneal xenograft-bearing female nude mice. A.
Comparison of tumor growth inhibition following IV administration of 5% dextrose (control)
or CDDP/LAE-rNG10k or (CDDP+NRT)/rNG10k or (CDDP + NRT)/LAE-rNG10k. Drug
formulations were injected in 100 μL at a dose of 4 mg CDDP or 4mg NRT equivalents/kg
body weight 4 times at 4-day intervals as indicated by the arrows. Data presented in terms
of relative whole-body bioluminescence units (Rt/R0) to day0. Values indicated are means
± SEM (n = 8), *P < 0.05. ****p < 0.0001. B. Kaplan–Meier analysis of overall survival in
5% dextrose (control) or CDDP/LAE-rNG10k or (CDDP+NRT)/rNG10k or (CDDP +
NRT)/LAE-rNG10k. Log-rank test was used to determine statistical difference between
(CDDP+NRT)/rNG10k and (CDDP + NRT)/LAE-rNG10k groups, *P < 0.05, and between 5%
dextrose (control) and CDDP/LAE-rNG10k groups **P <0.01. C. Tissue distribution of
platinum in different treatment groups as determined by ICP-MS. Mice were sacrificed at
day 14 of the treatment with (CDDP+NRT)/rNG10k or CDDP/LAE- rNG10k or
(CDDP+NRT)/LAE- rNG10k. Values indicated are means ± SD (n = 3), * p < 0.05. D. Organ
weights of mice sacrificed at day 14 of the treatments. Values indicated are means ± SD
(n = 3)
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Figure 43. Quantification of tumor progression in individual mouse treated with either
5% dextrose (control) or CDDP/LAE-rNG10k or (CDDP+NRT)/rNG10k or (CDDP +
NRT)/LAE-rNG10k based on whole body BLI imaging.
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Figure 44. Relative individual body weight (Wt/W0) to the day 0 were measured following
intravenous administration of 5% dextrose (control) or CDDP/LAE-rNG10k or
(CDDP+NRT)/rNG10k or (CDDP + NRT)/LAE-rNG10k. Body weight were measured every 4
days until day 60.

Advanced ovarian cancer patients frequently suffer from worsening nutritional status and
cachexia which is a debilitating condition characterized by progressive body weight loss
with wasting of skeletal muscle and adipose tissue, accounting for at least 20% of deaths
in cancer patients in part due to impaired respiratory or cardiac function [50-53]. Moreover,
weight loss has been considered as an indicator of terminal disease, poor prognosis, and
high recurrence [54-56]. Thus, reversal of such condition could improve the prognosis of
cancer patients and benefit the management of malignancy. Since muscle-wasting
process is pathologically reflected by progressive loss of skeletal muscle mass [57], weight
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change of skeletal muscle was utilized to evaluate whether the developed treatments
would ameliorate ovarian cancer-induced cachexia. Following the treatment, 3 mice were
sacrificed on day 10 and 28 to obtain left soleus and gastrocnemius muscles (widely
studied cachexia-affected skeletal muscles [53]). As shown in Figure 47A, response to
treatment with targeted binary drug combination-loaded NGs was only marginally better
than that for nontargeted combination group in terms of soleus muscle loss, while the
former treatment was significantly better than the targeted single CDDP loaded NGs group
(p < 0.05). Similarly, the most delayed gastrocnemius muscle loss was seen in mice
treated

with

targeted

(CDDP+NRT)LAE-NG

that

outperformed

nontargeted

(CDDP+NRT)/NG and targeted CDDP/LAE-NG in terms of gastrocnemius muscle mass
loss (p < 0.05) (Figure 47B).
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Figure 45. Weight change of soleus muscle (up) and gastrocnemius muscle (down) of left
triceps surae collected from mice sacrificed on day 13, day 28 and day 33. Data presented
in terms of relative weight units (Wt/W0) to day 13 of the treatment. Left: One-way ANOVA
was used to determine statistical difference on day 28 between CDDP/LAE-rNG10k and
(CDDP + NRT)/LAE-rNG10k groups, *p < 0.05, and between 5% dextrose (control) and
(CDDP + NRT)/ rNG10k groups, *p < 0.05. Right: *p < 0.05, between CDDP/LAE-rNG10k
and (CDDP + NRT)/LAE-rNG10k groups, between 5% dextrose and (CDDP + NRT)/LAErNG10k groups.
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Importantly, neither targeted formulations nor nontargeted formulations caused a
significant change in animal body weight, organ weight and blood cell counts (Figure 44,
42D, 45 and Table 22). Although we observed relatively higher exposure of liver and
spleen to CDDP in the formulation groups, there was no evidence of liver or splenic toxicity
by histopathology (Figure 45) and blood chemistry analysis (Table 22), collectively
indicating that the developed formulations are well-tolerated.

Figure 46. Light microscopy images (original magnification 10X) of hematoxylin and osinstained kidney, liver and spleen sections of mice. Tissue samples were collected at day
14.
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Table 22. Clinical chemistry parameters and hematocrit of blood samples collected

from animals sacrificed on day 14 across all treatment groups. Data are
represented as mean ± SD (n = 3).
ALP
(IU/L)

ALT
(IU/L)

BUN
(mg/dL)

RBC
(*1012/L)

WBC
(*109/L)

PLT
(*109/L)

5% Dextrose

42±6

35±1

19±1

8.2±0.6

2.0±0.8

32±2

CDDP/LAE-rNG10k

40±7

44±7

20±3

7.5±0.9

3.4±0.1

28±5

(CDDP+NRT)/rNG10k

45±13

42±3

23±2

7.3±2.7

3.6±0.4

40±5

(CDDP+NRT)/LAE-rNG10k

40±16

37±2

22±3

8.1±0.2

3.8±0.9

32±10

As further evidence of enhanced antitumor activity of CDDP/LAE-NG or (CDDP+NRT)/NG
or (CDDP+NRT)/LAE-NG, we performed histopathological analyses of the tumors excised
post-treatment (one day after last injection), using Ki-67 and Cleaved-caspase-3 (CC3) as
markers for proliferation and apoptosis, respectively. As expected, treatment with single
drug CDDP/LAE-NG caused a significant reduction in Ki67+ cells (p <0.0001) as well as
increase in CC3+ cells, consistent with the primarily cytotoxic effects of CDDP [58] (Figure
46). Notably, co-delivery of NRT further enhanced cell responses to CDDP/LAE-NG
treatment with increased impact on both parameters (p <0.01 for Ki67+ cells and p <0.05
for CC3+cells) (Figure 46), indicating that the combination is superior and promotes
substantial cytotoxic effect. Consistent with the observed significantly higher drug
retention achieved by the targeting strategy, targeted (CDDP+NRT)/LAE-NG treatment
led to a significant reduction in Ki67+ cells (p < 0.01) and an augmentation in CC3+ cells
(p < 0.05) as compared to the nontargeted counterpart. These data reinforced our
hypothesis that installation of the EGFR targeting ligand L-AE to the delivery vehicle could
enhance drug retention in the target site thereby further boost the cytotoxic activity of
CDDP + NRT combination chemotherapy in EGFR+ ovarian cancer.
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Figure 47. Quantification of dividing cells marked by Ki-67 staining (A) and apoptotic cells
marked by cleaved-caspase-3 (CC3) (B) staining in treated tumors (n = 4). Data are shown
as mean ± SEM; **P < 0.01; ****P < 0.0001. Representative immunohistochemical staining
of tumors from mice treated with 5% dextrose, CDDP/LAE-NG, (CDDP+NRT)/NG,
(CDDP+NRT)LAE-NG at original magnification × 2 (C) and magnification × 20 (D).
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In addition to the necessity of incorporating the targeting ligand to the carrier, we further
evaluated whether the synchronized and spatial temporal delivery of binary-drug is crucial
for exerting its cytotoxic activity. Following the same dosing frequency and timeline as the
previous study, each treatment was given intravenously for total of 4 times at 4-day
intervals at 4 mg/kg CDDP and 4 mg/kg NRT equivalents per dose. (CDDP+NRT) at 4
mg/kg for each drug was used as a control-free drug combination with the same dosing
schedule. The tumor progression, animal body weight and lifespan of animals were
monitored and shown in Figure 48 and Table 23. Tumor burden was significantly
decreased by free CDDP + NRT treatment (p < 0.05) compared to 5% dextrose control
(Figure 48A). However, CDDP-NRT combination administered as single NG formulation
was found to be significantly more effective than free drug combination (p < 0.05) (Figure
48A) as measured by BLI. The observed improved efficacy of drug combination treatment
in NG format is possibly due to the significantly enhanced drug retention in tumor as was
observed in the PK studies. While therapy with targeted (CDDP+NRT)/LAE-NG was
marginally more effective in inhibiting tumor growth as compared to a cocktail of targeted
single drug-loaded NGs (not statistically significant), the former group extended the
median survival time for 4 days suggesting that synchronized delivery of CDDP-NRT
combination chemotherapy using NGs plays an crucial role in its cytotoxic activity.
Malignant cells of ovarian cancer tend to spread into peritoneal fluid and disseminate
along the abdominal and pelvic peritoneum to form peritoneal metastases. Giving
chemotherapeutic agents intraperitoneally by infusion into the peritoneum has been
investigated in both bench and bed-side contexts, and demonstrated an improvement in
overall and disease-free survival [59, 60]. However, IP administration is associated with
higher toxicities due to the tissue exposure to high concentration of drugs. Therefore, we
utilize (CDDP+NRT)/LAE-NG to evaluate whether there are therapeutic benefits in
delivering targeted IP chemotherapy in ovarian cancer. As seen in Figure 48, the BLI data
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shows a trend towards enhanced therapeutic efficacy of (CDDP+NRT)/LAE-NG when
administered IP compared to IV regimen. Kaplan–Meier survival analysis also
demonstrated that mice given IP (CDDP+NRT)/LAE-NG appear to have the best
outcomes. However, the differences between groups were not statistically significant.
Overall, major improvement in the antitumor treatment was observed for all co-loaded drug
NGs which resulted in a pronounced tumor growth inhibition and an increase of the median
lifespan to ~54-68.5 days as compared to the treatments comprised of mixtures of the
single drug NGs (Table 23). The longest median survival (68.5 days) was observed in
mice treated with (CDDP+NRT)/EGFR-A-NG which was 9 days longer than that in group
treated with IP (CDDP + NRT)/LAE-NG.

Table 23. Median survival and p-values of different treatment regimens with respect to
control group (5% dextrose).
Treatment group

Median Survival
(days)

p-values (vs. 5%
dextrose control)

% survival at
censoring date(90
days)

5% Dextrose

36

-

0

LAE-rNG10k

36

0.89

0

Free CDDP+NRT

40

0.19

0

CDDP/rNG10k+NRT/ rNG10k

47

0.016

0

CDDP/LAE-rNG10k+NRT/LAErNG10k

50.5

0.0009

0

(CDDP+NRT)/LAE-rNG10k IV

54

0.0008

0

(CDDP+NRT)/LAE-rNG10k IP

59

0.0002

14.3

(CDDP+NRT)/EGFR-A-rNG10k

68.5

0.0028

25
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Figure 48. In vivo antitumor efficacy of (CDDP + NRT)/LAE-rNG10k and (CDDP +
NRT)/EGFR-A-rNG10k in OVCAR-5/Luc human ovarian cancer intraperitoneal xenograftbearing female nude mice. A. Comparison of tumor growth inhibition following IV
administration of 5% dextrose (control) or free CDDP + NRT, CDDP/LAE-rNG10k +
NRT/LAE-rNG10k or (CDDP + NRT)/LAE-rNG10k or (CDDP + NRT)/ EGFR-A-rNG10k. We
used one additional group which received IP injection of (CDDP + NRT)/LAE-rNG10k. Drug
formulations were injected in 100 μL at a dose of 4 mg CDDP or 4mg NRT equivalents/kg
body weight 4 times at 4-day intervals as indicated by the arrows. B. Comparison of tumor
growth inhibition of various treatments for the first 19 days. Data presented in terms of
relative whole-body bioluminescence units (Rt/R0) to the day 0. Values indicated are
means ± SEM (n = 8), *p < 0.05. **p < 0.01. C. Kaplan–Meier analysis of overall survival.
Log-rank test was used to determine statistical difference between CDDP/rNG10k +
NRT/rNG10k and (CDDP + NRT)/LAE-rNG10k IV groups, *p < 0.05, between CDDP/rNG10k
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+ NRT/rNG10k and (CDDP + NRT)/LAE-rNG10k IP groups, **p < 0.01. D. Relative individual
body weight change (Wt/W0) were measured following intravenous administration of
various formulations. Values indicated are means ± SEM (n = 3).

Assuming that the antitumor efficacy of a drug is related to the amount of this drug
delivered to the tumor, we next compared the Pt levels accumulated in the tumor tissue
as a result of different treatments (Figure 49A). Animals injected with CDDP/NG +
NRT/NG cocktail displayed significantly higher levels of Pt in tumors as compared to free
CDDP + NRT treatment group (p < 0.05) which may be attributed to the enhanced
permeability and retention (EPR) effect (Figure 49A). Moreover, treatment with cocktail
of targeted single drug NGs, CDDP/LAE-NG + NRT/LAE-NG, led to a further significant
increase in tumor Pt accumulation (p < 0.05) compared to nontargeted counterpart. It is
likely that EGFR-specific interaction of EGFR targeted NGs with cancer cells contributed
to this increase. Interestingly, we did not detect significant differences in Pt tumor
concentrations between targeted co-loaded drug NGs, (CDDP + NRT)/LAE-NG, and a
cocktail of two targeted single drug NGs, CDDP/LAE-NG + NRT/LAE-NG, when
administered via IV route. These results are generally consistent with the only marginal
improvement in lifespan observed upon treatment with co-loaded drug NGs compared to
single drug-loaded NGs cocktail (Table 23). Notably, the Pt tumor concentration for IP
(CDDP + NRT)/LAE-NG was increased ~1,5-fold compared to the same dose of drug for
IV (CDDP + NRT)/LAE-NG. Such an improvement in drug delivery to the tumor can be
related to a more efficient traffic to tumor sites and a slower intraperitoneal clearance.
Similar higher local drug retention upon IP route of administration was also reported in
previous studies [61-63]. IP group also displayed the higher plasma CDDP concentration
at 24 hrs post-injection as compared to IV counterpart (Figure 49B). This increase
appears to be due to a delayed absorption from the peritoneal cavity to the circulation.

169
However, this observation needs further investigation and possibly be dependent on type
of the nanocarrier and the cargo. The higher Pt retention in the tumors and plasma might
be the reason for the observed better tumor responsiveness to IP (CDDP + NRT)/LAENG treatment (Table 23). Consistent with the PK studies, CDDP level in plasma was the
lowest in group of free drug cocktail due to the rapid clearance by renal filtration (Figure
49B). In contrast, significantly higher level of CDDP was found in all formulation groups
showing their ability to achieve prolongation of drug circulation times and consequently
increase tumor exposure that is translating into enhanced antitumor efficacy (Figure 48).
CA-125 is a glycoprotein encoded by the MUC16 gene either bound to the cell membrane
or released in bodily fluid [64]. Due to the fact that elevated CA125 is detected in most
women with advanced ovarian cancer, CA125 is recommended for ovarian cancer
screening clinically in the U.S. Practice guidelines [65] with proved value in both detection
and disease monitoring [66]. Monitoring CA-125 blood serum levels is also useful for
predict the outcome of the therapy and tumor status after the completion of treatment [67].
To further characterize tumor response to the treatments, we analyzed the serum CA-125
levels in mice on day 14 (second day after last injection). As shown in Figure 49C, levels
of CA-125 were significantly low in the mice that received nanoformulated drug
combinations compared to either control group (p < 0.001) or free CDDP +NRT group (p
< 0.05). However, there was no significant difference among drug-loaded NGs groups and
CA125 levels in these groups were close to assay detection limit (5 U/mL) suggesting the
effectiveness of drug-loaded NGs therapy in reducing tumor burden (Figure 48A).
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Figure 49. (A). Pt content in tumor tissues measured 24 hrs post-injection with various
treatments (day 14). (B). Organ weights of mice sacrificed on day 14 of the treatments.
(C). CA-125 ELISA assay. Quantification of serum CA-125 levels in mice from various
treatment groups. (D). Quantification of plasma CDDP levels in mice from various
treatment groups on day 14. Values indicated are means ± SEM (n = 3).
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It should be emphasized that CDDP and NRT at the designated doses may induce toxicity
to the normal tissues as well. However, this was not the case in our studies. Figure 48C
shows that either single or binary drug combination-loaded targeted NGs did not induce
body weight loss while the same dose of the free CDDP + NRT produced a considerable
body weight loss. These effects were reversible after drug discontinuation, which indicated
systemic toxicity of free CDDP + NRT. In Mice treated with free CDDP + NRT combination
displayed significant decrease of the spleen (Figure 49D, p < 0.01) and kidneys weights
(Figure 49D, p < 0.05). We also observed marginal decreases in liver weights in these
animals but not statistically significant as compared to the naïve control on day 14. In
contrast, such organ weight loss was not observed in any of the drug-loaded NGs groups.
Complete Blood Counts (CBC) analysis on day 14 revealed that red blood cells and
platelets were within the normal range for all groups (Table 24) while there was evident
reduction in the count of white blood cells (WBC) (not statistically significant) in the mice
treated with free CDDP + NRT. It was reported that CDDP treatment could trigger
apoptosis in the bone marrow, affect cell progression through cell cycle and reduce
leukocyte [68]. In contrast, no differences in WBC counts between drug-loaded NG treated
and control mice were observed (Table 24). As expected, despite of relatively higher
exposure of liver and spleen to CDDP in NGs, there was no evidence of liver or splenic
toxicity by histopathology (Figure 50) and related enzyme levels (Table 24). Collectively,
these data demonstrate that the developed formulations are well tolerated with reduced
toxicity as compared to free drugs at the same dose.
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Table 24. Clinical chemistry parameters and hematocrit of blood samples collected from
animals sacrificed on day 14 across all treatment groups. Data are represented as mean
± SD (n = 3).
ALP
(IU/L)

ALT
(IU/L)

BUN
(mg/dL)

RBC
(*1012/L)

WBC
(*109/L)

PLT
(*109/L)

5% Dextrose

47 ± 2

48± 4

16 ± 2

8.8 ± 0.3

1.6 ± 0.3

357 ± 30

LAE-rNG10k

41 ± 6

42 ± 8

18 ± 3

8.4 ± 0.3

1.3 ± 0.3

304 ± 48

Free CDDP+NRT

58 ± 6

51 ± 6

16 ± 4

7.7 ± 0.5

0.9 ± 0.1

325 ± 28

CDDP/rNG10k +NRT/rNG10k

53 ± 4

50 ± 4

19 ± 1

8.6 ± 0.6

1.4 ± 0.4

395 ± 78

CDDP/LAE-rNG10k +NRT/LAErNG10k

47 ± 6

51 ± 4

19 ± 3

8.6 ± 0.5

1.7 ± 0.1

350 ± 64

(CDDP+NRT)/LAE-rNG10k IV

50 ± 7

51 ± 8

19 ± 4

8.5 ± 0.8

1.9 ± 0.2

322 ± 59

(CDDP+NRT)/LAE-rNG10k IP

49 ± 2

37 ± 6

17 ± 2

8.5 ± 0.7

1.5 ± 0.2

362 ± 91

(CDDP+NRT)/EGFR-A-rNG10k

53 ± 3

49 ± 7

18 ± 1

7.7 ± 0.4

1.9 ± 0.1

333 ± 14
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Figure 50. (A). Pt content in tissues measured 24 hrs post-injection with various
treatments (day 14). Values indicated are means ± SEM (n = 3). (B). Light microscopy
images (original magnification 10×) of hematoxylin and eosin-stained kidney, liver and
spleen sections of mice. Tissue samples were collected at day 14.
To further determine the molecular changes indicative of effectiveness of various
treatments on tumor progression, dividing cells and apoptotic cells in excised tumor tissue
sections were evaluated using Ki67 and CC3 biomarkers (Figure 51). The number of
proliferating cells were significantly lower in the tumors of animals treated with
(CDDP+NRT)/LAE-NG as compared with cocktail of CDDP/LAE-NG + NRT/LAE-NG (p <
0.05) or free (CDDP+NRT) (p < 0.01) (Figure 51A). In parallel, a significant increase in
number of apoptotic cells death was also observed in (CDDP+NRT)/LAE-NG treated
tumors (Figure 51A). This could explain the delayed tumor growth seen in animals treated
with (CDDP+NRT)/LAE-NG even in 2 weeks post- treatment, while the tumors of animals
treated with cocktail of CDDP/LAE-NG + NRT/LAE-NG showed a relatively higher rate of
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tumor progression (Figure 48A). Overall, these data manifest a strong synergy of
anticancer action of the combination of CDDP and NRT co-loaded into a single NG.
To mechanistically link the enhanced antitumor activity of CDDP+NRT combination with
the effects of drugs on activation of EGFR, we performed immunohistochemistry (IHC)
analyses of phosphor-EGFR levels in tumors of mice treated with various regimens.
Indeed, lower phosphor-EGFR levels were seen in tumors of (CDDP+NRT)/LAE-NG
treated mice (Figure 51C), correlating with the superior antitumor efficacy of a targeted
combination of DNA damaging agent + pan-HER inhibitor loaded NGs strategy.

Figure 51. Quantification of dividing cells marked by Ki-67 staining (A) and apoptotic cells
marked by cleaved-caspase-3 (CC3) (B) staining in treated tumors (n = 3). Data are shown
as mean ± SD; *p < 0.05; **p < 0.01. Representative immunohistochemical staining of
tumors from mice receiving various treatments at original magnification × 2 (C).
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Due to the much-extended survival of mice treated with (CDDP+NRT)/EGFR-A-NG, we
would like to understand whether the protein ligand itself exerts therapeutic effects. We
further evaluated the antitumor efficacy of EGFR-A-NG. To this end, OVCAR-5 cells were
treated with either EGFR-A (5 µM) or NRT (5 µM) for 2h. Then cells were stimulated by
EGF (100ng/mL) for 5 mins to trigger EGFR phosphorylation. Notably, both EGFR-A and
NRT could suppress the EGF-induced EGFR/Akt/ERK (1/2) phosphorylation (Figure 52).
However, EGFR-A were not as efficient as NRT in terms of blocking EGFR-mediated
signal transduction, indicated by less p-Akt and p-ERK(1/2) reduction.
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Figure 52. Effect of EGFR-A on phosphorylation of EGFR, MAPK (ERK1/2) and Akt in
OVCAR-5 cells. Cells were incubated in medium containing the 5 µM of either NRT or
EGFR-A for 2 hours. At the end of the 2-hour incubation, 100 ng/mL EGF was added for
5 minutes. Total proteins (10 µg) were prepared and separated by 8% SDS-PAGE. After
transferring to a nitrocellulose membrane, blots were probed with anti-phospho-EGFR,
anti-phospho-ERK1/2,

anti-phospho-Akt,

anti-HSC70,

respectively.

The

values

underneath the blots represent the relative changes of p-EGFR, p-ERK1/2 and p-Akt
levels present in the treated cells compared to the basal level of those in control cells after
normalization to HSC70, quantified by densitometric analysis using software ImageJ. Blots
are representative of 3 independent experiments.

Consistent with the what we observed in western blot assay, EGFR-A-NG exerts certain
tumor inhibition effects in mice bearing OVCAR-5 xenograft. On day 10, therapy with
EGFR-A-NG without CDDP and NRT was significantly more effective in inhibiting tumor
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growth as compared to the control group (p < 0.05) (Figure 53A), suggesting that
conjugation of protein ligand to NGs does not prevent their binding to EGFR+ cells in vivo
and inducing EGFR deactivation. However, the ligand along at the current dose could not
sufficiently suppress the tumor progression. On day 17, no statistical difference in tumor
growth was detected between EGFR-A-NG treated and control mice (Figure 53A). IHC
analyses of phosphor-EGFR levels in tumors of mice demonstrated a lower p-EGFR level
in tumors from EGFR-A-NG group as compared to the control group (Figure 56),
correlating with its behavior of blocking EGFR activation observed in in vitro setting. And
the conjugation of EGFR-A to NG didn’t render this ligand ineffective. Such behavior was
translated to its anti-proliferation effects shown in Figure 56C and D that proliferating cells
percentage in tumors of mice treated with EGFR-A-NG was lower as compared to the
control group (not significant). These data suggest that apart from the targeting ability, the
EGFR-A ligand also demonstrated antitumor activity through EGFR inhibition. Moreover,
anto-EGFR activity of EGFR-A ligand might contribute into the observed longer lifespan
of mice treated with (CDDP+NRT)/EGFR-A-NG as compared to (CDDP+NRT)/LAE-NG.
As expected, we didn’t observe any toxicity in terms of CBC results and levels of blood
serum enzymes related to liver and kidney functions in all groups (Table 26).
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Table 25. Median survival and p-values of different treatment regimens with respect to
control (5% dextrose).
% survival at
censoring date

Median Survival
(days)

p-values (vs. 5%
dextrose control)

5% Dextrose

35

-

0

EGFR-A-rNG10k

40

0.21

0

(CDDP+NRT)/EGFR-A-rNG10k

63

0.0007

14.3
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Figure 53. In vivo antitumor efficacy of (CDDP + NRT)/EGFR-A-rNG10k in OVCAR-5/Luc
human ovarian cancer intraperitoneal xenograft-bearing female nude mice. A.
Comparison of tumor growth inhibition following IV administration of 5% dextrose (control)
or EGFR-A-rNG10k or (CDDP+NRT)/ EGFR-A-rNG10k. Drug formulations were injected in
100 μL at a dose of 4 mg CDDP or 4mg NRT equivalents/kg body weight 4 times at 4-day
intervals as indicated by the arrows. Data presented in terms of relative whole-body
bioluminescence units (Rt/R0) to the day0. Values indicated are means ± SEM (n = 7), *P
< 0.05. ****p < 0.0001. B. Kaplan–Meier analysis of overall survival in 5% dextrose (control)
or EGFR-A-rNG10k or (CDDP+NRT)/ EGFR-A-rNG10k. Log-rank test was used to
determine statistical difference between (CDDP+NRT)/EGFR-A-rNG10k and EGFR-ArNG10k groups, **P < 0.01.
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Figure 54. Quantification of tumor progression in individual mouse treated with either 5%
dextrose (control) or EGFR-A-rNG10k or (CDDP+NRT)/EGFR-A-rNG10k based on whole
body bioluminescence imaging.
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Figure 55. Relative individual body weight change (Wt/W0) were measured following
intravenous administration of either 5% dextrose (control) or EGFR-A-rNG10k or
(CDDP+NRT)/EGFR-A-rNG10k. Body weight were measured every 4 days until day 36.

Table 26. Clinical chemistry parameters and hematocrit of blood samples collected

from animals sacrificed on day 14 across all treatment groups. Data are
represented as mean ± SD (n = 3).
ALP
(IU/L)

ALT
(IU/L)

BUN
(mg/dL)

RBC
(*1012/L)

WBC
(*109/L)

PLT
(*109/L)

5% Dextrose

31±11

39±8

20±4

9±1

1.2±0.2

44±10

EGFR-A-rNG10k

39±1

39±6

20±4

8±1

1.8±1.3

39±1

(CDDP+NRT)/EGFR-ArNG10k

32±4

38±6

23±3

7±2

2.2±0.3

39±1
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Figure 56. Quantification of dividing cells marked by Ki-67 staining (A) and apoptotic cells
marked by cleaved-caspase-3 (CC3) (B) staining in tumors from treated mice (n = 3). Data
are shown as mean ± SD; **P < 0.01; ***P < 0.001. Representative immunohistochemical
staining of tumors from mice treated with 5% dextrose, EGFR-A-NG, or
(CDDP+NRT)/EGFR-A-NG at original magnification × 2 (C) and magnification × 20 (D).
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It is important to note that in conducted independent animal studies, we repeated several
treatments including (CDDP+NRT)/EGFR-A-NG. When the quantification of Ki67+ cells
and CC3+ cells was compared side-by-side in a single graph (Figure 57), level of both
biomarkers in replicated experiments were quite similar in the same treatment groups
among repeated studies, demonstrating the reproducibility of the presented data.
Although we did observe the benefit of incorporating the EGFR-A ligand over LAE to
(CDDP+NRT)/NG in terms of inducing more apoptotic effects in tumors in repeated
experiments, this effect was not significant (p=0.088) possibly due to the limited
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Figure 57. Comparison of level of (A) Ki67+ cells and (B) CC3 positive cells in tumor
tissues from mice treated with either dextrose, or (CDDP+NRT)/EGFR-A-NG or
(CDDP+NRT)/LAE-NG in two replicated experiments. Data are shown as mean ± SD.
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3.4 Conclusions
In this study, we demonstrated that polypeptide-based NG were able to encapsulate both
NRT and CDDP in a molar ratio of 1:2. The drug combination at this ratio showed a high
level of synergy of cytotoxic action on EGFR overexpressing ovarian cancer cell lines
SKOV-3 and OVCAR-5. NRT was found to reverse the pro-survival signals induced by
CDDP treatment providing the molecular mechanism for the observed synergy in EGFR+
ovarian cancer cell lines. Further optimization of the drug carrier structure by extending
the length of PEG chains in the shell of NGs from 114 units to 228 units results in improved
PK parameters and biodistribution of NGs. Indeed, optimized PEG-based polymeric NG
displayed remarkably less spleen uptake, higher drug retention in tumor sites, and slower
clearance from circulation. Modification of NGs with EGFR targeting ligand further
improved the PK profile by directing more drugs to the target sites. When tested in an in
vivo intraperitoneal xenograft mouse model of high- grade serous EGFR-positive ovarian
cancer, EGFR targeted NGs carrying CDDP and NRT drug combination exerted enhanced
antitumor efficacy, both in terms of tumor growth inhibition and survival, compared to its
nontargeted counterpart. This enhanced efficacy was only observed when CDDP and
NRT are simultaneously delivered to the tumor sites. Our data also indicate that IP
administration of (CDDP+PTX)/LAE-NG can be more effective in the context of targeted
combination therapy without extending its cytotoxicity to the normal tissues.
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CHAPTER IV.

SUMMARY

Cytotoxic chemotherapy, such as cisplatin-based therapy, remains the standard
established systemic treatment of various cancer types, including TNBC and ovarian
cancer. However, monotherapy shows limited efficacy which arises from altered signaling
patterns of cancer cells, such as activation of pro-survival signal transduction (e.g.,
epidermal growth factor receptor (EGFR), AKT, PI3-kinase) and damage repair, etc.
Therefore, combinatorial chemotherapy remains the major strategy to combat cancer
since it works by different mechanisms to decrease the likelihood of developing protective
mechanisms by cancer cells. EGFR is one of the HER family of oncogenic receptor
tyrosine kinases, which actively participates in sustaining the growth and the survival of
carcinoma cells as well as the pathogenesis and progression of different carcinoma types.
It is frequently overexpressed in various cancer types making it a major therapeutic target
for the development of targeted drug delivery. EGFR inhibitors work synergistically with
standard chemotherapy including cisplatin-based standard cytotoxic treatment by blocking
oncogenic signal transduction and reducing the unfavored pro-survival signals induced by
those chemotherapies as reported. We therefore hypothesized that EGFR-inhibition would
potentiate the therapeutic efficacy of cisplatin towards cancers overexpressing EGFR by
reducing multiple cell-survival signal transduction and pushing cells towards apoptotic
death. To this end, neratinib (an inhibitor of HER family members including EGFR) and
cisplatin were selected as the combination regimen to treat EGFR+ cancers. However, the
administration of the combined drugs sometimes is limited by poor patient compliance due
to the inconvenience of repeated or extended duration of drug infusion. Besides, traditional
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chemotherapeutic small molecule drugs often show severe dose-limiting toxicities either
due to the drug actions or excipients used in the formulation, such as cisplatin that has
been linked to significant toxicities including nephrotoxicity, cardiotoxicity, hepatotoxicity
and neurotoxicity. Combining such binary drugs in one delivery carrier is therefore a
desirable and convenient strategy for controlling the pharmacokinetics and co-delivery of
the desired drug ratio in vivo, to maximize the therapeutic efficacy and minimize drugassociated toxicities.
Crosslinked polypeptide-based nanogel is an appealing platform to achieve this goal.
Such a biodegradable platform provides flexibility in adjusting size, loading capacity,
surface properties, deformability, softness, and responsive behaviors by tuning the
chemical compositions as well as crosslinking levels. Enhanced stability due to the
crosslinking adds benefits to prolonging the circulation, which in term enhances drug
exposure to the tumor by EPR effect. Their mild preparation procedures allow the
incorporation of labile drug molecules and biomacromolecules. The most prominent
advantage over other nano-sized carriers is their ability to incorporate molecules with
different physicochemical properties through versatile interactions, offering advantages
for combinatorial encapsulation of drugs. However, not all ratios of the same drug
combination would display strong synergistic activity. To exploring systems which allow
us to screen ratios of the drug combination for efficacy, in Chapter II we focused on
developing a panel of systems using the same polymer template with different fractions of
hydrophobic functionalities to achieve the goal. For the purpose of the current study, poly
(ethylene glycol)-block-poly (L-glutamic acid) modified with various numbers of
phenylalanine units (PEG-P(Glu-Glu/Phe)) for simultaneous loading and delivery of binary
CDDP and NRT combination. Such NGs have 1) a hydrophilic PEG shell which imparts a
stealth character against the immune system and extends the systemic circulation, 2) an
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anionic core, which incorporates CDDP through coordination with the carboxylic groups
of PGlu, 3) hydrophobic regions formed by Phe moieties, which serves as a reservoir for
NRT solubilization. Consistent with changes of chemical composition, NG with a high
content of hydrophobic functionalities displayed less swelling ability and more efficient
loading of the hydrophobic drug. Resulting binary drug combination-loaded NGs with 50
units of hydrophobic Phe units per polymer chain were able to encapsulate both CDDP
and NRT at a molar ratio of 2:1, and displayed the strongest synergistic effect towards
EGFR+ TNBC MDA-MB-468 cells compared with other screened regimens. Such superior
synergy was found to be selective and only displayed in the EGFR+ cell line. NRT was
found to reverse pro-survival signal transduction by CDDP mediated EGFR/Akt/Erk
activation as well as increased Cyclin D1 expression, which was believed to be the
molecular basis for the synergistic effect of a combination of CDDP and NRT. Altogether,
this study demonstrates a fundamental possibility for simultaneous delivery of
chemotherapeutics via single well-defined and structurally tunable polymeric nanocarrier.
Besides, such carriers grant us with flexibility in adjusting cargo ratio as well as dimensions
for the enhanced therapeutic outcome of carrier drugs.
However, this system is solely relying on the EPR effect for accumulation in tumor tissues
with leaky blood vessels. Such effect showed varied responses due to both inter- and
intra-tumor heterogeneity as reported. Installing targeting ligands on the surface of carriers
to specifically target biomarkers overexpressed on the surface of tumor cells is a wellsuited strategy to overcome delivery barriers including EPR limitations and further boost
drug performance. EGFR is one such biomarker of interest that overexpresses in more
than 50% of malignant ovarian tissue associated with high tumor grade and poor patient
outcomes. In Chapter III, two targeting ligands aiming to bind with EGFR was chosen in
our study: small L-AE peptide and EGFR-A protein. We designed ligand-installed NGs
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incorporating CDDP and NRT combination at a molar ratio of 2:1 and examined whether
EGFR-targeted concurrent delivery of synergistic combination of CDDP and NRT can lead
to enhanced therapeutic efficacy compared to nontargeted NG system. Two types of
ligand-installed drug-loaded NGs both demonstrated success in significantly increased
cellular uptake in EGFR+ cancer cells. Further optimization of NG structure was conducted
by extending the thickness of PEG stealth layer from 114 monomer units to 228 units for
sufficient protection from opsonization. Optimized PEG-based polymeric NG displayed
more favored PK properties, such as remarkably less spleen uptake, higher drug retention
in tumor sites, and slower clearance from circulation. NGs with EGFR targeting ligands
further improved the PK profile by directing more drugs to the target sites. When tested in
vivo, EGFR targeted NGs carrying CDDP and NRT drug combination exerted enhanced
antitumor efficacy, both in terms of tumor growth inhibition and survival, compared to its
nontargeted counterpart in rapidly growing mice model of EGFR-positive ovarian cancer.
We also confirmed the importance of simultaneous administration of the (CDDP+NRT) via
a single NG system which provides more therapeutic benefits than a cocktail of individual
drug-loaded NGs administered at equivalent doses. Besides, our data also indicate that
IP administration of (CDDP+PTX)/LAE-NG can be more effective in the context of targeted
combination therapy without extending its cytotoxicity to the normal tissues. These data
have shown the great potential of our carrier system in the delivery of a drug combination
to treat EGFR overexpressing cancers.
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LIMITATIONS AND FUTURE DIRECTIONS
Data in the second chapter demonstrated the evaluation of nanocarrier systems
encapsulated with CDDP + NRT. Such systems allow for varying the ratio of the two drugs
with different physicochemical properties and screening those ratios for efficacy. NPs
carried with a 2:1 molar ratio of CDDP and NRT were found to show superior synergistic
cytotoxicity activity in the treatment of TNBC in vitro. Our future efforts include detailed in
vivo studies which may help to elucidate whether the observed cytotoxicity would be
translated into antitumor efficacy in vivo using a TNBC orthotopic mice model. In this
chapter, our idea was to deliver the system to tumor sites solely relying on the EPR effect
to facilitate the delivery of the drug combination to the tumor site. However, the EPR effect
is highly heterogeneous even within the same tumor mass which affects the penetration
and accumulation of NPs in the tumor sites. One major strategy for achieving targeted
delivery to target tissues is by surface-installation of drug delivery systems with ligands
that can target specific biomarkers with a differential expression on the tumor cell surface,
which may enhance retention of drug carriers, as well as to improve internalization of
nanocarriers by target cells. In our chapter three, we designed ligand-installed carrier
systems to compare whether they can specifically deliver CDDP+NRT to EGFR+ ovarian
tumors and perform better antitumor efficacy than nontargeted systems. The ligandinstalled NPs were made from PEG-based polypeptide and showed great therapeutic
efficacy for the co-delivery of CDDP and NRT. This work demonstrated the advantages of
nanocarriers that are able to alter the PK properties of a small drug molecule with
prolonged circulation, enhanced retention in tumor and improved safety profile as
compared to the free drug. The nanocarrier underwent further optimization in terms of PK
properties through extending the thickness of the PEG stealth layer by 2 folds. While the
optimized NPs displayed remarkably less spleen and liver uptake with more retention in
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the target site, NPs still accumulate to a considerable extent in the liver and spleen. There
is always a scope to play with the stealth layer to provide sufficient protection for extended
circulation and elevated drug exposure. Another limitation is that the developed sub-100
nm NPs are not small enough for efficient tumor accumulation. Some intractable cancers
with inherent stromal barriers would prevent such NPs from penetrating into tumor tissues.
Current and future studies planned in our group include the design and fabrication of sub50 nm nanocarriers with improved stealth properties. One such system under investigation
is based on the copolymer of PEG-P(Glu-Glu/Phex)y utilizing Y-shaped PEG as the stealth
layer. Besides extending the length of PEG chains, utilizing Y-shaped PEG might increase
the surface brush density of PEG which further minimizes protein binding and RES uptake.
This carrier system is being screened with different ratios of hydrophobic and hydrophilic
moieties to obtain sub-50nm NPs, which can also be applied in some intractable cancers
such as pancreatic cancer and brain cancer. Another limitation is that repeated injections
of stealth NPs into mice might provoke the immune system to generate PEG-specific IgM,
which would decrease the half-life of the subsequently injected NPs [1]. Such
phenomenon might not be seen in nude mice due to the deficient immune system.
However, data from other groups have suggested that such accelerated blood clearance
phenomenon might not be PEG specific and is dose dependent. Besides, IgM may not be
able to opsonize the NPs if there is a sufficient PEG brush functionalized on the surface
[2]. To further assess if our systems exert any immunogenicity, a transgenic mouse model
could be a more appropriate platform to test. Although the OVCAR-5 intraperitoneal mice
model demonstrated good tumor engraftment take, this mice model does not fully
recapitulate human disease. Patient derived xenograft (PDX) model genuinely retains the
principal histologic and genetic characteristics of the primary tumor, remains stable across
passages and mimics the behavior of the primary tumor, such as the response to
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chemotherapeutics [3, 4]. Moreover, PDX models have demonstrated success in
predicting the clinical outcomes and are being used for preclinical drug evaluation, and
biomarker identification [4]. Therefore, the PDX model could be a valuable tool in the
prediction of the therapeutic efficacy of our formulations.
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